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ABSTRACT 
 
Context: Polycystic ovary syndrome (PCOS) is complex disorder associated with many 
metabolic abnormalities. PCOS is one of the most common endocrine disorders occurring in 
women of reproductive age and affects about 6-7% of the population. Women with PCOS have 
insulin resistance and hyperinsulinemia, thus increasing their risk of developing Type 2 diabetes 
mellitus, dyslipidemia, hypertension, cardiovascular disease, and endometrial cancer 
Overall Objective: To compare anthropometric features (weight, BMI, WC, body fat percent), 
antral follicle count (AFC), fasting glucose and insulin levels, HOMA score, menstrual bleeding 
patterns, and abdominal adiposity before and after a dietary intervention.  
Materials and Methods: The work presented herein represents a subset of the data being 
analyzed in an ongoing study titled "Lifestyle Intervention for Women with Polycystic Ovary 
Syndrome: The Role of a Pulse-Based Diet and Aerobic Exercise on Infertility Measures and 
Metabolic Syndrome Risk".  PCOS was diagnosed by two of the three diagnostic criteria as 
defined by the Rotterdam consensus: a history of cycles >35 days in length, hyperandrogenism 
as defined by a Ferriman and Gallwey score of >6 or hyperandrogenemia, as well as polycystic 
ovaries (PCO), defined by >25 follicles visualized upon transvaginal ultrasonography (TVU). 
Participants were randomized to either a 16 week pulse-based diet or to a TLC diet for 16 weeks. 
All participants were asked to follow an exercise program for the 16 week duration of the 
intervention. Changes in demographic, anthropometric features AFC, fasting insulin levels, and  
intervals between menstrual cycles were assessed. 
Results: Twenty four women completed the 16 week dietary intervention to date (pulse n=13, 
TLC n=11). Participants were found to be similarly matched for age, weight, BMI, WC, and 
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FAI. Weight (p=0.002) and body fat (p=0.0004) decreased significantly. No significant 
differences were detected in BMI and waist circumference. Antral follicle counts were decreased 
in the right ovary (p=0.04) but not the left ovary (p=0.11).  There was no change in fasting 
glucose levels detected. There was a decrease in fasting insulin levels (p=0.02) and  in HOMA 
score (p=0.02). No change in abdominal adiposity was detected (p=0.88). There was a tendency 
toward a change of fasting insulin levels and HOMA score due to the pulse-based diet. The 
average interval between menses decreased after the intervention (p=0.04). The longest length of 
time between menses also decreased after the intervention (p=0.01). 
Conclusions: Our hypothesis was partially supported. We observed significant decreases in 
weight, body fat percent, AFC in the right ovary, fasting insulin levels and intermenstrual 
intervals. In most women, the decreased intermenstrual interval translated into the resumption of 
menstrual cyclicity. However, the participants' BMI, WC, AFC in the left ovary, and abdominal 
adiposity were not affected. Consuming food of a lower glycemic index without a calorie 
restriction may help women with PCOS gain healthier anthropometric profiles, decrease serum 
insulin levels and insulin resistance, and increase the regularity of menstrual cycles. Further 
study involving weight reduction and dietary intervention with pulses may prove to be more 
successful than calorie reduction alone.  
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CHAPTER 1  
GENERAL INTRODUCTION 
 
Polycystic ovarian syndrome (PCOS) is complex disorder associated with many 
metabolic abnormalities. A positive diagnosis is made if two of the following three criteria are 
met: 1) clinical and/or biochemical hyperandrogenism; 2) chronic anovulation; and, 3) polycystic 
ovaries as visualized ultrasonographically. PCOS is one of the most common endocrine disorders 
occurring in women of reproductive age and affects about 6% to 7% of the population (1). The 
prevalence of PCOS is approximately 6.5% to 8% when biochemical/clinical features are used 
for diagnosis and approximately 20% using ultrasonography.  In Canada, approximately 1.4 
million women may exhibit varying degrees of PCOS (2).  
 Fifty to 70% of women with PCOS have insulin resistance and hyperinsulinemia, 
thus increasing their risk of developing Type 2 diabetes mellitus, dyslipidemia, hypertension, 
cardiovascular disease, and endometrial cancer (3). Women with PCOS are four times as likely 
to develop Type 2 diabetes mellitus as compared with BMI matched controls.  
There is no main treatment or drug to combat PCOS. Clinicians will often separate and 
treat the external signs of reproduction and not treat or ignore the metabolic complications 
associated with PCOS. The heterogeneity n the PCOS phenotype can also add to the complexity 
of treating PCOS. In the context of human diets and the present study, lifestyle interventions 
have been shown to have positive effects in improving clinical and metabolic parameters in 
women with PCOS. The effects include decreased insulin resistance, improvement in 
anthropometric features, and increased menstrual cycle regularity (4). 
 In the context of the present study, pulses refer to a group of more than sixty different 
grain legumes grown around the world that are classified as low-fat sources of proteins and 
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carbohydrates. Examples of pulse crops include chickpeas, beans, peas, and lentils. Pulse 
consumption decreases the rate of carbohydrate absorption, effectively lowering the glycemic 
index (GI) of a diet. Low GI diets prevent the onset and impact of Type 2 diabetes mellitus (5).   
 The cost of treating PCOS exceeds $4 billion in the United States alone. Therefore, early 
intervention by family doctors or allied health professionals should be undertaken in order to 
alleviate many of the physiologic and health concerns in women with PCOS (6).  
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Brief History of the Classification of PCOS 
Polycystic ovary syndrome (PCOS) was first established by Stein and Leventhal in 1935 
to describe women who presented with obesity, hirsutism, and chronic anovulation and enlarged 
ovaries postmortem (7). Their original characterization has been modified in subsequent years to 
include biochemical profiles and ovarian ultrasonographic morphology (8). In 1990, a National 
Institutes of Health (NIH) conference defined two criteria for the diagnosis of  PCOS: evidence 
of hyperandrogenism and ovarian dysfunction (9). In 2003, the representative experts from the 
European Society for Human Reproduction and Embryology (ESHRE) and the American 
Society for Reproduction (ASRM) met in Rotterdam, Netherlands and amended the definition of 
PCOS to reflect a positive diagnosis if two of the following three criteria were met: 1) clinical 
and/or biochemical hyperandrogenism; 2) chronic anovulation; and, 3) polycystic ovaries as 
visualized ultrasonographically. None of the criteria were considered absolutely required for 
diagnosis of PCOS due to the heterogeneity in presentation. PCOS was classified as a disorder of 
exclusion; other causes of anovulation, androgen excess, or related disorders, such as congenital 
adrenal hyperplasia, hyperprolactinemia, thyroid disease, and hypothalamic suppression must be 
excluded before diagnosis (10). 
 
2.2 Diagnostic Criteria of PCOS 
2.2.1 Hyperandrogenemia   
 Hyperandrogenemia, defined as elevated levels of androgens in systemic circulation, is 
present in 60% to 80% of women who present with PCOS (11).  Androgen excess appears to be 
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central to the symptoms of PCOS (12). Hormonal profiles used to test for hyperandrogenism 
include measurement of total, unbound, or free forms of testosterone (T, nmol/L).  Twenty 
percent to 30% of women with PCOS have adrenal androgen excess. The androgens secreted by 
the adrenal glands include dehydroepiandrosterone (DHEA) and its sulfate 
dehydroepiandrosterone (DHEA-S). Adrenal hyperandrogenism is a feature common to several 
diagnoses; non-classical adrenal hyperplasia (NCAH), adrenal androgen-producing tumors, and 
Cushing's syndrome. PCOS and NCAH may be clinically indistinguishable. Elevated levels of 
17-hydroxyprogesterone can be used as a diagnostic factor to distinguish NCAH from PCOS. 
Adrenal androgen-producing tumors are identified by imaging studies and venous sampling. If 
Cushing's syndrome is suspected, measurement of 24 h urinary free cortisol or a low dose 
dexamethasone suppression test is typically performed to diagnose adrenal causes of 
hyperandrogenicity, polycystic ovaries and anovulation (13).  
 Clinical hyperandrogenism may be manifest phenotypically by the presence of hirsutism, 
acne, and/or alopecia (8). Hirsutism is defined as excessive terminal hair growth that follows a 
male pattern of distribution. The most common method used to score hirsutism is the Ferriman-
Gallwey score. Nine body areas (upper lip, chin, chest, upper back, lower back, upper and lower 
abdomen, upper arm, and thigh) are assigned a score from 0 to 4 depending on the density of hair 
growth. The clinical evaluation of hirsutism is subjective and prone to inter-observer variability.  
Requisite threshold scores for hirsutism have varied from 6 to 8 (14). Is it important to note that 
the degree of hirsutism varies across ethnicities. There are racial variations in hair growth 
patterns with a lower prevalence in women of East Asian descent and a higher prevalence is seen 
in women of East Indian descent (8). Azziz et al. (8) observed that 659 of 1000 women who 
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presented with androgen excess exhibited hirsutism. Approximately 65% to 75% of women with 
PCOS are affected by hirsutism. 
Acne may be considered another sign of androgen excess. Acne affects approximately 
around 12% to 14% of Caucasian women with PCOS (15). Higher incidences of acne are 
observed in South Asian women (16). It is difficult to ascertain a causal relationship for acne in 
PCOS because of the prevalence of acne in the healthy population. There is also a lack of large 
scale studies of women with PCOS who present with acne but do not exhibit hirsutism (15).  
Alopecia is the loss of hair from the head or the body and its presence has an unclear 
relationship with PCOS. The typical pattern of hair loss in women with PCOS involves thinning 
of the crown with preservation of the anterior hairline (17). It is difficult to separate alopecia as a 
symptom separate from hirsutism or as a symptom independently correlated with 
hyperandrogenism (15). Alopecia may be the sole dermatological sign of PCOS, but further 
studies are needed to confirm this hypothesis (17). While 75% to 80% of women who present 
with hirsutism will have PCOS and 20% to 40% of women who present with just acne have 
PCOS, only 10% of women who present with alopecia will have a positive PCOS diagnosis (15). 
2.2.2 Anovulation 
        Women who ovulate regularly typically have regular menstrual cycles between 26 days to 
35 days (18). Anovulation in women with PCOS results in oligo-amenorrhea which is less than  
8 menstrual cycles per year or intervals of  ≥ 35 days between menstrual cycles (11).  A study of 
menstrual cyclicity in 873 women from the ages of 15 to 46 years revealed that 18% of the 
women had menstrual dysfunction and approximately 27% of the dysfunction group had PCOS 
as defined by the NIH criteria. It has been suggested that approximately 25% to 33% of women 
who present with menstrual dysfunction have PCOS (15). 
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2.2.3 Polycystic Ovaries 
       The morphology of polycystic ovaries (PCO) can be observed by ultrasonographic 
examination. Polycystic ovaries differ from “normal” ovaries by the distribution and number of 
ovarian follicles. Typically, follicles assume a characteristic peripheral ‘string of pearls’ 
distribution. The 2003 Rotterdam consensus defined PCO by the appearance of more than 12 
follicles measuring 2 to 9 mm or a volume of  >10mL (10). Recently, a higher threshold follicle 
number (more than 19 and 25 follicles) has been recommended to define the PCO. The higher 
threshold for follicle number obviates the growing misconception that polycystic ovaries have 
been highly prevalent in the general population of women who do not have PCOS (2).  
 
2.3 Reproductive Function in Women  
2.3.1 The Ovary and Its Structures 
 The primary roles of the human ovary are endocrine and exocrine functions. These 
include  production of reproductive hormones, release of an oocyte that has the capacity to 
undergo fertilization and embryonic development, and ensuring the accessory reproductive 
organs are ready to support a pregnancy. The ovary consists of two zones, an outer cortex and 
the inner medulla. The cortex is covered by an outer layer of connective tissue called the tunica 
albuginea and an inner zone that contains follicles.  A follicle is a fluid-filled sac that contains 
the oocyte. Primordial follicles are located in the avascular layer within the ovarian cortex 
beneath the tunica albuginea. Growing follicles and atretic follicles are found in the vascularized 
cortico-medullary border.  The medulla of the ovary contains dense connective tissue with a 
network of stromal cells, blood vessels, and lymphatics (19). 
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2.3.2 The Menstrual Cycle 
 The menstrual cycle is controlled by endocrine, autocrine, and paracrine factors that 
regulate follicular recruitment and development, ovulation, luteinization, luteolysis, and 
endometrial growth (18). The menstrual cycle is traditionally divided into a follicular phase and 
a luteal phase. During the follicular phase, a cohort of follicles is recruited to grow and one is 
physiologically selected to become the dominant follicle (DF) under the influence of follicle 
stimulating hormone (FSH). In women, usually the DF emerges on day 3 of the cycle at a 6 mm 
diameter (20). Visual identification of the DF usually occurs at approximately10 mm in diameter 
3 to 4 days later. The remaining cohort follicles undergo atresia.  Women have major follicle 
waves that lead to DF selection in addition to minor waves which have follicle recruitment but 
no DF selection. The DF ovulates in response to the elevation of estradiol which leads to the 
release of a surge of luteinizing hormone (LH). The formation of a corpus luteum (CL) after 
ovulation establishes the start of the luteal phase (21). During the luteal phase, the CL secretes 
progesterone to prepare the uterine lining for implantation and to maintain an early pregnancy. In 
women, if an oocyte is not fertilized there is no hormonal signal from an embryo to the CL to 
maintain CL activity. The CL degenerates and the progesterone levels drop leading to the start of 
menses (20).  
 Menses (menstrual bleeding) is the external sign that a reproductive cycle has progressed 
from follicle growth to ovulation to CL regression. Menses occurs cyclically at the end of the 
luteal phase and at regular intervals in women who ovulate regularly and signals the beginning of 
the next follicular phase.  Menses usually lasts for 3 to 6 days (18).  
 The average reproductive lifespan of a woman is approximately 36 years and is described 
as the time from menarche as early as 8.5 years of age to 13 years of age to menopause at 
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approximately 51 years of age. The menstrual cycles may change becoming exceedingly 
irregular after 35 years of age as women grow older and the number of oocytes decrease (22, 23).   
 Tracking human reproductive cycles using only the observation of menses is challenging 
as ovulation is not an obvious physical event. In addition, observation of cyclic menses does not 
necessarily indicate that there is normal ovulation. Seven percent of women with menstrual 
cycles of normal length are anovulatory (22). A menstrual cycle (the interval from the first day 
of menses to the first day of the next menses) in young healthy women of proven fertility is on 
average 28 days: the follicular phase lasts approximately 14.6 days and the luteal phase lasts 13.6 
days (24). However, menstrual cycle length is highly variable among women of a similar age (21 
to 35 days) with wide ranges in the follicular (10 to 23 days) and luteal phase (7 to 19 days) (22, 
25, 26). Most of the variability in cycle length is due to variability of the follicular phase (18). 
 There is a close relationship between follicle wave development in the ovary, DF 
selection, and the pattern of FSH release from the pituitary (27). In women with regular intervals 
between menstrual cycles (21 to 35 days), FSH increases about 4 days before menses at the 
luteal-follicular transition, peaks on the day of emergence of the DF, and then slowly declines 
until the LH surge preceding ovulation (28, 29). A rise in estrogen during the follicular phase 
begins after the day of emergence of the DF and rapidly rises after DF selection (29). Twenty-
four to 36 hours after the estrogen peak, an LH surge occurs, which stimulates ovulation (23). 
Progesterone levels begin to rise slightly two days before the LH surge and ovulation. Following 
ovulation, progesterone is consistently secreted by the luteinized cells of the former follicle wall, 
which develops into a discreet transitory organ, the CL. The CL is stimulated by low levels of 
LH, and progesterone is produced. Progesterone levels peak 6 days post ovulation and decline 
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thereafter if pregnancy is not established. Menses occurs after progesterone and estradiol levels 
decline (18). 
 Other hormones involved in the menstrual cycle include inhibin A, inhibin B, and activin 
A. The luteal-follicular transition phase is coupled with the fall in inhibin A, estrogen, and 
progesterone and a rise in activin A (29, 30). Secretion of estrogen and inhibin A by the 
dominant follicle bring about the decline in FSH during the follicular phase and luteal secretion 
of both inhibin A and B maintain low FSH following ovulation (31). 
2.3.3 Folliculogenesis in Women with Regular Reproductive Function 
 The primordial follicle consists of an oocyte arrested at the diplotene stage of prophase 
one which is surrounded by squamous granulosa cells (GC). When growth is initiated in 
primordial follicles, the oocyte begins to synthesize RNA followed by enlargement of the 
squamous GC. The first stage is a single layer of mixed squamous and cuboidal GC 
(intermediate follicles) and later change into cuboidal cells (primary follicle). Once GC 
proliferation develops into two or more layers, a secondary follicle is formed. Theca interna cells 
are recruited from surrounding stromal stem cells and are organized into layers around the 
follicle and are responsible for mesenchymal-epithelial cell interactions that aid in development 
of the follicle and oocyte (32, 33). 
 Primordial follicle growth is controlled by autocrine and paracrine factors. Primordial 
follicle growth is only minimally dependent upon FSH because of a low concentration/number of 
FSH receptors but is dependent on paracrine/endocrine factors (33). Granulosa cell-derived 
paracrine factors can activate or inhibit primordial follicles (kit ligand KL, TGF-α, EGF) 
depending on the environment of secretion (34).  Granulosa cell-derived KL and its receptor, c-
kit, is important in initiation, mesenchymal-epithelial cell signaling, and developing the oocyte in 
early folliculogenesis. Kit ligand causes secondary follicles to acquire FSH, estrogen, and 
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androgen receptors and to be coupled by gap junction to facilitate cellular interactions (33). 
Follicle recruitment ends with the formation of antral (tertiary) follicles. Antral follicles are 
characterized by slower oocyte growth, extracellular fluid which accumulates to form an antrum 
and differentiation of GC layers into mural and cumulus cell subpopulations. In humans, growth 
of hundreds of primordial follicles is initiated, but during each menstrual cycle only about 10 to 
20 antral follicles (2 to 5 mm in size that respond to FSH) remain and one physiologically 
selected follicle proceeds to ovulation.  The process from initiation of growth to follicle selection 
takes approximately 150 days. Only the final two weeks of follicular development are dependent 
on systemic cyclic gonadotropic changes (32, 33). 
 
2.4 Physiological Differences in Reproductive Function in Women with PCOS 
2.4.1 The Cause and Effect of Hyperandrogenism 
In the late 1960s, Ryan and Petro first proposed the two cell/two gonadotropin theory.  
They proposed that thecal cells produced androgens which were converted to estrogens by 
aromatase present in GC (35). Theca cells are located in close proximity to the basement 
membrane surround the GC layer, and are the major source of follicular androgens (36). One 
mechanism by which hyperandrogenism may be manifest in women with PCOS is through 
hyperactivity of the thecal cell layer. Follicles in polycystic ovaries contain an increased number 
of steroidogenic cells in the thecal layer and a decreased number of GC compared with ovaries of 
healthy women (37). An increase in testosterone production by thecal cells has been shown to 
arise from an increase in the synthesis of testosterone precursors and is not a result of 
dysregulation of testosterone synthesis (38).  Theca cells in women with PCOS have increased 
expression of steroidogenic enzymes involved in androgen biosynthesis, such as cytochrome 
P450, 17 alpha-hydroxylase/17-20-lyase (P450c17), and 3beta-hydroxysteroid dehydrogenase 
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(39). There is also an increase in 5α-reductase activity in GC and an increase in the conversion of 
androstenedione to 5α-androstane-3,17-dione, a competitive inhibitor of aromatase activity. In 
women with PCOS, there is a sufficiently elevated concentration of 5α-androstane-3, 17-dione in 
the follicular fluid to alter aromatase activity (40). 
Sixty percent to 80% of women with PCOS have elevated circulating androgens (11). 
Reproductively active sex steroids, such as testosterone and dihydrotestosterone circulate bound 
to sex-hormone binding globulin (SHBG), a plasma glycoprotein, and other proteins (12, 41). 
Sex hormone binding globulin is synthesized in the liver and is regulated by several metabolic 
and hormonal factors such as insulin. Insulin has been found to down-regulate SHBG production 
(41). Down-regulation of SHBG results in an increase in free testosterone which can enter cells 
and alter cellular function (12). The free androgen index (FAI) is a ratio of total testosterone to 
SHBG levels in the blood [(total testosterone/SHBG)*100], which is used as a measure of 
androgen status (42). Approximately 70% of PCOS patients have increased free testosterone 
blood levels and subsequently a higher FAI. Unfortunately, many of the of the commonly 
available, less expensive assays used to measure testosterone are most effective for higher levels 
detected in men and are highly variable  in women who have lower levels and therefore 
unreliable for assessing women with PCOS. It is difficult to ascertain a consistent, reliable 
standard for the normative testosterone range in circulation (12).  
2.4.2 Menstrual Cycle Irregularity in Women with PCOS 
 Women with PCOS can have ovulatory cycles; however, most women with PCOS 
experience menstrual cycle irregularity due to anovulation (12).  An ovulatory menstrual cycle is 
characterized by endometrial growth that is stimulated by estrogen produced by the dominant 
follicle (DF) during the follicular phase.  After the DF ovulates, progesterone is produced by the 
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CL. Endometrial proliferation decreases under the influence of progesterone. If pregnancy does 
not occur, the CL undergoes atresia, progesterone decreases and menses occurs as a consequence 
of progesterone withdrawal. The decrease of progesterone precipitates menstruation where the 
entire endometrial lining is shed. Menses occurs cyclically in women who ovulate at regular 
intervals (18). 
Women with PCOS who do not ovulate have irregular, non-cyclic bleeding patterns. 
Anovulatory bleeding arises from estrogen stimulated endometrial tissue that has not been 
exposed to progesterone. Androgens synthesized in ovarian stromal tissue are aromatized to 
estrogen in peripheral tissues (adipose, muscle, liver).  Women with PCOS who do not ovulate 
have irregular, non-cyclic bleeding patterns. Bleeding occurs following chronic anovulation 
when endometrium growth is stimulated by estrogen in the absence of progesterone-mediated 
growth inhibition and progesterone-mediated development of stromal support. As a result, 
women with PCOS have variable endometrial bleeding episodes. Women with PCOS can present 
with menstrual dysfunction that presents as bleeding less than ≤ 8 times per year or ≥ 35 days 
between menstrual bleeding.  In contrast, menses occurring at regular intervals, especially 
intervals between 24 to 35 days are predictive of regular ovulation (43-45).  
 The pathophysiology of PCOS is hypothesized to result from an increased pulsatile 
frequency of gonadotropin releasing hormone (GNRH) which selectively increases LH secretion 
(46). Women with PCOS often have mildly elevated levels of serum LH and an elevated LH to 
FSH ratio (47). LH stimulates theca cells in the ovary to produce androgens. FSH levels in 
women with PCOS are normal or suppressed and never reach the elevated threshold levels 
required in the early menstrual cycle to stimulate follicle growth (47, 48). Because of a relative 
insufficiency of FSH, androgens such as testosterone are ineffectively aromatized to estrogen by 
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the GC. Androgens leave the ovary and are aromatized to estrogen in peripheral sites, such as fat, 
liver and muscle. Estrogen levels in anovulatory women with PCOS are typically constant at 
levels seen in the early to mid-follicular range in ovulatory cycles (48).  
2.4.3 Polycystic Ovarian Morphology 
 In the scientific community, there is scant agreement on the morphological definition of a 
polycystic ovary (PCO). This controversy exists because the criterion put forth by the Rotterdam 
consensus, that the PCO contains over 12 follicles, has been characteristic of ovarian 
morphology of women who do not have PCOS. There are several studies that have challenged 
the Rotterdam criteria and have recommended revising the definition of PCO (2, 49). 
 Jonard et al. (50) investigated whether there was a rationale for increasing the threshold 
number of follicles to diagnose PCO from 10 to 15 follicles. It was found that increasing the 
threshold range of follicle numbers for a PCOS diagnosis had a higher specificity but not a 
higher sensitivity for using PCO as diagnostic criteria. The use of a threshold value of 12 
follicles (the current standard) maintained the sensitivity at 75% and the specificity at 99%. 
 Dewailly et al. (49) suggested revisiting the threshold antral follicle count (AFC) in the 
diagnosis of PCOS as counts of 12 follicles per ovary resulted in an artificial inflation of the rate 
of PCOS in the population. It was suggested that advances in ultrasound imaging technology 
from the time of the Rotterdam consensus in 2003 would allow for improved visualization of 
follicles, especially of follicles in smaller diameter ranges (1 mm to 2 mm range). It was 
postulated that use of the Rotterdam definition of the PCO when there was a higher visual acuity 
for small follicles resulted in artificial inflation of diagnoses of women with PCOS (2, 49). 
Therefore, a higher threshold of the number of follicles to define PCO would represent a more 
accurate means to diagnose PCOS. In addition, real time ultrasonography was used to count the 
number of follicles when defining the PCOS criterion for the Rotterdam consensus. Dewailly 
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noted that detailed post-hoc analyses using tracking software allowed for follicles to be counted 
that were previously uncounted. It was suggested that post-hoc analyses also led to an artificial 
inflation in follicle number using the definition from the Rotterdam consensus (2, 49) . Dewailly 
therefore assessed follicle numbers in a clinical population of infertile women using a cluster 
analysis. The cluster analysis consisted of counting follicle numbers in the lowest “cluster” of the 
non-PCO group and highest follicle numbers in the PCOS group. Dewailly used the cluster 
analysis to recommend a threshold of greater than 19 follicles for the diagnosis of the PCOS 
(49).  
 In 2013, Lujan et al. (2) recommended that the threshold follicle number of a PCO be 
increased to 26 follicles. In contrast to the work completed by Dewailly, Lujan recruited women 
of normal reproductive age (18 years to 35 years) with and without PCOS that did not present 
with infertility. Real-time imaging and post-hoc analyses were used to characterize follicle 
number. Women without PCOS who did not have infertility typically had greater follicle 
numbers than the control group with infertility that were evaluated by Dewailly. Inter-observer 
variability was evaluated by Lujan and used detailed post-hoc analysis to derive the antral 
follicle count. The sensitivity and specificity were 85% and 94% (49). 
 The use of anti-mullerian hormone (AMH) has been suggested to be a more reliable and 
less subjective marker of PCO morphology than use of the AFC. Anti-mullerian hormone is 
made by GC present in growing follicles until they reach about 8 mm in size. The production of 
AMH declines when a follicle is selected for dominance. Measurement of AMH compared is 
considered to be an increasingly reliable measure of ovarian follicle reserve. AMH levels are less 
prone to fluctuations and may also be less subject to inter-observer variability compared with the 
assessment of AFC and therefore be easier to reproduce during multi-center trials (51).  
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2.4.4. Antral Follicle Dysfunction in PCOS 
 Polycystic ovaries are characterized by a (2 to 3 fold) increase in antral follicle number 
compared to non-polycystic ovaries. Polycystic ovaries are also characterized by theca cell 
hyperplasia and concomitant thickening within the ovarian cortex (52, 53). When observing the 
PCO morphology in women with PCOS, it is important to distinguish between women who are 
ovulatory and anovulatory even though there is a greater tendency toward shared morphological 
characteristics. Gross morphology of anovulatory PCO consists of multiple 2 to 8 mm diameter 
antral follicles. The follicle sizes are consistent with follicular arrest prior to the pre-ovulatory 
stage (54). Granulosa cells found in the follicles of women with PCOS are steroidogenically 
competent. The GC from anovulatory women with PCOS show in vitro evidence of increased 
estradiol and progesterone production when compared with GC from follicles of similar size 
from ovulatory PCO and non-PCO women (55-57). In contrast, steroidogenesis by theca cells is 
abnormal in both anovulatory and ovulatory PCO suggesting an intrinsic abnormality in theca 
cell function (54). The overactive theca cells secrete increased amounts of androstenedione, 17-
α-hydroxyprogesterone and progesterone compared with normal ovaries. Antral follicles in 
ovulatory PCO hypersecrete androgens but do not secrete excessive estrogen whereas antral 
follicles from anovulatory PCO have an increased secretion of both androgens and estrogen (58).  
 Androgens appear to influence the number of follicles in the ovary. In primates, 
androgens stimulate early follicle growth (54, 59). Androgen treatment in monkeys increases the 
number of primary, preantral and small antral follicles, and the proliferation of GC. Female 
rhesus monkeys exposed prenatally to excessive levels of testosterone or dihydrotestosterone 
(DHT) exhibited ovulatory dysfunction in adult stages, presenting with enlarged, 
hyperandrogenic polycystic ovaries (54).  
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 Hyperandrogenism is unlikely the major cause of anovulation in PCOS; however, 
increased androgen levels may contribute to anovulation by inducing an abnormal environment 
that affects follicle maturation (54). The mechanism for androgens to induce abnormal follicle 
maturation in PCOS is taken from evidence of folliculogenesis and ovulation in non-PCOS 
women.  In a typical ovulatory menstrual cycle, GC in the dominant follicle acquires LH 
receptors and the ability to respond to LH only in the mid-follicular phase. LH stimulates 
steroidogenesis and triggers terminal differentiation and arrest of follicle growth in a pre-
ovulatory follicle. The arrest of follicle growth is thought to occur by exceeding a threshold level 
of intracellular cyclic AMP (cAMP) which is triggered by the LH surge. Possible mechanisms of 
follicular arrest include the hypersecretion of LH, insulin, and androgens and the production of 
supra-physiological intracellular concentrations of cyclic cAMP in the GC. In women with 
PCOS, the premature arrest of follicular growth is unlikely to be due solely to excessive LH 
secretion as many women have normal serum concentrations of LH. However, a synergistic 
effect of insulin and LH to stimulate estradiol and progesterone secretion could augment LH-
induced steroidogenesis by GC (60). The synergistic effect of insulin on LH also may be due to 
premature acquisition of LH receptors prior to the mid-follicular phase. In non-PCO or in 
ovulatory PCO, the GC secretes estradiol in response to LH when the DF has reached 9 to10 
mm. However, in anovulatory PCO, LH stimulated secretion of estradiol and progesterone could 
occur from follicles that were as small as 4 mm. Antral follicles that were 6 mm to 8 mm in 
diameter produced levels of estradiol and progesterone in vitro that were similar to those 
observed in normal, preovulatory follicles. In addition, androgens may contribute to follicular 
arrest by augmenting cAMP production within GC. Androgens have a negative effect on follicle 
growth and maturation in PCOS (57). 
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2.4.5. Reasons for the Increased Follicle Population in the Polycystic Ovary 
 There are two reasons hypothesized for the increased follicle population found in PCO: 
increased follicle recruitment and decreased follicle atresia. In both anovulatory and ovulatory 
PCO, there appears to be an increased recruitment from the resting follicle pool in comparison 
with observations of ovaries in women without PCO.  An increase in the follicle resting pool is 
determined by observing an increased number of both primordial and primary follicles in PCO 
(61). Hughesdon et al. (53) found approximately twice the number of primary and secondary 
follicles in PCO compared with non-PCO. The density of small preantral follicles in the ovarian 
cortex was significantly higher in women with PCOS. It was hypothesized that the increased 
follicle density was primarily comprised of primary stage follicles. This hypothesis was tested 
using morphometric analysis of human ovarian cortical biopsies taken from groups of women 
with and without PCOS. More than 90% of the follicles in both PCO and non-PCO ovaries were 
at the primordial and primary stage. Occasional secondary follicles were observed in both 
groups. One early antral follicle was observed in a non-polycystic ovary. The population density 
of small preantral follicles differed between the PCO and non-PCO groups. The lowest density 
of small preantral follicles was seen in the non-polycystic ovaries. An intermediate density was 
noted in the ovulatory PCO and anovulatory PCO had the most dense follicle population. There 
was also a significant difference in density of primary follicles among all the groups. The median 
density of small preantral follicles was six fold greater in anovulatory PCO than in normal 
ovaries. Polycystic ovaries had greater density of the primary follicle population. 
  Webber et al. (61) found an increase in both primordial and primary follicles in women 
with PCOS as well as an increased density of follicles when compared with women without 
PCOS. Further analysis into the proportion of primordial (resting) and primary (growing) 
follicles indicated that there was increased initiation of growth of follicles from the resting pool 
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regardless of ovulatory status in women with PCOS compared with the non-PCO population. 
Webber et al. hypothesized different possible mechanisms for the higher density of primary 
follicles in anovulatory PCO: an excess of primordial germ cells to the fetal ovary and more 
mitotic divisions of the oogonia in the fetal ovary. Other hypotheses included enhanced assembly 
of somatic cells around the naked oocyte during follicle formation around the twelfth week of 
gestation or a decreased rate of loss of germ cells and the surrounding somatic cells in the PCO 
compared to non-PCO. Anovulatory women with PCOS displayed abnormalities in the later 
stages of antral follicle growth, demonstrating an arrest of follicular growth, typically at a 
diameter of approximately 5 mm to 8 mm. The proportion of atretic follicles did not differ 
between PCO and non-PCO.  Therefore, the difference in follicle density was not attributable to 
a reduced atresia rate. There was a trend toward a higher proportion of atretic follicles in 
anovulatory PCO (61). 
 Webber et al. also studied the health of the follicles by observing follicle morphologies. 
Histologic features of an atretic follicle included a degenerated oocyte nucleus, uneven or folded 
nuclear membrane, vacuoles in the oocyte, and pyknotic nuclei in the GC (61, 62). The 
proportion of healthy primordial follicles was significantly lower in PCO compared with a non-
polycystic population. A greater proportion of early primary follicles was observed in the ovaries 
of anovulatory and ovulatory women with PCOS and a reciprocal decrease in primordial follicles 
was also observed (61). 
 
2.5 Insulin Resistance and Hyperinsulinemia 
2.5.1 Insulin Action in vivo 
 Insulin stimulates glucose uptake in tissues such as adipocytes, skeletal and cardiac 
muscle, and suppresses glucose production by the liver (63, 64). Insulin also decreases lipolysis 
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and thereby decreases the level of circulating free fatty acids (FFA) in the body (65). Insulin 
resistance (IR) can often be confused with the inability of the body to produce insulin. More 
insulin is needed to achieve glucose homeostasis.  Insulin resistance is coined to describe the 
decreased ability of a certain amount of insulin to efficiently mediate glucose uptake, glucose 
production, and/or lipolysis (66). Accordingly, insulin resistance is characterized by increased 
amounts of circulating insulin (66, 67). 
 Fasting glucose levels reflect hepatic glucose production in the body.  Fasting insulin 
levels are a reflection of insulin sensitivity, secretion, and clearance (68, 69). The “gold 
standard” measure for insulin resistance is the euglycemic clamp technique. This test assesses 
insulin-mediated uptake of glucose. In lean healthy individuals, skeletal muscle accounts for 
85% of insulin-mediated glucose disposal (IMGD) (70).  As fat mass increases, skeletal muscle 
insulin sensitivity decreases (71). The clamp test is completed during steady state conditions, and 
the amount of glucose that is infused into an individual reflects the amount taken up by the 
peripheral tissues (67, 70). Dunaif et al. (72) demonstrated that IMGD was decreased 
significantly (35% to 40%) in women with PCOS compared to controls matched for age and 
body composition. The difference in IMGD was similar to the pattern described in Type 2 
diabetes mellitus (T2DM).  Insulin-mediated glucose disposal (uptake into muscle) was also 
decreased in lean women with PCOS with normal glucose tolerance. Although the clamp test 
adequately assesses IR, its use is limited because it is expensive and there is a requirement for  
highly trained personnel and specialized equipment (67, 70).  
 Another reproducible, quantitative measure of whole body insulin sensitivity is the 
frequently sampled IV glucose tolerance test (FSIGT) with minimal model analysis. This 
technique uses a mathematical model to analyze glucose and insulin concentration time courses 
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after a glucose intravenous injection (70). The FSIGT test allows a direct stimulation of 
pancreatic β-cells without having gastrointestinal factors as confounders. The FSIGT provides a 
dynamic image of glucose and insulin concentration and the given dose of glucose is known as 
well as its appearance in systemic circulation (70, 73). Other measures that correlate with the 
gold standard tests have been developed to approximate degrees of IR because the clamp and 
FSIGT are expensive and complex procedures. All tests to calculate IR are based on fasting 
glucose and insulin levels and include homeostatic model assessment (HOMA), fasting 
glucose:insulin ratio, and quantitative insulin index (74-76).   
 Homeostasis model assessment of insulin sensitivity is a simple alternative to measure 
IR. The HOMA score is calculated from the following formula: [fasting plasma glucose 
(mmol/L)*fasting serum insulin (pmol/L)/22.5] (77). Bonora et al. (77) found a strong 
correlation between HOMA score and glucose clamp technique results and supported the use of 
HOMA as an index for in vivo insulin sensitivity. A HOMA score of 2.6 or higher indicates 
insulin resistance (78). 
 Oral glucose tolerance tests (OGTT) are used to measure glucose and insulin sensitivity 
but have shown insensitivity to large changes in insulin (71). Oral glucose tolerance tests lack 
precision for a quantitative measure of IR compared with the clamp or FSIGT measures (76, 79). 
However, there is no validated, universally accepted clinical test to detect IR (80).  The fasting 
glucose: insulin ratio can be useful as a screening test but a 75g OGTT is more sensitive than the 
glucose:insulin ratio in determining impaired glucose tolerance (75, 80). 
2.5.2 How Insulin Resistance and Hyperinsulinemia Affect Women with PCOS 
 Basic physiological differences in women with PCOS may account for much of the 
increased IR and subsequent hyperinsulinemia. Hyperinsulinemia can affect the ovaries through 
ovarian and non-ovarian linked pathways resulting in disrupted ovarian hormonal balance and 
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regulation. Disruption of the menstrual cycle and infertility
 
are present in addition to IR 
stimulating thecal cell mediated androgen production (81, 82).  Ovarian mechanisms include 
insulin stimulation of thecal cells. Non-ovarian linked pathways include LH enhanced pituitary 
pulse amplitude and suppression of SHBG formation in the liver. Suppression of SHBG would 
result in decreased binding of testosterone subsequently raising the FAI in conjunction with 
insulin stimulation of cytochrome P450c17α activity resulting in an increase in adrenal 
androgens. Another way IR manifests itself in women with PCOS is by the impaired glucose 
uptake into skeletal muscle. Impairment occurs at the level of the insulin signaling pathway with 
the down-regulation of phosphorylation of some key signal molecules. Down-regulation of these 
molecules results in an impaired expression of glucose transporter 4 (GLUT4) and decreased 
glucose uptake into cells (83). Insulin signaling in women with PCOS has also been 
characterized in fibroblasts. The cultured fibroblasts from women with PCOS have shown 
decreased insulin receptor binding or auto-phosphorylation which could reflect mutations of 
genes regulating these pathways (84). 
 The distribution of adiposity in women with PCOS can also contribute to IR. Women 
with PCOS typically present with a higher amount of abdominal obesity compared with obese 
women without PCOS when matched for body mass index (BMI). Approximately 35% to 50% 
of women with PCOS have truncal obesity with an increased waist circumference (WC) (85). 
Adipocytes in visceral fat may contribute to IR because the visceral adipocytes are more 
metabolically active (83). The incidence of IR is up to 20% in lean women with PCOS and can 
be greater than 40% in the obese PCOS population (72, 80). The clinical features of PCOS, such 
as oligomenorrhea or amenorrhea, anovulation, and phenotypic presentations of 
hyperandrogenism, such as hirsutism and acne are exacerbated with concurrent obesity (80).  
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2.5.3 Cellular Basis of Insulin Resistance in Women with PCOS 
 Women with PCOS exhibit glucose intolerance, IR independent of obesity, and fasting 
hyperinsulinemia that are consistent with reduced insulin sensitivity and T2DM (86).  Insulin 
insensitivity has been recorded despite normal insulin receptor occupancy which may suggest a 
deficiency in the insulin signaling pathway (87). Differences in the adipocyte insulin receptor 
pathway have been seen in women with PCOS compared to women without PCOS. The pathway 
involves the tyrosine kinase and skeletal muscle insulin receptor substrate-1 (IRS-1) associated 
phosphatidylinositol 3-kinase (PI3-K) (87, 88).  
 Ciaraldi et al.(86) conducted tests on adipoctyes and skeletal muscle cells in women with 
PCOS to investigate the expression and function of insulin signaling molecules in women with 
PCOS with both normal glucose tolerance (NGT) and impaired glucose tolerance (IGT). 
Impaired insulin sensitivity was present in both systemic circulation and in adipocytes but was 
not reflected in GLUT4 expression in women with PCOS. There were no detectable metabolic 
differences in glucose transport in adipocytes ex vivo. Differences between control and PCOS 
women were detected in vivo. In adipoctyes from the control population, 0.17 nm of insulin 
attained 50% of the maximal insulin effect. In adipocytes taken from women with PCOS, the 
same amount of insulin was able to stimulate only 15% to 20% of the final effect (86). Insulin 
action in skeletal muscle cells was studied by growing and differentiating them into myotubes 
which are phenotypically, morphologically, and metabolically similar to skeletal muscle cells 
donated by donors (89). Basal and insulin-stimulated glucose uptake into muscle cells was 
reduced by 50% for both NGT and IGT PCOS women compared to the controls. It was 
hypothesized that there was an intrinsic deficiency in the muscle cells of women with PCOS as 
the myotubes were not cultured in a hyperinsulinemic environment as found in women with 
PCOS.  There was no noticeable difference between the NGT and the IGT PCOS myotubes in 
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vivo. It was hypothesized that since the subjects were not postprandial (after having ingested a 
meal), the postprandial hyperglycemic state could not be evaluated to detect differences between 
the NGT and IGT groups. It was concluded that impaired sensitivity was apparent in the whole 
body context and was not intrinsic to muscle cells in women with PCOS. In addition, reduced 
insulin sensitivity in adipocytes could be an induced and reversible factor (86).  
 
2.6 Obesity and Android Body Fat Distribution in Women with PCOS 
 Women with PCOS have increased android body fat distribution (BFD) characterized by 
mainly visceral and abdominal deposition of adipose tissue compared with age and BMI matched 
women (90). Women with PCOS are often hyperandrogenemic and hyperandrogenemia also 
results in visceral fat deposition. Studying the individual elements found in women with PCOS is 
difficult because it is difficult to isolate the effects of different confounders such as obesity and 
IR. Women with PCOS have a tendency to be overweight or obese (38% to 88%) and have a 
characteristic distribution of body fat around the abdomen (83). The development of obesity in 
women with PCOS is related to possible genetic predisposition to obesity and behavioural 
environmental factors such as poor diet and reduced exercise. Barber et al. (83) have put forward 
the suggestion that it is the development of obesity that unmasks the biochemical and clinical 
abnormalities of PCOS. Further evidence is taken from the finding that modest weight loss (5% 
to 10 %) results in a significant decrease in IR and hyperandrogenism in conjunction with an 
increase in menstrual cyclicity and ovulation. The nature of IR in women with PCOS is multi-
faceted and multi-factorial.  Studies evaluating the effect of insulin sensitizing medications have 
demonstrated there was a tendency to improve reproductive function and resolve the physical 
characteristics that result from hyperandrogenism (83).  
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2.6.1 Android Body Fat Distribution 
 An android BFD is seen more frequently in women with PCOS when compared with 
women without PCOS.  Android BFD is characterized primarily by visceral and abdominal 
deposition of adipose tissue (83). Increased android BFD is associated with IR. The difference in 
IR in women with PCOS compared with controls is much less marked if women are matched for 
abdominal adiposity than matched for BMI (91). Exposure to high concentrations of androgens 
during fetal development is one possible mechanism of an android BFD (92). Studies with 
prenatally androgenized female rhesus monkeys show greater abdominal adiposity as compared 
with controls. Although hyperinsulinemia may play a role in the development of an android BFD 
in women with PCOS, it is difficult to determine a causal relationship. Android BFD contributes 
to hyperandrogenemia through increasing insulin resistance and the consequential 
hyperinsulinemia leads to the increase of android BFD. The android BFD causes and is a 
consequence of itself. This cycle can be disrupted by dietary/exercise interventions and insulin 
sensitizing medications (83). 
2.6.2 Measuring Body Fat 
 It is a challenge to accurately measure body fat. Fat depots are mostly subcutaneous or 
intra-abdominal. These depots can also reside among and inside muscles (93). Recently, waist to 
hip ratio (WHR) and waist circumference (WC) both have been positively correlated with 
estimating abdominal fat. Waist circumference was determined to be more accurate than WHR 
(94, 95). It is better to consider both BMI and WC for a more accurate measure of visceral fat 
and cardiovascular risk although BMI has been widely used as the sole measure to evaluate body 
fat content (96, 97). The most accurate technique for measuring abdominal adipose tissue in vivo 
is computed tomography (CT). However, there is limited access to CT imaging equipment, 
increased exposure to ionizing radiation and the technique is expensive. Dual energy x-ray 
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absorptiometry (DEXA) relies on the differential absorption of x-rays to distinguish different 
body tissues with a minimal exposure to radiation and is a comparable and validated alternative 
to CT scanning (98). 
2.6.3 Clinical Observations Related to Abdominal Adiposity 
 Toscani et al. (93) investigated the influence of androgens on IR and central obesity in 
overweight or obese hirsute women with or without PCOS. They also tested the reliability of the 
sum of truncal skinfolds (subscapular, suprailiac, and abdominal) in estimating truncal adiposity. 
Hirsute patients with PCOS had a higher percentage of truncal adiposity, greater testosterone 
levels, and a higher FAI than women of similar age and hirsutism without PCOS. Women with 
PCOS also had increased WC, sum of trunk skinfolds, and DEXA- measured trunk fat. There 
was a strong correlation observed between the DEXA trunk fat measurements, WC, and trunk 
skinfold measurements. Trunk skinfold measurements were easier, cheaper, and readily available 
to perform; however, it was highly dependent on the individual, type of caliper, and the body 
composition of the person being measured. Waist circumference was suggested as a single, 
simple measurement that had a high correlation with DEXA measured trunk fat and had less 
variability than trunk skinfold measurements. Whole body DEXA was used to determine 
whether there was a greater amount of abdominal fat in women with PCOS than in weight-
matched controls. The insulin levels and sensitivity in both groups were also assessed. Women 
with PCOS exhibited increased levels of testosterone and higher degrees of IR, independent of 
BMI. Body mass index was not found to be a predictor of central adiposity. Overweight and 
obese women with PCOS also had significantly higher WC, central abdominal fat, and serum 
insulin levels than women of a normal weight with PCOS.  Higher insulin levels and reduced 
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sensitivity were present in the entire PCOS population indicating that abdominal fat was not 
necessarily the only determinant of hyperinsulinemia in women with PCOS (93). 
 Carmina et al. (99) conducted a study to determine the relation of total and abdominal fat 
and IR in women with PCOS compared with weight-matched controls. Women with PCOS had 
higher testosterone and insulin levels, total fat, and trunk fat measured using whole body DEXA, 
despite similar values in BMI
 
. Women with PCOS also had a significantly higher WC, percent 
trunk fat, abdominal (R1) fat quantity and percent R1 fat. Women with PCOS had similar 
quantities of trunk and total body fat compared to their weight-matched controls; however, they 
had an increased quantity of abdominal fat. Body mass index and WC measurements were not 
predictive of central abdominal fat excess. Overweight women with PCOS with increased 
abdominal fat also had significantly higher values of serum insulin and lower insulin sensitivity 
than those with normal central adiposity. Women with PCOS with normal abdominal fat were 
matched for insulin and insulin sensitivity values to overweight controls but not matched to 
overweight controls with increased abdominal fat. Hyperinsulinemia and IR found in women 
with PCOS seem to be a consequence of abdominal obesity even if abdominal obesity was not 
the only determinant. Women with PCOS with decreased abdominal fat content still showed 
signs of hyperinsulinemia and IR. It was difficult to determine whether IR was the cause or 
consequence of the android BFD (99). 
 Hutchinson et al. (100) conducted an investigation into the effect of a 12 week structured 
exercise program on IR and body composition in overweight and obese women with and without 
PCOS. Abdominal visceral fat was measured using CT scanning. After adjusting for age, 
abdominal adiposity was higher in women with PCOS. Abdominal adiposity also correlated 
independently with IR. The 12 week exercise program resulted in lower IR, abdominal adiposity 
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(by 11%), and triglycerides despite weight maintenance in women with PCOS. Abdominal 
adiposity was an independent predictor of IR, dyslipidemia and cardiovascular risk factors. 
Hutchinson et al. suggested that weight loss should not necessarily be the sole focus of exercise 
in PCOS because exercise has been shown to increase the cardiometabolic health profile without 
weight loss.  
 
2.7 The Relationship between Hyperandrogenism, Hyperinsulinemia, and Increased              
      Android Body Fat Distribution in Women with PCOS 
 
2.7.1 Androgens and Insulin Resistance 
 Hyperinsulinemia contributes to hyperandrogenemia in women with PCOS in several 
ways: 1) enhancing LH stimulated androgen production in theca cells; 2) decreasing the amount 
of SHBG, subsequently increasing the levels of free testosterone; and, 3) binding of insulin to the 
insulin-like growth factor (IGF-1) receptors on theca cells which also stimulates androgen 
production (101-103). In obese women, it has been demonstrated that there is an adipocyte site-
specific increase of the expression of 17β-HSD which is the main reductive isoenzyme 
responsible for conversion of androstenedione to testosterone. The increase in the conversion to 
testosterone can be attributed to increasing androgenicity corresponding with increasing BMI 
(104).  
 Hyperinsulinemia causes hyperandrogenism but hyperandrogenism does not cause 
hyperinsulinemia. Decreasing serum insulin levels by insulin sensitizing drugs lowers serum 
androgen levels (105). However, decreasing serum androgen levels by bilateral oophorectomies 
or with GNRH agonists does not affect circulating insulin levels (106, 107). Prenatal exposure to 
high androgens may cause a visceral adiposity deposition leading to IR and subsequent 
hyperinsulinemia (108). 
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 Insulin resistance becomes more pronounced with increasing age in women with PCOS 
and can be more pronounced compared with healthy women.  The increase in IR could be 
attributable to an increase in abdominal obesity as measured by BMI, WC, and WHR (109).  
Pasquali et al. (110) showed no changes in plasma insulin levels and OGTT curves for women 
who did not experience change in BMI, WC, or WHR. There was a decrease in circulating 
androgens in women with PCOS as they aged and this change was more pronounced compared 
with normal women. The decline in androgen levels was accompanied by a decrease in the 
prevalence of the classic phenotypic presentation of PCOS (hyperandrogenism, anovulation, and 
PCO) and an increase in the phenotype that contained anovulation and PCO, but not 
hyperandrogenism (109).  
2.7.2 Effects of Androgenization in Animal Models 
 We were unable to locate any published studies determining the effect of androgen 
signaling in women, however, the relationship has been studied in rats (111). Androgenizing 
female rats resulted in a decrease in whole body insulin sensitivity in intact and ovariectomized 
animals (112). The reduction in insulin sensitivity was not associated with increased free fatty 
acid or glycerol levels which led to the interpretation that increased lipolysis was not the cause of 
decreased insulin sensitivity (113). It has been postulated that androgenization deregulates post 
insulin receptor signaling events although the specific mechanisms have not yet been elucidated 
(114). 
2.7.3 Adipocyte and Steroid Metabolism 
Adipocytes are also involved in steroid metabolism and inter-conversion of steroidal 
hormones. Sex hormones, such as testosterone and estrogen, are derived from cholesterol and are 
steroid hormones. The first and the rate-limiting step in the biosynthesis of all steroid hormones 
is the conversion of cholesterol to pregnenolone.  All sex steroids are produced through the 
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DHEA conversion to androstenedione and subsequently to testosterone and estradiol by 17β-
HSD and aromatase, respectively. Approximately half of the testosterone in female circulation is 
secreted directly from the ovaries and the adrenal glands. The remainder of the conversion of 
androgens occurs peripherally. Testosterone is further metabolized in target tissues, such as 
adipocytes, into the more potent form, called 5α-dihydrotestosterone by the enzyme 5α-reductase 
or into estradiol by aromatase. The increase in abdominal adiposity in women with PCOS results 
in increased peripheral conversion of androgens into DHT or estradiol. Peripheral conversion of 
androgens leads to unopposed estrogen levels causing endometrial growth and proliferation, 
possibly leading to endometrial hyperplasia and cancer (83). 
2.7.4 Adiposity and Insulin Resistance 
 Weight gain in women with PCOS is associated with increased insulin resistance. 
Increased abdominal fat accumulation is correlated with reproductive dysfunction (115).  It 
follows that a loss of abdominal fat is correlated with resumption of ovulation (116).Weight loss 
is linked to increased insulin sensitivity, resumption of menstrual cyclicity, increased ovulatory 
function, and increasingly healthier metabolic profiles.  It is difficult to isolate the sole effects of 
hyperinsulinemia as increased adiposity is a confounding variable in women with PCOS (83).  
 
2.8 The Effect of Lifestyle Interventions in Women with PCOS 
 Lifestyle modification has been determined to be beneficial in women with PCOS. A 
modest amount of weight loss (5% to14%) improves cardiovascular risk factors, reduces 
abdominal fat, blood glucose, blood lipids, IR, serum androgens and increases menstrual 
cyclicity, ovulation, and fertility (81, 117). Reduction in insulin levels is considered to be the 
most beneficial determinant of reproductive health. Metabolic parameters are correlated with 
reduction in abdominal fat (85, 118).  
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2.8.1 Why Exercise Training? 
 Exercise training improves health parameters such as decreasing abdominal fat and 
increasing insulin sensitivity. Exercise prevents development of cardiovascular disease (CVD), 
Type 2 diabetes mellitus (T2DM), decreases morbidity, and mortality in addition to having 
psychological benefits (81). Long-term exercise is beneficial for long term weight management 
and maintenance. The combination of exercise and a healthy diet is most effective for losing and 
maintaining weight (119). Aerobic exercise improves CVD risk markers and body composition 
independent of weight loss in overweight or obese individuals (120). Resistance training on its 
own is beneficial for improving sensitivity to insulin as well increasing the amount of lean body 
mass, thereby increasing the basal metabolic rate (121).  The combination of aerobic and 
exercise training reportedly has a synergistic effect on improving metabolic parameters, IR, 
reproductive functionality, and reducing abdominal fat in people that are obese (122, 123). 
2.8.2 Exercise Training in PCOS 
 It is important to establish whether women with PCOS have physical limitations different 
than clinically healthy women. There were no differences reported in three studies assessing 
maximal aerobic capacity (VO2max) in women with PCOS compared to age and BMI matched 
controls (124-126). VO2max usually has an inverse relationship with IR (81). Orio et al. (127) 
found that there was a decreased maximal and submaximal cardiorespiratory response in young 
overweight women with PCOS. In the study conducted by Orio et al., the fasting insulin 
concentrations were much higher than in the other studies assessing VO2max in women with 
PCOS (20.2 IU/L vs. 15 IU/L). Increased IR could be the reason for the submaximal 
cardiorespiratory response in this population although the specific mechanism of action has not 
yet been elucidated (127). 
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 Thomson et al. (116) conducted a 20 week study to assess the effect of diet only, aerobic 
training by itself, or aerobic-exercise training combined with a moderate hypocaloric weight-loss 
regimen on body composition, cardiometabolic and hormonal profiles, and reproductive 
functions in overweight or obese women with PCOS. Exercise combined with the diet did not 
provide any additional benefits compared with diet only in terms of weight loss. Exercise 
facilitated changes in body composition. A 45% reduction in fat mass and 60% better 
preservation of fat-free mass was observed. There was a significant difference in body fat 
percentage, fat mass, and free fat mass in the diet and exercise groups compared to the diet only 
group. There was no difference observed among the exercise group (aerobic or aerobic and 
resistance training). Waist circumference was reduced by 11.1% across all groups. There was an 
inverse relationship between SHBG and weight loss and a lower body fat percentage correlated 
with a decreased amount of testosterone. Almost half of the participants reported improvements 
in ovulation and/or menstrual cyclicity with no differences observed between treatments. The 
hormonal profiles of the women in the study, specifically insulin, showed no change over the 
intervention. The authors speculated that this was a reflection of the sensitivity of the assay. 
Most of the changes in health parameters were attributed to energy restriction and weight loss. 
Exercise improved the body composition and fat distribution of the participants which was more 
important in long-term weight loss management and sustainability. 
Another study was designed to compare exercise and the role of physical function to IR 
in overweight and obese women with and without PCOS (124). Participants were asked to 
undergo a maximal exercise test, skeletal muscle function assessments, and blood tests. Aerobic 
exercise capacity was not related to PCOS, however, an inverse relationship was observed 
between VO2max and IR. There was also an inverse relationship of VO2max to WC.  It was 
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hypothesized that IR, not PCOS, increased the risks of CVD. The presence of PCOS did not limit 
an individual’s ability to tolerate physical exercise. Women with PCOS with higher IR may have 
impaired cardiorespiratory function and muscle strength which could impact exercise tolerance 
(124). 
 Vigorito et al. (128) conducted a study to assess the effects of exercise training on the 
cardiopulmonary functional capacity in women with PCOS (120). Women were randomly 
allocated into a PCOS-T (trained) group and PCOS-UnT (untrained) group. The trained group 
underwent a 12 week structured exercise training program. There was a significant decrease in 
BMI, WHR, baseline insulin and WC in the PCOS-T group as opposed to the PCOS-UnT group. 
Structured exercise training programs were beneficial due to the increase in cardiopulmonary 
functional capacity, increased weekly energy expenditure score, BMI and WC reduction, 
improved IR and reduced chronic inflammatory state. 
 Palomba et al. (129) compared the efficacy of a structured exercise training (SET) 
program versus a hypocaloric diet on the reproductive function in obese PCOS patients with 
anovulatory infertility. Pregnancy rate was the primary end-point. The SET group undertook a 24 
week SET program while the diet only group followed a 24 week hypocaloric hyperproteic diet 
intervention. The SET program and the diet intervention were equally effective in allowing for 
increasingly regular menstrual cyclicity and an increase in fertility. Conclusions about pregnancy 
rates could be not be drawn due to a lack of statistical power, but a tendency toward higher 
pregnancy rates was noted with the SET group. There were significant improvements in body 
weight, BMI, WHR, WC, FAI, serum testosterone and SHBG in both interventions. In the diet 
only group, the body weight and BMI were significantly decreased. The SET group exhibited a 
decrease in WC related to a decrease in visceral fat and an increase in muscle mass. Taken 
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together, these observations indicated there were a variety of ways to improve IR that caused a 
hyperandrogenic profile in women with PCOS. 
 Hutchinson et al. (100) conducted an investigation into the effect of a 12 week structured 
exercise program on IR and body composition in overweight and obese women with and without 
PCOS. At screening, advice about lifestyle and diet interventions were given to all participants. 
The focus was on weight maintenance and not weight loss. Weight did not decrease significantly 
within groups.  BMI was significantly reduced within the PCOS group. Waist circumference was 
reduced in the non-PCOS population. Total and abdominal fat mass decreased in both the PCOS 
and non-PCOS groups. In addition, IR and triglyceride components were reduced in women with 
PCOS but no changes were exhibited in the non-PCOS group.  
 It appears that exercise has a beneficial effect in women with PCOS in terms of reducing 
IR, improving fitness, body composition, menstrual cyclicity, and ovulation (100, 124, 128, 129).  
However, most intervention studies had small sample sizes, a high drop-out rate, and a low 
compliance rate, thereby decreasing their overall power. The challenges in doing a complete 
study could be a reflection of the psychological characteristics of the PCOS population. 
Behavioural characteristics may predispose women to factors that contribute to the PCOS 
phenotype (81). In addition, not all studies reviewed were randomized and/or they were looking 
only at short term effects of diet and exercise rather than long term sustainability. The design 
weaknesses reduced generalizability of the data sets (116). 
2.8.3. Combined Dietary and Exercise Lifestyle Interventions in Women with PCOS 
 A systematic review was conducted by Moran et al. (130) on randomized controlled trials 
(RCT)  that focused on the effect of lifestyle interventions (dietary, exercise, behavioural 
management, and/or combination of all three) compared to minimal treatment for women with 
PCOS. The outcomes measures observed included reproductive factors (pregnancy, menstrual 
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cyclicity, ovulation, total testosterone, SHBG, clinical hyperandrogenism),  anthropometric 
factors (weight, BMI, android BFD, WC, WHR), and metabolic factors (OGTT, fasting glucose 
and insulin levels, lipid profile). Out of 21 articles retrieved, 13 were excluded on the basis of a 
lack of a control group (n=9), not being a RCT (n=1), and no access to a full text article (n=2). 
Six studies were included in the systematic review (128, 131-135).  
 The number of participants in the studies that were included ranged from 11 to 90.   The 
drop-out rate and its relation to the time period of the intervention were as follows: there was a 
0% drop out at 12 weeks (128, 133), 18% at 24 weeks (135), 25% at 24 weeks, 35% at 48 weeks 
(133), and 43% to 46% at 16 weeks (131, 134). The interventions were physical activity 
interventions (128, 131, 134) or combined dietary and exercise interventions (132, 133, 135).  
There was no clear benefit on reproductive factors such as pregnancy, menstrual cyclicity, or 
ovulation. There was no evidence for decreased FAI indicating that effects of lifestyle treatments 
on hyperandrogenism should be carefully examined. Lifestyle interventions improved 
anthropometric measurements such as a reduced endpoint weight (7% weight change). No 
differences were observed in OGTT, fasting glucose, or lipid profiles of women with PCOS 
undergoing the lifestyle interventions compared with minimal treatment (136). It was difficult to 
extrapolate the effect of combined dietary and exercise interventions in women with PCOS due 
to the high drop-out rate, low compliance rate and low statistical power. 
2.8.4 Metformin 
 Metformin is currently used as an oral anti-hyperglycemic medication and is approved by 
the American Food and Drug Administration (FDA) and Health Canada for the management of 
Type 2 diabetes mellitus.  Metformin use has been associated with decreased IR through 
inhibition of hepatic glucose production, decreasing intestinal glucose uptake and increasing 
peripheral insulin sensitivity. The observed treatment effects included increased menstrual 
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cyclicity, improved ovulation rates and decreased circulating androgen levels. Combination 
therapies in women with PCOS using metformin are being used to determine if there is a 
synergistic effect of metformin on lifestyle interventions to enhance weight loss (137). 
 Ladson et al. (137) studied the combination therapy of metformin and lifestyle 
interventions in women with PCOS. The participants were randomly allocated into a metformin 
or a placebo group. Both interventions contained a dietary and exercise intervention component 
over a period of 6 months. The primary outcome measure was ovulation rate as determined by 
urinary progestin levels. The two treatment groups retained very similar baseline characteristics 
such as similar drop-out rates, racial distributions, hormonal profiles, ultrasonographic measures 
and metabolic profiles. There were no significant differences in the outcomes (i.e., primarily 
ovulation rates, but also hormonal and metabolic profiles) between the metformin and placebo 
arms. However, the study had limited power due to the drop-out rates. Women in the metformin 
arm lost more weight. It was hypothesized that the insulin sensitizing nature of metformin would 
make it easier for women to respond positively to diet and exercise interventions although 
metformin did not necessarily contribute to the effect of diet and exercise in women with PCOS. 
This hypothesis would lend support to circumvent the high drop-out rate and the low motivation 
and sustainability rate in such kinds of interventions.  
 Hoeger et al. (133) carried out a pilot study to evaluate metformin therapy or lifestyle 
modification and a combination of the two therapies over a 48 week period on ovulation 
induction and reduction of serum androgens in women with PCOS. Participants were assigned to 
four groups:  1) metformin 850 mg (n=9); 2) lifestyle modification with placebo (n=11); 3) 
lifestyle modification with metformin (n=9); and, 4) placebo only (n=9). The lifestyle 
interventions included counseling by a registered dietician and an exercise physiologist and a 
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diet that was 500 to 1000 calories lower than their regular consumption. Significant weight 
reduction occurred in all the groups. The most significant weight reduction (7% to 10%) 
occurred in the combined group. Significant reduction in androgens (testosterone and FAI) was 
also noted only in the combined group. There was no significant change in fasting serum glucose 
concentrations nor were there significant differences in ovulatory events between the treatment 
and placebo groups. Subgroup analysis showed that women who lost weight with or without 
metformin were estimated to be 9 times more likely to become ovulatory (OR = 8.97, 95% CI 
1.24-64.68). However, the small sample size resulted in a wide confidence interval which in turn 
decreased statistical power and generalizability. As observed in previous studies, weight loss has 
an influence on resumption of ovulation. The addition of metformin is another predictor of a 
tendency toward resumption of ovulation. A combined metformin and lifestyle intervention 
group is 16 times more likely to resume ovulation (OR=16.19, 95% CI = 4.36 - 64.22) (125).  
 
2.9 PCOS and Long-Term Risk 
2.9.1 Economic Burden 
  PCOS has a high prevalence (approximately 1 in 15 women) and a strong association 
with many metabolic and fertility abnormalities. Financial burden of women with PCOS on the 
healthcare system is an important issue to address (6, 138). Azziz et al. (6) established the 
prevalence of PCOS among women in the United States, assessed the prevalence of various 
morbidities associated with PCOS and then calculated the economic impact of treatment during 
the reproductive years. The morbidities included menstrual dysfunction and anovulation, 
endometrial hyperplasia and carcinoma, infertility, T2DM and hirsutism. The economic burden 
was evaluated by including the cost of the initial diagnosis and evaluation and treating each of 
the morbidities. The cost of treating PCOS exceeded $4 billion in the United States alone, taking 
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into account care provided only during the reproductive lifespan while ignoring other 
complications associated and not counting repeat doctor visits.  Approximately 40% of the 
burden was due to development and care for T2DM. An estimated 12.8% of the $12.6 billion 
spent on diabetic management for people under 45 years old has been attributed to women with 
PCOS (139, 140). Therefore, widespread screening and amelioration of PCOS are options to be 
highly considered by health professionals, especially in countries where health insurance is 
provided as a national expectation. 
2.9.2 Endometrial Hyperplasia and Cancer 
 Women with PCOS need increasingly regular menstrual cycles to increase fertility 
outcomes when desired and to decrease the risk of endometrial hyperplasia or cancer. Women 
with PCOS who have irregular cycles still contain peripherally aromatized estradiol (in adipose 
tissue) initiating unopposed endometrial growth and proliferation. The hyperinsulinemic 
environment also down-regulates SHBG and increases the amount of free estradiol and 
testosterone in the periphery. Endometrial hyperplasia occurs in 35% of women with PCOS who 
do not have regular cycles (artificial or natural). Endometrial cancer represents 8% of all cancers 
occurring in women and the highest risk populations are women who are obese, have 
hyperinsulienmia, T2DM and PCOS. Insulin stimulates cell proliferation, promotes tumor 
angiogenesis and stimulates aromatase activity. All of these factors play a role in augmenting 
cellular proliferation of the endometrium leading to atypic differentiation which then may 
progress to cancer (22). 
2.9.3 Type 2 Diabetes Mellitus 
 Insulin resistance is complex and has a variety of genetic and environmental bases in 
women with PCOS. Insulin resistance results in hyperinsulinemia which in turn affects lipid 
metabolism, protein synthesis, and androgen production. A sub-group of women with PCOS who 
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have IR also go on to develop insufficient pancreatic insulin output or β-cell failure. Theresulting 
hyperglycaemia results in T2DM (141). Approximately 15% of postmenopausal women with 
PCOS have T2DM (142). The diagnosis also increases the risk of CVD by a factor of 4 to 7.  The 
mechanisms by which T2DM increases CVD include directly increasing sympathetic activity, 
inducing abnormalities in endothelial function, indirectly impairing fibrinolysis, altered lipolysis, 
and induction of hypertension (143-147). 
2.9.4 Metabolic Syndrome 
 Metabolic syndrome (MBS) has been classified by the presence of three or more of the 
following:  1) WC greater than 88 cm in females; 2) blood pressure (BP) of at least 130/85 mm 
Hg; 3) serum levels of high density lipoprotein (HDL) below <1.03 mmol/L for men and <1.3 
mmol/L for women; 4) triglyceride (TG) levels >1.7 mmol/L; and, 4) increased fasting serum 
glucose levels at least >5.6 mmol/L. Metabolic syndrome is associated with a higher risk for 
developing T2DM as well as cardiovascular disease (148). Factors defining MBS are common in 
women with PCOS. A prevalence of MBS in women with PCOS was found to be approximately 
46% in a cross sectional study conducted by Korhonen et al. (149).  
 Apridonidze et al. (143) conducted a retrospective chart review comparing the prevalence 
of MBS in women with PCOS compared to an age and BMI matched population. They also tried 
to determine if there were any phenotypic or hormonal differences between PCOS women with 
MBS and those without MBS. The prevalence of MBS in women with PCOS was 43%. The 
prevalence was higher than the age-adjusted rate of 24% obtained by the Third National Health 
and Nutrition Examination Survey (NHANES III). Higher prevalence persisted even when 
matched for age and BMI, the latter suggesting that obesity by itself did not account for the 
differences of the prevalence in the PCOS population.  Women with PCOS and MBS presented 
more frequently with acanthosis nigricans, a phenotypic characteristic of IR, in addition to more 
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severe hyperandrogenism (increased serum free testosterone, lower serum SHBG). Further 
evaluation showed that 91% of the women with PCOS presented with at least one of the 
abnormalities of MBS and 69% had at least two of the abnormalities present. Low HDL 
concentrations occurred most frequently (68%), followed by elevated BMI (67%), high blood 
pressure (45%), high triglyceride levels (35%), and high fasting glucose levels (4%). 
2.9.5 Pulses and Their Relation to Type 2 Diabetes Mellitus 
 A pulse crop refers to a group of more than sixty different grain legume crops grown 
around the world. A pulse refers to the seeds of pulse crop, such as chickpeas, beans, peas, and 
lentils. They are typically made up of 20% to 25% protein and 40% to 50% starch. Pulses are 
also rich in dietary fibre. Pulses are a good source of starch, fiber, vegetable protein, and anti-
nutrients, such as phytates, phenols, lectins, and enzyme inhibitors, some of which are natural α-
glucosidase inhibitors (150). Jenkins et al. (146) documented an exceptionally low glycemic 
response when pulses were fed to healthy volunteers and demonstrated that pulses contained a 
carbohydrate component that was more slowly absorbed as compared to other grains (5, 151). 
The slower absorption led to decreased postprandial glucose and insulin releases and effectively 
lowered the glycemic index (GI) index of the diet (150).  
 The prevalence of T2DM has passed 13% of the global population and continues to be on 
the rise (152). Anti-hyperglycemic agents such as metformin prevent the development of T2DM 
and reduce the risk of microvascular complications such as new or worsening nephropathy or 
retinopathy (153, 154). However, anti-hyperglycemic agents cannot reduce macrovascular 
morbidities, such as death from cardiovascular causes, nonfatal myocardial infarction, or 
nonfatal stroke (154). α-glucosidase inhibitor acarbose is an anti-hyperglycemic agent and can 
reduce macrovascular morbidities (150, 151). Acarbose slows down the rate of absorption of 
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dietary carbohydrate so that it is converted into slowly absorbed or 'lente' carbohydrates. Low 
glycemic index (GI) diets with acarbose are beneficial for glycemic control and greatly aid in 
decreasing either the incidence or severity of T2DM in addition to reducing cardiovascular 
disease risk (145). 
 Abeysekara et. al (155) observed a benefit of pulses in reducing total cholesterol and low 
density lipoprotein (LDL) in older adults, another age group at increased risk for CVD.  The 
reduction in cholesterol, especially LDL, remains consistent with younger age groups as well 
(155).Sievenpiper et al. (5) conducted a systematic review and meta-analysis of RCT observing 
the effect of pulses on glycemic control in people with or without T2DM. The analysis of 41 
RCT supported a beneficial effect of consumption of dietary pulses in T2DM. Glycemic effects 
varied by pulse with the strongest evidence for benefit linked to chickpeas. Both acute and 
chronic consumption of pulses resulted in reduced postprandial blood glucose and insulin 
releases.  
 Our review of the literature led us to the notion that the incorporation of a lower glycemic 
diet coupled with an increase in exercise should demonstrate positive health benefits in 
anthropometric features, reduction in risk factors for metabolic syndrome, and reduction in the 
symptoms present in PCOS. Therefore, the combined effects of pulse consumption and aerobic 
exercise should result in positive changes in metabolic and fertility outcomes in women with 
PCOS. 
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CHAPTER 3 
OBJECTIVES AND HYPOTHESES 
 
3.1 General Objectives 
 A larger scale clinical trial was designed to evaluate the short and long term effects of a 
pulse-based diet and aerobic exercise on infertility measures and metabolic syndrome risk in 
women with PCOS. The work presented in the thesis represents a subset of data from the larger 
scale clinical trial. The full trial protocol is included in Appendix A. 
 
3.1.1. Specific Objectives 
 The objective of the work presented in the present analysis and work comprising the 
thesis was to compare anthropometric features (weight, BMI, WC, body fat percent), antral 
follicle count (AFC), fasting insulin levels, menstrual cyclicity, and abdominal adiposity before 
and after a dietary intervention.  
 
3.2 General Hypotheses 
 To put the work presented in the current thesis in context, we hypothesized that for the 
large scale clinical trial, a pulse-based dietary intervention there would lead to: 1) a reduction in 
insulin levels; 2) improvement of markers of metabolic syndrome (i.e., reduced fasting glucose 
levels, triglycerides, blood pressure, abdominal fat, and increased HDL); and, 3) a change in 
physiological measures of PCOS. The measures assessed included decreased number of ovarian 
follicles, decreased menstrual cycle length and demonstration of menstrual cyclicity, increased 
levels of estradiol and progesterone, and decreased androgens.  
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 We also hypothesized that women participating in the study would continue to consume 
pulses 6 to 12 months after the intervention. There would be a decrease in insulin levels, markers 
of metabolic syndrome, and symptoms of PCOS at 6 and 12 months post intervention compared 
with the pre-study indices.  A pulse-based diet would also indirectly increase the quality of life 
of women with PCOS. 
 
3.2.1 Specific Hypotheses 
 For the work presented in this thesis, we hypothesized that following the pulse-based 
dietary intervention there would be a decrease in: 1) weight, BMI, waist circumference, and body 
fat percent; 2) antral follicle count; 3) fasting insulin levels; and, 4) abdominal adiposity. We 
also hypothesized that women participating in the study who had menstrual cycles that were 
unpredictable would notice that their menstrual cycles would be more predictable in timing after 
the intervention. The null hypothesis was that the intervention would have no effect on any of 
these factors.  
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CHAPTER 4 
MATERIALS AND METHODS 
 
4.1 Study Participants 
 The work presented herein represents a subset of the endpoints being analyzed in an 
ongoing study titled Lifestyle Intervention for Women with Polycystic Ovary Syndrome: The 
Role of a Pulse-Based Diet and Aerobic Exercise on Infertility Measures and Metabolic 
Syndrome Risk (Appendix A). The full study is being conducted in collaboration among 
members of the College of Pharmacy and Nutrition, College of Kinesiology, and Department of 
Obstetrics, Gynecology and Reproductive Sciences in the College of Medicine at the University 
of Saskatchewan. The clinical trial was approved by the University of Saskatchewan's research 
ethics board (Appendix B).  
 Recruitment was performed using advertisements placed in newspapers and online 
venues and with posters placed in clinics and hospitals across the city. The advertisements were 
seeking women of reproductive age (18 to 38 years) with concerns about irregular or absent 
menstrual cycles, difficulty losing weight, and excess hair growth. 
 All participants signed a consent form prior to starting the study (a copy can be found in 
Appendix A). A diagnosis of PCOS was made with the identification of at least two of the three 
diagnostic criteria by a clinician specializing in reproductive endocrinology . The diagnostic 
criteria were: 1) irregular or absent menstrual cycles as defined by a history of cycles >35 days in 
length; 2) hyperandrogenism as defined by a Ferriman and Gallwey score of  >6 or 
hyperandrogenemia; and, 3) polycystic ovaries (PCO) as defined by >25 follicles visualised upon 
transvaginal ultrasound (TVU), with no follicle >10 mm or corpus luteum (2, 15).  
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 A diagnosis of PCOS was excluded in women with the following conditions: 1) taking 
anti-seizure or anti-psychotic medications known to induce development of PCO; 2) untreated 
hyperprolactinemia or thyroid disease; or, 3) excessive adrenal androgen production confirmed 
by a diagnosis of congenital adrenal hyperplasia or an adrenal tumor.  Women were excluded 
from the study if they were using reproductive hormones, including contraception or fertility 
medications for a period of at least 3 months before the start of the study. Other exclusion criteria 
included: 1) a medical condition limiting the ability to exercise to 60% of maximal heart rate;  
2) an inability to consume a pulse-based diet (allergies or intolerances); 3) an uncontrolled 
medical condition that interfered with ovarian or system hormone production; 4) pregnant or 
breastfeeding state;  and, 5) residency outside of the local geographic area. 
 One hundred and sixty seven women (n=167) expressed interest in participating in the 
study. Eighty five women (n=85) were either excluded following the exclusion criteria or 
decided they were no longer interested in participating prior to any diagnostic visits. Forty nine 
women (n=49) who completed all of the initial measures (diagnostic visit, diagnostic bloodwork, 
diagnostic ultrasound, OGTT, DEXA, and diet instruction) were randomized either into the 
group receiving the pulse-based diet or into a control group following the National Cholesterol 
Education Program therapeutic lifestyle changes diet (TLC). Both dietary groups participated in 
an aerobic training program. The inclusion of the TLC arm (as the control group) and the aerobic 
training program were considered the most ethical approach to our study design (i.e., the TLC 
diet and aerobic program were considered “standard of care” for women with a condition 
negatively affecting health). For this ethical reason we did not have an untreated control group. 
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4.2 Diet and Exercise Program 
 All participants were asked to attend a 90-minute dietary education session with a 
registered dietician to learn about the composition of the TLC diet which used meat-based 
protein sources. All participants followed the TLC diet during the first two week “lead-in 
period”. Following the “lead-in period”, participants were randomized to either a 16 week pulse-
based diet or to continue the TLC diet for 16 weeks. Pre-intervention measures were obtained 
before the start of the 16 week diet and exercise intervention and post-intervention measures 
were obtained after week 12 of the intervention was completed, depending on the menstrual 
bleeding pattern of the individual. 
 Participants randomized to the pulse-based group received 2 pulse-based meals each day 
for 16 weeks. The pulse-based meals were prepared with dry peas, lentils, chickpeas, or beans. 
The meals contained approximately 90 g of dried green peas, 225 g chickpeas or fava beans, or 
150 g lentils. Participants were asked to follow TLC guidelines for breakfasts and snacks. 
 All participants were asked to follow an exercise program for the 16 week duration of the 
intervention. The exercise program involved 5 sessions of aerobic exercise per week; 3 sessions 
of supervised exercise training and 2 sessions of unsupervised at-home exercise were to be 
undertaken. The supervised exercise training occurred in the College of Kinesiology physical 
activity complex.  Exercise was completed on a treadmill, rowing machine, elliptical trainer, or 
exercise bike. Participants were asked to exercise for 45 minutes each day at an intensity of at 
least 60% of their age-predicted maximal heart rate (i.e., 220-age). 
 
4.3 Measurements of Demographic, Androgenic, and Anthropometric Features 
4.3.1 Age 
 The participant age was calculated at the time of the first diagnostic visit. 
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4.3.2 Height 
 Standing height was measured by placing the participant without footwear, arms hanging 
by the sides, feet together, against a meter stick attached to the wall. The participant was 
instructed to look straight ahead, stand as tall as possible, and take a deep breath while the 
measurement was taken. The measurement was taken by placing a set square on the head, 
depressing the hair to make firm contact with the top of the head. A mark was made at the level 
of the lower border of the square on the wall. The distance from the floor to the pencil mark was 
recorded to the nearest 0.5 cm (Figure 4.1a). 
4.3.3 Weight 
 Weight was measured using an analog scale (Bridgeview, IL, Health-O-Meter; model 
160KL) placed on a flat surface. The participant was measured without footwear and in light 
clothing. The weight was measured in kilograms to the nearest 0.1 kg (Figure 4.1b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.1. Measurement of standing height and weight (a,b). Placement of the participant 
against a wall and placing the set square on the head, while depressing the hair to make firm 
contact with the top of the head (a); and, measurement of weight by placing the participant on 
the analog scale (b). 
a b 
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4.3.4 Body Mass Index 
 Body mass index (BMI) was calculated from the recorded height and weight using the 
formula: [body weight (kg)/(height squared) (m
2
)] (99). 
4.3.5 Waist Circumference 
 Waist circumference was measured in accordance with the protocol provided by the 
Canadian Society for Exercise Physiology (CSEP). The participant's abdomen was cleared of all 
clothing and accessories. The participant was positioned with feet shoulder width apart and arms 
crossed over their chest in a relaxed manner. The WC was taken at the top of iliac crest as 
specified by the National Institute of Health (156).  The top of the iliac crest was identified by 
palpating the right hipbone of the participant until the uppermost lateral border was located. A 
horizontal line was drawn at this landmark. An anthropometric tape measure was positioned 
directly around the abdomen with the inferior edge of the tape level with the landmarked point. 
A cross-handed technique was used to bring the zero line of the tape in line with the measuring 
aspect of the tape. The tape was positioned in a horizontal plane around the abdomen with 
enough tension to ensure that it was snug without causing indentation at the skin (Figure 4.2). 
The measurement was taken to the nearest 0.5 cm.  
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4.3.6 Free Androgen Index 
 Participants underwent clinical evaluation before the first diagnostic visit. The measures 
evaluated included serum levels of testosterone and SHBG and were analyzed by the Saskatoon 
Health Region. Blood was collected in a red top glass tube and was centrifuged after a complete 
clot was formed. Total testosterone was measured using the IMMULITE 2000 Systems 
Analyzers (Tarrytown, NY, USA) solid-phase, competitive chemiluminescent enzyme 
immunoassay. SHBG was measured using the IMMULITE 2000 Analyzers solid-phase two-site 
chemiluminescent immunometric assay. The free androgen index (FAI) was calculated by the 
following formula: [(total testosterone/SHBG)*100] (41).  
4.3.7 Body Fat Percent 
 Percent body fat was calculated from measurements with the whole body dual x-ray 
absorptiometry (DEXA) scan before and after the intervention. DEXA technicians used a 
Hologic© Discovery W (Bedford, MA) machine for all scans (99). To prepare for the scan, the 
Figure 4.2. Measurement of waist circumference (a,b). Marking the top of the iliac crest after 
palpation of the top of the right hipbone (a); and, cross-handed technique used to bring the zero line 
of the tape in line with the measuring aspect of the tape using enough tension to ensure it is snug 
without causing indentation of the skin (b). 
a b 
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participant was cleared of anything made of metal and all footwear was removed. The participant 
was placed in a supine position on the DEXA scan table with the centerline marking dividing 
their body in half. The participant's head was placed approximately one inch below the 
horizontal line at the top of the table pad. The participant was positioned with their hands palms 
down and their arms extended beside the body, fingers together, with no limb overlap. The 
participant's feet were angled inwards with great toes touching; masking tape was used to hold 
the feet in position (Figure 4.3). The participant was instructed to not move while the whole body 
scan was in progress.  
 
  
 
 
 
 
 
 
 
 
 The images from the whole body scan was analyzed by the DEXA technician 
immediately using the Hologic© program. The images were sectioned as follows: left arm, right 
arm, neck, L1to L4, pelvic area, left leg, and right leg (Figure 4.4). The Hologic© program 
automatically calculated body fat percentage from the data collected from each (n=20) 
participant.  
Figure 4.3. Photographs illustrating participant placement on the DEXA scan table (a,b). 
Placement of the head approximately one inch below the horizontal line at the top of the table 
pad (a); and, toes were located facing inward (b). 
a b 
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4.4 Pelvic Ultrasound Examination 
4.4.1 Data Collection 
 Transvaginal ultrasonography was used to examine each participant before and after the 
intervention (Ultrasonix RP, 6-9MHz curvilinear array transducer, Burnaby, BC, Canada and GE 
Voluson® 730 Pro, Voluson® Endocavity Transducer RIC5-9-D, Zipf, Austria). The 
Figure 4.4. Whole body DEXA scan sectioned as follows: a) left arm; b) right arm; c) neck/head 
area; d) L1to L4; e) pelvic area; f) left leg; and, g) right leg. 
a b 
c 
d 
e 
f g 
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reproductive organs of all participants were evaluated by two experienced ultrasonographers. 
The ultrasound examinations were conducted on cycle days 1 to 5 for women who had regular 
menstrual cycles. Women with irregular cycles had an ultrasound examination on a random day 
provided all follicles were below 10 mm in diameter (Figure 4.5). For our clinical trial, rigorous 
ultrasonographic criteria were defined as: 1) non-PCO <20 follicle; 2) borderline PCO ≥20<30 
follicles; and, 3) definite PCO ≥30 follicles. The PCO criteria reflected the high resolution 
ultrasound machines and detailed post-hoc analyses (2).  Ovaries were examined in transverse 
and sagittal planes and images were captured as real-time cine-loop recordings and 3-
dimensional images (GE Voluson®).  
 
 
 
 
 
 
 
 
  
 
 
4.4.2 Antral Follicle Counts 
 Digital cine-loop recordings of each ovary were converted into DICOM file format and 
analyzed using Santesoft DICOM editor software (©Emannouil Kanellopoulus, Athens, Greece). 
The cine-loop in the transverse or sagittal plane with the best visual acuity for both the left and 
Figure 4.5. Ultrasound image of a polycystic ovary with characteristic "string of pearls" distribution 
of follicles around the edges of the ovary. 
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the right ovary per participant was chosen for analysis. The cine-loops were analyzed on a frame-
by-frame basis in a single plane. Follicle diameters were measured in the widest plane in order of 
appearance as each frame was examined. (Figure 4.6). Care was taken to ensure that individual 
follicle positions were assessed so that there was no overlap from frame to frame when assessing 
the number follicle in each ovary. Each follicle was measured using the measuring tool found in 
the Santesoft DICOM editor. Measurements were taken in pixel units. 
  
 
 
 
 
 
  
 
 
 
 
 
 
 Follicle positions were illustrated manually on a schematic illustration of an ovary in 
order of appearance (Figure 4.7). Follicle measurements (in pixels) were transferred digitally into 
an Excel spreadsheet (Microsoft Excel, Redmond, Washington).  
Figure 4.6. Ultrasound image of a polycystic ovary demonstrating the use of the measuring tool  
found in Santesoft DICOM editor to measure follicles in their widest planes in pixels. 
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 To convert the follicle size from pixel units into millimeters (mm), the scale bar found on 
the left of the Santesoft DICOM editor was measured in pixels (Figure 4.8).  The scale bar is an 
internal ultrasound reference scale and each notch was equal to 5 mm. The follicle size in pixels 
was converted to mm using the following formula: [follicle width in pixels*(mm length of scale 
bar/pixel length of scale bar)]. 
 
 
 
 
 
 
 
Figure 4.7. Schematic illustration of the follicle measurements in pixel units as drawn from the 
Santesoft DICOM editor. 
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 The number of follicles drawn was transferred to a spreadsheet and counted to determine 
a value for the antral follicle count (AFC) for the left ovaries (LO) and right ovaries (RO) for 
each participant before and after the intervention (RO n=20, LO =17) as per the standard 
operating procedure (SOP) in our laboratories (2). 
 
4.5 Fasting Glucose and Insulin Levels 
 Fasting insulin levels were obtained at the beginning and end of the intervention during 
the fasting oral glucose tolerance tests (OGTT). The subjects were asked to fast for 10 to12 hours 
prior to the OGTT. Fasting blood was collected in a red top glass and a lavender EDTA plastic 
tube by a phlebotomist. The blood was analyzed by the Saskatoon Health Region laboratory 
c 
Figure 4.8. Measurement of the scale bar (left of image surrounded by white box) of the Santesoft 
DICOM editor in pixel units. 
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using the IMMULITE 2000 Systems Analyzers solid-phase enzyme-labelled chemiluminescent 
immunometric assay (n=20). 
4.5.1 HOMA Score 
 The HOMA score was calculated using the following formula: [fasting plasma glucose 
(mmol/L)*fasting serum insulin (pmol/L)/22.5] (77).  
 
4.6 Abdominal Adiposity 
 Abdominal adiposity estimates were derived from a region analysis of the whole body 
DEXA scan. The region of interest (R1) was determined by evaluating the central abdominal 
region between the lateral iliac crests and the lowest rib margins and spanning the area of the 
first and fourth lumbar vertebrae (Figure 4.9) (99). The Hologic© program then automatically 
calculated the amount and percent of abdominal adiposity in R1 using a propietary algorithm 
(n=13). The change in adiposity during the study was derived from adiposity measurements 
taken before and after the intervention. 
 
 
 
 
 
 
 
 
 
 
c 
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4.7 Menstrual History 
 Menstrual histories were taken before and during the intervention. A menstrual cycle was 
defined as the start of one cycle (menses or menstrual bleed) to the start of another cycle.  
Participants were asked to recall their menstrual bleeding patterns 6 months before the 
intervention. The shortest period of time between menses and the longest period of time between 
menses was recorded. Menstrual bleeding was tracked during the intervention by informing the 
research associate about the date on which menses began. The average length between menses 
and the longest length between menses were calculated.  
Figure 4.9. a) Whole body DEXA scan; and, b) R1determined by the area around the midpoint of  
the midline between the lateral iliac crests and the lowest rib margins and spanning the area of the 
first and fourth lumbar vertebrae. 
b a 
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4.8 Statistical Analyses 
 The primary endpoints were the changes in participant weight, BMI, body fat percent, 
AFC, fasting insulin levels, menstrual cyclicity and abdominal adiposity after the intervention. 
Differences between the pulse and the TLC interventions were evaluated for each endpoint.  
 Non-parametric statistical analyses were used due to the small population. The Wilcoxon 
signed-rank tests (for dependent samples) were used to compare weight, BMI, waist 
circumference, body fat percent, AFC, fasting glucose and insulin levels, HOMA score, 
abdominal adiposity, and length between menses of pooled pulse and TLC groups before and 
after the intervention in order to evaluate an effect due to the intervention.  
 To evaluate the effect of a pulse-based diet, the mean difference between the pulse and 
TLC group was calculated by subtracting the measures after the intervention from the measures 
before the intervention. The mean difference, also known as the change variable, was analyzed 
using the NPAR1WAY procedure (for independent samples) to identify differences between the 
pulse and TLC groups. Alpha was set at 0.05. All statistical analyses were conducted using 
Statistical Analysis System (SAS, version 9.2, Cary, NC, 2012). 
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CHAPTER 5 
RESULTS 
 
Out of the 167 women who expressed interest in participating in the study, Eighty five 
women (n=85) were either excluded or decided they were no longer interested in participating 
prior to any diagnostic visits. Fourteen women were excluded based on living outside of the city, 
23 women were no longer interested after reading the consent form, 20 women did not respond 
after initial contact, 7 women wanted to try to conceive immediately, 8 were excluded after they 
were not diagnosed with PCOS, and 6 women were on birth control. The other 21 women that 
were excluded were due to other various reasons. Forty nine women (n=49) completed all of the 
initial measures (diagnostic visit, diagnostic bloodwork, diagnostic ultrasound, OGTT, DEXA, 
and diet instruction) were randomized either into the group receiving the pulse-based diet or into 
a control group following the National Cholesterol Education Program therapeutic lifestyle 
changes diet (TLC). Twenty four women completed the 16 week dietary intervention to date 
(pulse n=13, TLC n=11). Sixteen women dropped out of the study at the intervention phase 
(pulse n=8, TLC n=8). The overall drop-out rate was 33% 
There are different numbers of participants for each of the results due to several reasons: 
data was only available for 7 of the 11 TLC members as we did not obtain all of the data points 
of some of the participants in the beginning of the study. Abdominal adiposity could only be 
evaluated in 19 participants instead of 20 participants as the archived DEXA scans of one of the 
participants could not be located. The number of right ovaries (n=20) was different than the 
number of left ovaries (n=17) due to left ovaries being harder to visualize and subsequently, we 
were unable to do an antral follicle count on left ovaries in all participants. Abdominal adiposity 
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could only be evaluated on 13 of the participants due to the inability to locate older archived 
DEXA scans. 
 
A comparison of anthropometric features at baseline of all study participants in the pulse 
and the TLC group are presented in Table 1. There were no significant differences in 
anthropometric features between the pulse (n=13) and the TLC group participants (n=7) at 
baseline. Participants were similarly matched for age, weight, BMI, WC, and FAI. Body fat 
percentage tended to differ (p=0.09) between the groups. 
 
Table 1. Demographic, anthropometric and androgenic measures at baseline of all participants  
               by study group: pulse and TLC 
 
 
 
Pulse ± SD 
(n=13) 
Range  
TLC ± SD 
(n=7) 
Range p value 
Age 
(years) 
27.4 ± 5.65 19.0 - 36.0 28.3 ± 3.44 24.0 - 33.0 0.25 
Weight 
(kg) 
81.2 ± 15.08 56.3 - 102.8 90.4 ± 18.22 69.0 - 115.0 0.13 
BMI 
(kg/m
2
) 
30.8 ± 6.45 20.7 - 41.6 33.7 ± 6.89 24.2 - 40.3 0.18 
WC 
(cm) 
102.0 ± 22.62 69.1 - 164.4 108.9 ± 16.24 87.8 - 125.0 0.12 
Body Fat 
(%) 
40.8 ± 7.22 25.0 - 51.0 44.4 ± 8.33 30.0 - 54.0 0.09 
FAI 6.8 ± 5.37 1.6 - 16.9 5.4 ± 2.97 2.0 - 10.4 0.94 
.  
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The difference in the anthropometric features of pooled study participants before and 
after the intervention and the difference within the pulse and TLC group is presented in Table 2. 
Weight decreased from 83.0 ± 15.92 kg to 79.3 ± 14.12 kg (p=0.002). Body fat percent also 
decreased from 41.6 ± 7.51% to 39.1 ± 6.53% (p=0.0004).  There were no significant differences 
detected in BMI or waist circumference. There was no significant difference of the pulse-based 
intervention detected on weight (p=0.69), BMI (p=0.87), WC (p=0.56), or body fat percentage 
(p=0.51) compared with the TLC group. 
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Table 2. The effect of the overall intervention and the pulse-based diet on anthropometric features evaluated using the Wilcoxon    
               signed-rank test and NPAR1WAY procedure 
 
 
Mean Pre 
Intervention  
± SD 
Range 
Mean Post 
Interventio
n  
± SD 
Range 
Mean 
Difference 
Between 
Groups  
± SD 
p 
value 
of 
pooled 
groups 
Mean 
Difference 
(Pulse) 
Mean  
Difference 
(TLC) 
SD of  
Mean 
Difference  
p value 
of pulse 
vs. TLC 
group 
Weight  
(kg; n=20) 
83.0  
± 15.92 
56.3  
- 115 
79.3 
 ± 14.12 
55.5  
- 106.0 
3.8  
± 4.44 
0.002 3.5 4.3 12.62 0.69 
BMI  
(kg/m
2
; 
n=20) 
31.4 
 ± 6.48 
20.7 
- 41.6 
31.2  
± 5.55 
21.8  
- 41.7 
0.3 
 ± 3.62 
0.81 0.4 0.1 12.62 0.87 
WC 
 (cm; n=20) 
102.6 
 ± 21.32 
69.1  
- 164.4 
97.3  
± 13.65 
71.4  
- 123.6 
5.2  
± 20.25 
0.23 7.3 1.5 12.62 0.56 
 
Body Fat 
 (%; n=19) 
41.6 
 ± 7.51 
25.0  
- 54.0 
39.1 
 ± 6.53 
24.2  
- 49.3 
2.1 
 ± 2.21 
0.0004 1.9 2.6 11.43 0.51 
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The effect of the overall intervention and the pulse-based diet on study participants on 
AFC in the right ovary and the left ovary, fasting insulin levels and abdominal adiposity are 
presented in Table 3. Antral follicle counts were decreased in the right ovary (p=0.04). Follicle 
number in the right ovary decreased from a count of 43 ± 14.9 follicles to 34 ± 12.9 follicles; 
however, a decrease in AFC was not observed in the left ovary (p=0.11).  The difference 
between an ovary of the same participant before and after the intervention as seen on an 
ultrasound examination is presented in Figure 5.1. Fasting glucose levels did not show a 
significant difference. Fasting insulin levels decreased (p=0.02) in the pooled groups from 89.7 ± 
69.05 pmol/L to 67.9 ± 54.02 pmol/L. The HOMA score also showed a decrease (p=0.02) in the 
pooled groups from 22.7 to 14.9. No change in abdominal adiposity was detected (p=0.88). 
There was no difference detected in AFC in either the right ovary (p=0.46) or the left ovary 
(p=0.40) due to the pulse-based diet. However, there was a tendency toward a change between 
groups in fasting insulin levels (p=0.07) and HOMA score (p=0.08). There was no difference in 
the abdominal adiposity between the groups (p=0.56). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. Ultrasound images of a left ovary in the transverse plane (a,b). Ultrasound image of a 
left ovary in the transverse plane before the intervention (a). Ultrasound image of the same left 
ovary in the transverse plane after the intervention (b). 
 
a b 
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Table 3. The effect of the overall intervention and the pulse-based diet on antral follicle count, fasting glucose and insulin levels,   
HOMA score, and abdominal  adiposity before and after the intervention using the Wilcoxon  signed-rank test and 
NPAR1WAY procedure 
 
 
Mean Pre 
Intervention  
± SD 
Range 
Mean Post 
Intervention  
± SD 
Range 
Mean 
Difference 
± SD 
p 
value 
of  
pooled 
groups 
Mean 
Difference 
(Pulse) 
Mean 
Difference 
(TLC) 
SD of 
 Mean 
Difference 
p 
value 
of 
pulse 
vs. 
TLC  
Antral Follicle 
Count  
(Right Ovary) 
 (n=20) 
43  
± 14.9 
13  
- 76 
34  
± 12.9 
13  
- 66 
9  
± 15.6 
0.04 7 12 12.6 0.45 
Antral Follicle 
Count  
(Left Ovary) 
 (n=17) 
38  
± 14.0 
16  
- 77 
32  
± 14.1 
7  
- 68 
6.5  
± 17.9 
0.11 2 14 9.9 0.21 
Fasting Blood 
Glucose Levels 
(mmol/L, n=20) 
5.2 
± 0.860 
4.0 
- 8.4 
4.87 
± 0.457 
3.8 
- 5.5 
0.4 
± 0.87 
0.09 0.5 0.3 12.6 0.94 
Fasting Insulin 
Levels 
(pmol/L; n=20) 
89.7  
± 69.05 
14.4  
- 268 
67.9 
 ± 54.02 
14.1  
- 224 
21.8 
 ± 53.25 
0.02 37.0 -6.5 12.62 0.07 
HOMA score 
(n=20) 
22.7 
± 22.64 
3.3 
- 100.1 
14.9 
± 12.17 
2.4 
- 49.78 
7.79 
± 18.72 
0.02 12.1 -0.2 12.62 0.08 
 
Abdominal 
Adiposity  
(%; n=13) 
34.7  
± 9.68 
 
22.2  
- 53.1 
33.9  
± 8.25 
 
21.5  
- 49.5 
0.85 
 \± 5.941 
0.88 -0.42 1.65 6.831 0.56 
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The mean length of time and the longest time of time between menses is presented in 
Table 4. The average length of time of menses decreased from 71 ± 82.4 days to 39 ± 15.9 days 
after the intervention (p=0.04). The pattern of change in average lengths of time between menses 
is illustrated in Figure 5.2. The longest length of time between menses decreased from 91 ± 87.6 
days to 43 ± 19.1 days (p=0.01) and is illustrated in Figure 5.3. 
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Table 4. The effect of the lifestyle intervention and the pulse-based diet on average length of time and longest length of time between     
               menstrual cycles using the Wilcoxon signed-rank test and NPAR1WAY procedure 
 
 
Mean Pre 
Intervention  
± SD 
Range 
Mean Post 
Intervention  
± SD 
Range 
p value 
of  pooled 
groups 
Mean 
Difference 
(Pulse) 
Mean 
Difference 
(TLC) 
SD of 
 Mean 
Difference 
p value 
of pulse 
vs. TLC 
group 
Mean 
Length Between 
Menses  
(days, n=16) 
 
71 
 ± 82.4 
29-365 
34  
± 12.9 
29-365 0.04 -11 -109 8.2 0.32 
Longest Length 
Between Menses  
(days; n=16) 
91 
 ± 87.6 
27-85 
32  
± 14.1 
28-90 0.01 -28 -20 6.9 0.48 
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Figure 5.2. Comparison of mean intervals between menses in pooled study participants before 
and after the intervention. Data were analyzed using the Wilcoxon signed-rank test. 
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Figure 5.3. Comparison of longest intervals between menses in pooled study participants before 
and after the intervention. Data were analyzed using the Wilcoxon signed-rank test. 
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CHAPTER 6 
DISCUSSION 
 
6.1 General Discussion 
 Our objectives were to evaluate the effect of a pulse-based diet and exercise lifestyle 
intervention in women with PCOS. Women with PCOS are prone to insulin resistance (IR) and 
subsequent hyperinsulinemia which affects lipid metabolism, and androgen production. A 
subgroup of women with PCOS who have IR also go on to develop insufficient pancreatic β-cell 
failure resulting in hyperglycaemia and Type 2 diabetes mellitus (15).   
 We theorized that the diet and exercise intervention would result in a decrease of several 
attributes of the body composition of our participants. Specifically, we thought that weight, BMI, 
waist circumference, body fat percent, antral follicle count, fasting glucose insulin levels, 
HOMA score, abdominal adiposity and length between menstrual bleeds would be reduced on 
the pulse diet. Our hypothesis was supported with regards to fasting insulin levels and HOMA 
score. Although we observed a significant decrease in weight, body fat percent, AFC in the right 
ovary, fasting insulin levels, HOMA score, and a significant decrease in time between menses 
due to the lifestyle intervention, it was not due solely to the pulse-based diet. The participants' 
BMI, WC, AFC in the left ovary, and abdominal adiposity were not affected. 
 The results generated in the present study are consistent with the data found in previous 
combined dietary and exercise lifestyle interventions. The intervention in the present study did 
not encompass any calorie restriction but encouraged a low-GI diet. The majority of protein, 
carbohydrates and protein in the pulse arm came from pulse sources (chickpeas, peas, beans and 
lentils) and the TLC diet followed the National Cholesterol Education Program. Pulses, such as 
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chickpeas, split peas, beans, and lentils are a form of a slower absorption carbohydrate that 
contributes to a lower glycemic index (GI) diet.  It follows that pulses thereby help to prevent the 
onset and the impact of Type 2 diabetes mellitus (151).  Marsh et al. (157) conducted a 12 month 
study looking at the effects of a low-GI diet as opposed to a high-fiber, high-GI diet in 
overweight and obese women with PCOS. They reported that women who were randomized to 
the low-GI diet arm had 3-fold greater improvement in whole-body insulin sensitivity as 
measured from responses to the oral glucose tolerance test. In addition, a larger proportion of 
women following the low-GI diet reported increased menstrual regularity. Both of these results 
are consistent with what we have observed in our intervention. 
 Numerous diet and exercise lifestyle interventions have been shown to have positive 
effects in terms of clinical and metabolic parameters in women with PCOS. Exercise 
interventions have reduced IR, improved body composition measures (such as weight, BMI, and 
WC), and increased menstrual cyclicity and ovulation. Combined dietary and exercise lifestyle 
interventions have been shown to improve anthropometric measurements, especially weight loss 
in addition to reduced IR and increased reproductive function (158). A recent systematic review 
and meta-analysis has demonstrated that lifestyle modifications in women with PCOS have been 
shown to have a small but significant effect on glucose and insulin blood levels. In addition, 
weight loss in the PCOS population was significantly and directly correlated with improvements 
in metabolic parameters, such as reduced IR (159).  
 It could be speculated that an intervention based purely on exercise would show a greater 
change in physical aspects such as WC and BMI. Women having a calorie restricted diet would 
be expected to have more of an effect on all anthropometric features. Since our study 
encompassed a change in diet with no calorie restriction in addition to exercise, it was reasonable 
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to expect a modest amount of weight loss and subsequent resumption in menstrual cyclicity (5). 
It would also be reasonable to expect changes in insulin levels due to the consumption of a lower 
glycemic diet coupled with nutrition and health education in the PCOS population. Our 
participants exhibited significant decreases in weight, fasting insulin levels, and length in 
between menstrual cycles.  
 One diagnostic criterion for PCOS is polycystic ovaries on ultrasound examination. 
Polycystic ovaries contain more than 12 follicles measuring 2 to 9 mm following a characteristic 
peripheral ‘string of pearls’ distribution or a volume of >10mL as defined by the Rotterdam 
consensus in 2003. Dewailly et al. (49) and Lujan et al. (2) suggested increasing the threshold for 
the diagnostic criteria for PCO because newer ultrasound technologies and detailed post-hoc 
analyses of ultrasound images resulted in artificial inflation of women with PCOS using only the 
follicle numbers used in the Rotterdam consensus. Therefore, we used the diagnostic criteria of 
over 25 follicles to diagnose a polycystic ovary. We speculated that the intervention would create 
metabolic changes that were reflected in a decrease in follicle population. 
 We observed that antral follicle counts were significantly decreased in the right ovaries of 
the participants but not in the left ovaries. No difference in follicle number was detected between 
the pulse and TLC groups. Therefore, follicle numbers from the pulse and TLC groups were 
pooled to discern any trends in follicle number before and after the intervention. In the right 
ovary, 20 ovaries were able to be evaluated. During the study, it became apparent that the body 
size of some of the participants made the left ovaries difficult to examine. We were unable to 
demonstrate a decline in antral follicle count in the left ovaries of participants even though a 
trend of decreased follicle numbers was observed (38 to 32 follicles). It is possible that by 
increasing the participant number we may find a decline in follicle number following changes in 
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diet and exercise. The reduction in follicle number over the intervention was indicative of a short 
term effect of diet and exercise changes in women with PCOS. It could be expected that follicle 
reductions would be observed in a greater capacity over an intervention that spanned a longer 
period of time or during follow-up appointments in participants who continued to follow diet and 
exercise modifications. 
 We were unable to locate any published research focused on the AFC of women with 
PCOS before and after a diet and/or exercise intervention. Most research trials were focused on 
resumption of ovulation implied by the onset of regular menses. It is difficult to say whether a 
reduction in the number of follicles detected in the ovary is a beneficial measure in women with 
PCOS. Follicle number on its own is not an indicative measure of reproductive health in women 
with PCOS. A participant with PCOS could demonstrate no change in follicle number after the 
intervention but could have started ovulating. Perhaps we should have focused on detecting 
improvements in the health of the follicles and the resumption of ovulation in addition to follicle 
number to gain a better understanding of the impact of diet and exercise changes in reproductive 
health measures in women with PCOS. However, we speculated that a reduction in follicle 
number may indicate that a smaller number of follicles remained in a static state. Typically, 
follicles that remain in a static state are induced by increased ovarian androgens (32). A 
decreased AFC could possibly be associated with decreasing ovarian hyperandrogenism, an 
improvement in the metabolic state of an individual (decreasing hyperinsulinemic environment) 
and a better follicular response to gonadotropins (39).  
The decreasing hyperinsulinemic environment seen post intervention may have been a 
result of a significant decrease in fasting insulin levels. There was also a tendency toward a 
change in insulin levels between the pulse and TLC group. This observation has been consistent 
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with previous findings in a variety of lifestyle intervention studies with PCOS. Insulin acts to 
regulate glucose homeostasis by stimulating glucose uptake in target tissues. Insulin also 
suppresses hepatic glucose production and lipolysis. Women with PCOS often present with 
higher than normal fasting insulin levels and IR.  
We also observed a decrease in the HOMA score of participants before and after the 
intervention, with a tendency toward a difference due to the pulse based diet. It should be noted 
that our population was very insulin resistance with a mean HOMA score of 22.7 before the 
intervention and a mean HOMA score of 14.9 after the intervention. Clinically, the cut off for IR 
is 2.6 (78). Insulin resistance is often associated with increased fat storage, decreased fat 
breakdown and an increase in LH mediated androgen production in women with PCOS. 
Therefore, decreasing insulin levels and subsequently, insulin resistance in the PCOS population 
holds a variety of health benefits. A decrease in fasting insulin levels is related to decreasing the 
acquisition and impact of hyperinsulinemia and T2DM (83). Decreasing insulin resistance is 
highly associated with gaining reproductive function through decreasing androgens and 
improving the ovarian hormonal environment allowing maturation of follicles (90).   
 We did not detect a significant change in abdominal adiposity although a reduction in 
fasting insulin levels was observed post intervention. Abdominal adiposity was measured using 
whole body DEXA scanning. The most accurate technique for measuring abdominal adipose 
tissue in vivo is computed tomography (CT). CT scanning was not readily available because of 
its cost, limited access to equipment, and exposure to ionizing radiation that was not clinically 
justified. The DEXA method relies on the differential absorption of x-rays to distinguish 
different body tissues with minimal exposure to radiation and allows the direct measure of the 
quantity of fat present in different body regions can be obtained from DEXA imaging. DEXA 
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scanning is a comparable and validated substitute to CT scanning and is sensitive to small 
changes in body composition (98, 99).  We used DEXA scanning to measure abdominal 
adiposity before and after the intervention.  
 Abdominal adiposity is usually elevated in women with PCOS and affects between 50% 
to 60% of women with PCOS, despite matching for age and BMI (95). The development of 
abdominal adiposity in women with PCOS is multifactorial. There is a genetic basis for the 
increased abdominal adiposity with the most likely candidates being the genes involved in the 
regulation of ovarian steroidogenesis, BMI, and adiposity in addition to the effect of 
hyperandrogenism on the adipocyte. These factors may be exacerbated by an obesogenic 
environment (poor diet and exercise). Abdominal adiposity is often associated with IR. 
Hyperinsulinemia occurs as a consequence of IR and contributes to androgen excess. Visceral 
adiposity develops as a result of a hyperinsulinemic environment and hyperinsulinemia induce 
additional hyperinsulinemia and increased IR. Visceral adipose tissue may also contribute to 
hyperandrogenism using mechanisms independent from IR via secretion of inflammatory factors, 
adipokines, and local metabolism of sex steroids (83).   
 Abdominal adiposity as determined by DEXA is highly correlated with waist 
circumference. Women with PCOS often have a higher WC in parallel with higher abdominal 
adiposity. We did not observe a significant decrease in WC which was consistent with the 
abdominal adiposity measured obtained. It could be speculated the lack of caloric restriction in 
our diet and exercise intervention contributed to no decline in stationary WC. An exercise based 
intervention would be expected to have a greater effect on body composition and induce a 
decrease in WC and abominal adiposity. A hypocaloric diet intervention would be expected to 
result in a decreased body weight and BMI (116).  Prior investigations have demonstrated that 
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there are a variety of ways to improve insulin resistance to alter a hyperinsulinemic and 
hyperandrogenic profile can be applied to women with PCOS. A decrease in abdominal adiposity 
(and WC) is important for women with PCOS because it is correlated with decreasing IR and 
visceral adiposity (134). 
  
 Menses can be used as an external sign to mark an increase in fertility in addition to 
decreasing the risk of uterine cancer in this population (126). Resumption of cyclic menstrual 
bleeding patterns and possibly ovulation typically follows even a modest loss of weight 
(approximately 5%  to 10%) (8). These findings are consistent with our results. We observed a 
decrease in the average length between menses as well as a decrease in the longest length 
between menstrual cycles after the intervention. Clinically, menstrual cycles are classified as 
regular (bleeding every 21 to 35 days) and irregular (bleeding >35 days). Regular menstrual 
bleeds demonstrate a cyclic pattern whereas irregular cycles are anovulatory and demonstrate no 
cyclicity. In most women, a decreased interval between bleeds translated into the resumption of 
menstrual cyclicity. Over duration of the intervention, we noticed a pattern of resumption of 
menstrual cycles that were not classified as regular but did have a cyclic pattern (33 to 50 days).  
This prolonged cycle pattern is not referenced in literature but can be observed clinically in 
participants with PCOS who undergo diet and exercise changes for when attempting to 
ameliorate infertility.  The cyclic pattern indicates that ovulatory incidences probably occur with 
a possibly elongated follicular phase compared to previously longer intermenstrual intervals with 
no discernable pattern. Follow up studies in women with PCOS should be conducted to 
determine the length of the follicular phase and the incidence of ovulation post intervention. 
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 Resumption of menstrual cyclicity could be used as a positive marker of the benefit of 
lifestyle interventions in conjunction with decreasing AFC. Even though AFC and menstrual 
cyclicity are related measures, they may also be used to infer different factors in the fertility and 
metabolic parameters in women with PCOS. It is difficult to ascertain whether reduction in 
follicle number alone is indicative of women with PCOS benefiting from diet and exercise 
interventions. Decreasing AFC is correlated with decreasing ovarian hyperandrogenism and a 
better follicular response to gonadotropins (97). Folliculogenesis is highly dependent on ovarian 
paracrine factors; only the last two weeks of antral follicle growth are dependent on circulating 
gonadotropins (26). Reduction in follicle number can then be attributed to a reduction in local 
ovarian hyperandrogenism and possibly a local reduction of a hyperinsulinemic environment. 
The local reduction coupled with a systemic reduction in insulin levels and correlated IR could 
synergistically lead to an increase in menstrual cyclicity without necessarily having a significant 
reduction in PCO morphology. 
 
6.2 Study Limitations 
 There were several limitations encountered by the research team during the trial. Long-
term adoption of diet and lifestyle modifications have been difficult to attain and proven efficacy 
of long term changes has not been realized. One of the most difficult aspects of diet and lifestyle 
interventions, especially in the PCOS population, is the high rate of non-compliance and dropout 
in lifestyle interventions.  Our drop-out rate of 33% was consistent with previous studies 
conducted in women with PCOS and limited our observations to a small participant number 
(158). Although 49 women with PCOS were randomized into our intervention, only 25 women 
completed the intervention. Only 20 of the 25 women could be adequately examined 
ultrasonographically to evaluate for a change in AFC before and after the intervention. The 
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ovaries could not be visualized clearly for AFC analysis because of abdominal adiposity, 
therefore there were fewer results for the study. A greater number of participants are needed to 
provide statistical power. Numerous investigations have recommended diet and lifestyle 
modifications to women with PCOS.    
 We found that consumption of the pulse diet was difficult for most participants as pulses 
were not part of their past diet. The accommodation to the pulse diet took some time. Frequent 
complaints about the pulse-based dietary intervention included poor flavour and texture (bland, 
unusual spices, lack of meat flavours), excess food volume and adverse gastrointestinal effects 
associated with the consumption (i.e., gas, nausea, fullness).  Compliance with the study protocol 
was also affected by social factors, such as eating different foods at family meals, in restaurants, 
and during holidays.  Exercise compliance was difficult to attain for most participants in the 
program. The recommended exercise (3 to 5 times a week) was difficult for many participants to 
achieve. Reasons for non-compliance in exercise included having a previously sedentary lifestyle 
(no gradual shift from nothing to full compliance) and issues with time (i.e., not being able to go 
to the gym because of night shift hours, family commitments and gym hours).  We could not 
determine specific numbers for exercise compliance at this point in time in the intervention. 
 The blood samples taken during the intervention were analyzed in the clinical laboratory 
of the health region. Because of the expense involved with the analyses, we were limited to 
accepting a wider standard error that exists in health laboratories that analyze samples without a 
single control. There may be a benefit to re-analyze certain blood samples using assay techniques 
with standard controls used in research to generate increasingly precise metabolic and hormonal 
profiles to gain more accurate results for with more sensitive assays. 
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6.3 Future Directions and Clinical Applications 
 The preliminary results of participants who had finished the study are promising. The 
results are consistent with previous lifestyle intervention studies conducted in women with PCOS 
especially in terms of anthropometric features, menstrual cyclicity and fasting insulin levels. A 
logical next step would be to assess the impact of the intervention on other metabolic parameters, 
such as lipid profiles, HbA1c, and changes in markers of inflammation such as C-reactive protein 
(CRP). An decrease in the HDL:LDL ratio may indicate positive impact of the intervention on 
lipid levels and decreased risk of cardiovascular disease.  Glycated hemoglobin (HbA1c) is 
measured to identify the average plasma glucose concentration over a prolonged period of time. 
A small decrease in HbA1c levels, coupled with decrease in fasting insulin levels, would 
strongly support a positive benefit of the intervention in long term glucose in women who do not 
have diabetes. A decrease in CRP would indicate decreased systemic inflammation which would 
be a positive effect of the intervention. 
 Behavioral data of the participants before and after the intervention have been collected 
and are available for further analysis using an online survey as part of the larger study. It will be 
valuable to assess education, knowledge, and attitudes in women with PCOS toward various 
aspects of PCOS before and after the intervention. Topics of interest including fertility, diabetes, 
body image, nutrition, and exercise will provide an insight into the psychological disposition of 
women with PCOS and the impact and benefit of education about PCOS on participants' overall 
well-being. In addition, accelerometer data has been collected to document participants' activity 
levels before and after the intervention, which will provide good insight into long-term 
acquisition and retention of activity (5). Six and 12 month follow-ups are ongoing to assess the 
long-term sustainability of the diet and exercise lifestyle intervention study. It is important to 
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assess how well changes in diet and exercise can be maintained in women with PCOS as it is a 
lifestyle change that is necessary to prevent future health problems such as Type 2 diabetes 
mellitus and metabolic syndrome in the PCOS population. 
 
6.4 General Conclusions 
 Polycystic ovary syndrome has a large heterogeneity in presentation and is one of the 
most common endocrine disorders occurring in women of a reproductive age. PCOS affects 
about 6% to 7% of the population (1). Women with PCOS are predisposed to developing obesity, 
Type 2 diabetes mellitus, cardiovascular disease, and uterine cancer and also report a decreased 
quality of life (15).   
 In the present study, we have learned that consuming food of a lower glycemic index  
(pulse crops) without a calorie restriction shows promise in helping women with PCOS gain 
healthier anthropometric profiles, decrease serum insulin levels and insulin resistance and 
increase their menstrual cyclicity. Arguably, early intervention by a multidiscplinary team of 
dieticians, exercise physiologists, and gynecologists would benefit women with PCOS and 
alleviate many of the physiologic and health concerns with PCOS.  
 Further study involving weight reduction and dietary intervention with pulse crops 
included as part of a regular diet may prove to be more successful than calorie reduction alone. 
Additional work regarding attitudes toward dietary interventions is needed to address how 
women with PCOS can include pulses in a diet that has been generally devoid of pulses. Pulse 
crops are a sustainable food resource that contain high levels of proteins and a slow absorbing 
carbohydrate component that lowers the GI of a diet. The acceptance of pulses is imperative to 
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mediate positive health benefits in a long-term capacity with the increasing rise of T2DM, 
especially in the PCOS population. 
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 BACKGROUND 
 
Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders in women 
of reproductive age, affecting approximately 105 million women worldwide (Azziz, 2005) and 
an estimated 1.4 million women in Canada (Lujan et al, 2008). Women with the syndrome 
present with several clinical signs, which include menstrual and ovulatory dysfunction, 
hyperandrogenemia (excess male sex hormones), hirsutism (male-pattern hair growth in women 
e.g. facial, chest, abdominal hair), polycystic ovaries, insulin resistance, and hyperinsulinism 
(Azziz et al., 2009). A diagnosis of PCOS is accompanied with an increased risk of severe and 
devastating consequences such as infertility, dysfunctional uterine bleeding, endometrial 
carcinoma, obesity, type 2 diabetes mellitus, dyslipidemia (alterations in blood lipids), 
hypertension, and possibly cardiovascular disease (Azziz, et al., 2009; Ehrmann, 2005; Liepa, 
2008; Lujan et al, 2008). 
 
The pathogenesis of PCOS is not fully understood; however, insulin resistance and associated 
hyperinsulinemia are believed to be the key contributing factors (Douglas, 2006; Moran & 
Norman, 2004). Insulin resistance and the subsequent production of excessive amounts of insulin 
are directly associated with the increased ovarian production of androgens. Increased androgen 
levels impede ovarian follicle growth, inhibit ovulation and normal menstruation, lead to the 
polycystic ovarian morphology, and generate male pattern hair growth seen in PCOS (Blank, 
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McCartney, & Marshall, 2006). Between 50% to 70% of women with PCOS exhibit insulin 
resistance..  
 
Metabolic complications of insulin resistance are higher among women with PCOS than the 
general population and include the development of dyslipidemia (i.e. increased cholesterol 
levels), type 2 diabetes mellitus, metabolic syndrome  and increased risk for cardiovascular 
disease (Azziz et al., 2009; Ehrmann, 2005) (Apridonidze, Essah, Iuorno, & Nestler, 2005).. 
Metabolic syndrome is a clinical diagnosis for individuals who exhibit insulin resistance, 
hypertension, abnormal serum lipid levels (i.e. high triglycerides and low high-density 
lipoproteins) and abdominal obesity (Liepa, 2008). Serum androgen levels are higher in women 
with PCOS who develop the metabolic syndrome when compared with absence of metabolic 
syndrome.  Women with PCOS who are obese present with greater insulin resistance / 
hyperinsulinemia, anovulation, abnormal uterine bleeding and tend to be at greater risk for early 
development of  metabolic and neoplastic complications (Lau, 2007). Many of the medical 
therapies for PCOS are less effective in women who are obese (Palomba, 2008). 
 
Lifestyle modifications directed at reducing insulin resistance, including diet and exercise, are 
essential for effective management of PCOS. Little is known about the insulin lowering effect on 
the polycystic ovarian morphology. Most therapies are directed at short-term goals, to induce 
ovulation and restore fertility or to ameliorate hirsutism or abnormal bleeding. Exercise and 
dietary lifestyle changes are recommended as the first line of therapy to restore ovulation. 
Because lifestyle changes are often difficult to achieve, medical therapy is used to induce 
ovulation. Long term therapeutic management needs to be implemented to control obesity, 
hirsutism, irregular menstruation and infertility and to prevent metabolic syndrome, diabetes, 
heart disease and cancer that afflict this vulnerable group of women (Marsh, 2005).  
 
The proposed study will examine a pulse-based diet as a nutrition intervention for the PCOS 
population. The rationale for this intervention is supported by the association of pulse-based diets 
with improved glycemic control (Sievenpiper et al. 2009). The use of a pulse-base diet is further 
supported by data originating from our research group which has shown positive effects of 
including pulses in the diet of individuals at risk for metabolic syndrome.  
 
 
 PURPOSE 
 
The purpose of this study is to evaluate a lifestyle intervention for women with PCOS. 
 
 
OBJECTIVES 
 
There are five main objectives of the proposed study:  
 
1. To characterize the lifestyles (i.e. diet including pulse consumption and exercise), quality of 
life, other health indicators for risk of disease (e.g. blood parameters, anthropometry, body 
composition) menstrual history and fertility in a large sample (n>150) of women with PCOS 
(from baseline measures) 
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2. To determine the short-term therapeutic effects of a pulse-based diet on multiple disease 
measures of PCOS, metabolic syndrome, and quality of life after 16 weeks. 
3. To determine the long-term therapeutic effects of a pulse-based diet on the multiple disease 
measures of PCOS, metabolic syndrome, and quality of life after the 16 week therapeutic 
intervention through follow-up measurements of the participants (at 6 months and 12 months 
post-intervention) 
4. To measure the rate of long-term adoption of a pulse-based diet during the 6-12 months 
following the lifestyle intervention. 
5. To measure the effect of a pulse-based diet intervention on participants’ consumption of 
pulse foods after completion of the intervention diet. 
 
 HYPOTHESES 
 
1. Introduction of a pulse-based diet for 16 weeks will reduce hyperinsulinemia and 
improve other markers of the metabolic syndrome (i.e. reduce glucose, triglycerides, 
blood pressure, abdominal fat, and increase HDL); and therefore reduce the disease 
measures, symptoms of PCOS (i.e., increased number of ovarian follicles, increase levels 
of estradiol and progesterone and decrease androgens). 
2.  Women with PCOS who are given a 16 week pulse-based diet will continue practicing 
the consumption of pulses for 6 and 12 months after the intervention and this will 
continue to improve their resting insulin levels, markers of metabolic syndrome, and 
symptoms of PCOS. 
3. The pulse-based diet will increase the quality of life of women with PCOS. 
 
 
 DESIGN 
 
8.1 See Appendix A Research Participant Information Sheet and Consent Form and   
            Appendix B for the Researcher’s Summary Form. 
 
8.2 The study is a single-blind parallel stratified-randomized design. Randomization will be  
            stratified based on medication use (i.e. medications for PCOS symptoms, glucose control,    
            lipid-lowering, or hypertension and those who are not taking medications). 
 
 8.2.1. Participants will be randomly assigned to one of two diet programs:  
     1) Participants in Program 1 will receive the placebo diet (n= 84) 
     2) Participants in Program 2 will receive the pulse-based diet (n= 84). 
 
 8.2.2. All participants will also receive supervised aerobic exercise training to provide           
           recommended standard of care and to reduce variability in this lifestyle factor between     
           participants. To control for diet variability, all participants will be instructed to follow the     
           dietary recommendations of the Therapeutic Lifestyle Changes (TLC) guidelines              
          developed by the National Cholesterol Education Program (NCEP) Expert Panel on    
 
       Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment     
       Panel III, 2002).  
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Table 1: TLC Guidelines: Recommended Nutrient Composition 
Saturated fat less than 7% of total calories 
Trans fatty acids are another LDL-raising fat that should be kept at a low intake. 
Polyunsaturated fat up to 10% of total calories 
Monounsaturated fat up to 20% of total calories 
Total fat 25-35% of total calories 
Carbohydrate 50-60% of total calories (carbohydrate should be derived predominantly from 
foods rich in complex carbohydrates including grains, especially whole grains, fruits, and 
vegetables) 
Fibre 20-30 g/day 
Protein approximately 15% of total calories 
 
 
DIET PROGRAMS 
 
* A separate manual exists for specific dietary guidelines* 
 
9.1 Program 1: Placebo Diet 
 
9.1.1 Participants assigned to Program 1 (placebo) will be asked to follow the Therapeutic 
Lifestyle Changes (TLC) diet. Participants will be asked to attend a 90-minute long diet 
education session, where a Registered Dietitian will explain the TLC guidelines.  
 
9.1.2 The first two weeks of the program are referred to as the “lead-in period” (the period of 
time where all participants will follow the TLC diet). Following the “lead-in period” 
participants in Program 1 will be asked to continue the TLC diet for 16 weeks. Two meals 
will be supplied daily for 16 weeks to those participants in the placebo group. Meals will 
follow TLC guidelines and will be based on lean-meats for the protein source. The meals 
will exclude pulses.  
         
9.2 Program 2: Pulse-Based Diet 
Participants assigned to Program 2 will be asked follow the TLC diet and will receive a pulse-
based diet. Participants will be asked to attend a 90-minute long education session, where a 
Registered Dietitian  (RD) will explain the TLC diet guidelines. Participants will follow the TLC 
diet during the lead-in period and will be asked to follow the TLC diet for 16 months in addition 
to consuming a pulse-based diet. The pulse based-diet will include meals prepared with dry peas, 
lentils, chickpeas, and beans. Two meals will be supplied daily for 16 weeks to those participants 
on the pulse-based diet program. Meals will contain approximately 90 g dried green peas, 225 g 
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chickpeas or fava beans, or 150 g lentils. The length of this intervention was based on a review 
of pulse-based diets that improve insulin and glucose levels (Sievenpiper et al., 2009).  
 
 
EXERCISE PROGRAM 
 
All participants (Program 1 and Program 2) will follow an exercise program for the 16 weeks of 
the study. The exercise program involves 5 sessions of aerobic exercise per week: 3 sessions of 
supervised exercise training and 2 sessions of unsupervised at-home exercise. The supervised 
exercise training will occur in the College of Kinesiology at the Williams Building (treadmill 
walking, exercising on a rowing machine, elliptical trainer, or exercise bike). Each exercise 
session will be 45 minutes long. This amount of aerobic exercise is the minimal level of exercise 
shown to be beneficial for increasing high-density lipoproteins and lowering triglyceride levels 
(Durstine, 2002). We also have an exercise training laboratory that is fully equipped with all the 
required exercise machines and reserved exclusively for research participants. Participants will 
be encouraged to exercise at an intensity of at least 60% of their age-predicted maximal heart 
rate (i.e. 220-age).  
 
 
SELECTION AND WITHDRAWAL OF PARTICIPANTS 
 
11.1 Inclusion Criteria 
Women between the ages of 18-35 years  who have  a diagnosis of PCOS. To daignoseFor a 
diagnosis of PCOS, two of three criteria must be present:  
1) irregular or absent menstrual cycles,  
2) high blood level of male hormone or male pattern hair growth, and  
3) polycystic ovaries (enlarged ovaries with multiple small follicles (egg sacs) in the 
ovary) confirmed by transvaginal ultrasound examination. 
 
11.2 Exclusion Criteria 
Women are excluded from the study if they: 
11.2.1  Are using hormonal birth control or fertility medications, antiseizure or antipsychotic 
medications known to induce the development of polycystic ovaries or 
hyperprolactinemia 
11.2.2  Have a medical condition that limit their ability to exercise to 60% of their maximal heart 
rate 
11.2.3  Cannot consume a pulse-based diet (allergies or intolerances).  
11.3.4  Hhave an uncontrolled medical condition that interferes with ovarian or systemic 
hormone production  
 
11.3 Participant Withdrawal Criteria 
11.3.1 A participant who develops any of the above exclusion criteria will be withdrawn  from 
the study by the principal investigator. 
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11.3.2  If an adverse event involving a participant is mild or moderate, the participant will still be 
allowed to continue in the program if there is no contraindication following medical 
assessment. but may also withdraw if she chooses.  
11.3.3  See Appendix C for Adverse Events Forms. 
11.3.4  Withdrawn participants are not to be replaced. 
 
11.4 Discontinuation Criteria for Individual Participants and for the Trial 
Because we are including an “intent-to-treat” analysis, participants who are not compliant with 
the pulse diet or exercise training will not be excluded from analysis. 
 
 
SAMPLE SIZE 
 
12.1 A recruitment target of 166 women (n=83 per group). However, to facilitate randomization, 
a new recruitment goal of 168 has been established (n=84 per group). 
 
12.2 Participants will be staggered into the intervention over a year so that an equal number of 
participants are assessed across the different seasons (winter, spring, summer, and fall). This 
is to account for the known seasonal variation in blood lipid variables (Ockene et al., 2004). 
Every three months for a year, 42 women (21 for each Program 1 and 2) will enter the study 
(8 groups of 21 women) for a total of 168 women.  See Table 2.  
 
 
12.3 Table 2: Study Groups 
 
 Placebo Diet Pulse-Based Diet 
Season 1 21 21 
Season 2 21 21 
Season 3 21 21 
Season 4 21 21 
 
12.4 The sample size calculation was based on the measurement of fasting insulin levels. A 
recent meta-analysis conducted by Sievenpiper et al. (2009) showed an effect size for pulse 
diets on insulin as -0.49. Women with PCOS have a fasting insulin level of approximately15 
uU/mL and a SD of 9 uU/mL (Macut et al. 2008; Glueck et al. 2009). An effect size of -0.49 
with a pulse-based diet would result in end-of-treatment insulin level of about 10 uU/mL. 
To achieve a power of 80% and alpha of 0.05, 66 participants per group are required. This is 
a long-term study; therefore, we anticipate that there may be participant drop-outs. 
 
12.5In previous studies by the researchers, a drop-out rate of __% has been noted in addition      
      to participants not completing all elements of the study. To account for this we are enrolling    
     84 participants per group to achieve at least 66 participants for analysis. 
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RECRUITMENT  
 
13.1 Status of Clinical Trial 
        When recruitment officially begins, the kinesiology RAs  will contact Lindsay Tumback to     
        update the status of the trial to “recruiting” on ClinicalTrials.gov. 
 
13.2 Methods of Recruitment 
 
13.2.1 Women will be recruited through posters and online advertisements (e.g. PAWS), Kijiji, 
throughout the University of Saskatchewan, SIAST, physician offices, health care 
establishments, and advertisements in local newspapers. First, inexpensive forms of 
advertizing will be used (e.g. posters, online). If deemed necessary, Dr. Chilibeck will 
arrange for the advertisement to be posted in the newspapers. 
 
13.2.2  See Appendix D for the recruitment poster. Smaller pieces of paper with the study name 
and contact information should be printed to accompany the posters (for interested 
women to take home with them). The kinesiology RAs will speak to Dr. Chizen and Dr. 
Pierson regarding where to display the posters (based on their experience with previous 
PCOS studies). 
 
13.3 Inquiries from Interested Women 
 
13.3.1  Kinesiology RAs will be answering inquiries from women who respond to the 
advertisements. The kinesiology RAs will provide general information regarding the 
study and will go over the Inclusion and Exclusion Checklist (Appendix E). The 
Inclusion and Exclusion Checklist will determine if the women might possibly have 
PCOS. The kinesiology RA will explain that the diagnosis of PCOS will need to be 
confirmed by a medical appointment with Dr. Chizen. 
 
13.3.2 If eligible to participate, a copy of the consent form will be forwarded to the potential 
volunteer by email or Canada Post mail. The volunteer will meet with a Kinesiology RA 
or with Dr Chizen, Dr Pierson or Shanni Serrao to review and sign the consent form. 
 
13.4 Booking Medical Evaluation 
13.4.1 Once consent has been obtained, the kinesiology RAs will: 
-assign a participant code 
-schedule each potential recruit to attend a medical evaluation with Dr. Chizen during a 
PCOS Research Clinic time to confirm the presence of PCOS. (See 14.1 below) 
 
13.4.2 To schedule the appointment with Dr. Chizen, the kinesiology RA’s will contact Shanni 
Serrao at the.Women’s Health Imaging Research Laboratory (WHIRL); alternately, 
contact Ms Heather Schultz, Dr. Chizen’s office assistant 
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 PCOS RESEARCH CLINIC TIMES AND ENROLMENT 
 
14.1 Establishing the PCOS Clinic Times 
14.1.1 As of March 2011 Dr Chizen will make time available on Thursday all day and Tuesday  
before 1030 am; alternately Friday afternoon after am appointment and ultrasound 
appointments. 
 
14.1.2 Shani Serrao (966 7873- Women’s Health Imaging Reproductive Laboratory (WHIRL) 
grad office) will coordinate appointment scheduling with Dr Chizen;  
 
14.1.3 Alternately, Dr Chizen’s office assistant, Heather Schultz will arrange appointments (966 
8623).  
 
14.1.4 If alternate clinic appointment times are needed, appointment times will be arranged in  
            consultation with Dr Chizen. 
 
14.2 Researchers Present for PCOS Clinic Times 
Dr Chizen and  Shani Serrao. Dr Pierson may also perform ultrasound examinations. 
 
14.3 Initial Appointment 
14.3.1 Dr. Chizen will complete a Medical Assessment Form (Appendix F).   
 
14.3.2 Dr Chizen will perform a transvaginal ultrasound examination. Following appropriate  
            training, Shani Serrao may perform the transvaginal ultrasound examination. 
 
14.3.3 Dr. Chizen will provide a requisition for screening blood work if a preliminary diagnosis 
of PCOS is made 
 
14.3.4 The potential recruit may attend any SHR lab for the screening bloodwork 
 
 
14.4 Follow-up Appointment 
 
14.4.1  Scheduling the Follow-Up Appointment 
 
14.4.1.1 All women who attend the initial appointment will receive a call from Dr. Chizen’s 
office (Shani Serrao) when their blood analysis results are available to schedule a 
follow-up appointment. (Alternately, Heather Schultz may schedule an appointment). 
      14.4.1.1.1        The follow-up appointment will be booked between day 1-5 of menses for women    
                               with regular cycles. 
  
14.4.1.1.2  The follow-up appointment may be booked without regard to a menstrual cycle 
dates for women who have unpredictable menstrual cycles. 
   
14.4.1.1.3 This appointment will occur during the 2 week lead-in period.  
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14.4.1.2 The kinesiology RA will be contacted by Shani / Heather/ Dr Chizen to begin the 
enrollment procedure to coincide with the period of performance of 2 hour fasting blood 
tests/repeat ultrasound.  
 
14.4.2 Follow-up Appointment Activities 
At this appointment, if a diagnosis of PCOS is confirmed, Dr. Chizen (with Shani Serrao) will: 
14.4.2.1 Execute the fasting blood tests and 2hr GTT  blood tests in her office, and 
transport the blood samples to the RUH chemistry lab for separation and freezing. 
(see details, section 18) 
14.4.2.2 Review the results of the participant’s PCOS diagnosis blood tests  with the 
participant, between the blood draws. 
14.4.2.3 Complete the 2
nd
 ultrasound between  the blood draws. The second ultrasound 
examination will be completed during the 2 week lead in period, prior to the 
diet/exercise intervention 
14.4.2.4 Confirm that the participant has seen or has an appointment with the kinesiology 
RA to begin the enrolment procedure  
14.4.2.5 Women who do not have PCOS will be informed of the results and be advised 
about suitable follow-up elsewhere as indicated by their examination and blood 
samples.  
 
14.5 Enrolment Procedure 
 
14.5.1  Accelerometers are used at the beginning of the study to measure the participants’ usual 
activity (i.e., before exercise program). Accelerometers are not used for activity 
monitoring during the program. More information on the use of accelerometers is found 
in the efficacy data section. 
 
14.5.2 Once a diagnosis of PCOS has been confirmed, the participant will have been informed 
by Dr. Chizen to contact the kinesiology RA to being the enrolment procedure.  
 
14.5.3 At this contact, the kinesiology RA will book a time for the participant to come in to the 
Williams Building Gym, where the kinesiology RA will follow the enrollment procedure:  
14.5.3.1 The RA will provide a binder for the participant (to keep all the instructions, 
appointment bookings, etc.) 
14.5.3.2 The participant will fill out the Subject Information Form (Appendix G) 
14.5.3.3 The RA will administer the PAR-Q (Appendix H).  
 
14.5.3.3.1 Certain Par-Q responses may require permission from Dr. Chizen or a 
family physician to start the exercise program (e.g., if on blood pressure 
medication, etc.).  
 
14.5.3.4 RA will administer the Leisure-Time Exercise Questionnaire (see Appendix I) 
 
14.5.3.5 RA will provide the participant with a package containing: 
14.5.3.5.1 A 4-day food record (and review the food record with the participant) (see 
Appendix J) 
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14.5.3.5.2 Instructions for accessing the online Quality of Life Questionnaires or, if 
the participant doesn’t have internet access, will provide paper copies and 
a self-addressed postage paid envelope 
 
14.5.4 The RA will book the participant to attend the TLC guidelines presentation  
 
14.5.5 The RA will provide the accelerometer and instructions on how to use the accelerometer 
(Appendix K) 
 
14.5.6 The RA will schedule the first DEXA scan and provide instructions on how to find the 
DEXA office  
 
14.5.7 The RA will take the physical measurements described in the efficacy data section  
 
 
14.6 Follow-up Email 
14.6.1 The kinesiology RA will send a reminder email to the participant (or phone call if no 
email access) approximately 3 days following enrolment.  
14.6.2 The reminder email will remind participants to:  
o contact the RAs at any time with questions 
o fill out the 4-day food record 
o access online questionnaires 
o the date of the TLC presentation  
o return accelerometers at TLC presentation 
 
14.7 Subsequent Appointments at the PCOS Clinic 
 
The kinesiology RAs will book an early a.m. appointment for the participants with Dr. 
Chizen(see section 14.1) at the end of their intervention (within the last 2 weeks). At this 
appointment, Dr Chizen will repeat fasting blood tests including a 2hr GTT, complete an 
ultrasound examination and review the menstrual history. The history and examination will be 
scheduled between blood draws.  
 
 TLC GUIDELINES PRESENTATION AND LEAD-IN PERIOD 
 
15.1 The TLC Guidelines Presentation 
15.1.1 To control for diet variability, all participants will be instructed to follow the dietary 
recommendations of the Therapeutic Lifestyle Changes (TLC) guidelines developed by 
the National Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel 
III, 2002).  
 
15.1.2 Participants will be asked to attend a 90-minute long diet education session, to occur 
approximately a week after recruitment, where a Registered Dietitian (the nutrition RA) 
will explain the TLC guidelines. Handouts will be given to provide tips on healthy 
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meals (developed by the nutrition RA) and healthy snacks, beverages and breakfasts 
(developed by nutrition students as professional practice projects). 
 
15.1.2.1 At the TLC presentation, the nutrition RA will provide a package containing two 1-
day food records 
 
15.1.3  One kinesiology RAs will be present at the presentation to: 
15.1.3.1  Collect the accelerometers (which will contain activity data that has been collected 
since enrolment -section 14.5.5). 
15.1.3.2  Give two Leisure-time Exercise Questionnaires 
 
15.2 The Lead-In Period 
 
15.2.1 The first two weeks of the program are referred to as the “lead-in period” (the period of 
time where all participants follow the TLC diet). The lead-in period begins as soon as 
the participant has attended the TLC presentation. The purpose of the lead-in period is 
to standardize the placebo and study groups.  
 
15.2.2 The exercise program and meal program do not begin until the lead-in period has 
finished. 
 
15.2.3 During the lead-in period, the kinesiology RAs will contact the participant to book 
exercise times (which will begin immediately after the lead-in period). 
 
 
HARD-COPY PARTICIPANT FILE 
 
Each participant will have a hard-copy file with all data entered onto paper. This serves as a hard-copy back-up for 
the data entered onto the database. The hard-copy files will be located in a locked filing cabinet in the William’s 
Building Gym office. The kinesiology RAs are responsible for maintaining the hard-copy files.
  
 
1
0
9
 
 
TIMELINES 
 
Table 3 provides a general overview of the phases and main activities of the study. Table 4 details when each measure occurs during 
the phases. 
 
Table 3: Timeline of Phases and Activities 
 
Timeline of Phases and Activities 
Phase  0:  
Enrolment 
1: 
Lead-In 
2: 
Sixteen-week program 
3: 
Follow-up 
Week # 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
 
6-
months 
after the 
end of 
w20 
12-months 
after the end 
of w20 
Activities Enrolment 
 
Accelerometers 
worn starting at 
enrolment for 9 
days 
 
The TLC 
presentation 
will occur at 
the end of this 
phase (end of 
w2) 
 
Participants 
will return 
accelerometers 
at the TLC 
presentation 
All 
participants 
follow the 
TLC 
guidelines 
for two 
weeks 
 
No meals 
provided 
 
No exercise 
program 
During these sixteen weeks: 
 
All participants continue to follow the TLC guidelines 
 
Meals will be provided for placebo and treatment groups 
 
All participants will follow the exercise program 
No diet 
or 
exercise 
program 
No diet or 
exercise 
program 
 
Accelerometers 
will be worn 
for 9 days 
  
 
1
1
0
 
 
Key:  
w: week 
 
 
Table 4: Timeline of Measures 
 
This table responds to Dr. Chilibeck’s comments on original timeline (i.e. requiring more information on when measures will be taken 
during each phase).  I think it is important to review, as your thoughts on the timing and frequency of the measures may change now 
that you see the table in this format (more detailed). Make take wt, BP, WG more often? 
 
Note: change to original protocol: the lead-in ultrasound and DEXA were eliminated as they were deemed as unnecessary participant 
burden. 
 
Timeline of Measures 
Phase 0: 
Enrolment 
1: 
Lead-In 
2: Sixteen-week program 3: Follow-up 
Week # 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 6-months 
after end 
of w20 
12-months 
after end of 
w20 
Ultrasounds S                   E S S 
DEXA One measure once during 
these four weeks 
               E S S 
BP and WC S                   E S S 
Weight and 
height 
S                   E S S 
Accelerometers S   *                  S 
Par-Q S                      
Leisure Time 
Questionnaire 
S  E E    E    E    E    E S S 
1-day Food 
Record 
  E E    E    E    E    E   
4-day Food 
Record 
S                    S S 
Pulse S                   E S S 
  
 
1
1
1
 
Consumption 
Questionnaire 
Other 
Questionnaires 
S                   E S S 
Routine PCOS 
Blood 
Measures 
S   E            E    E S S 
Routine 
Metabolic 
Syndrome 
Blood 
Measures 
S   E            E    E S S 
Two-hour 
Blood 
Measures 
S   E            E    E S S 
Saved Blood 
Measures 
S   E            E    E S S 
Key: 
E: end of week 
S: start of week 
w: week 
*ONLY if there is a lag between recruitment and when the participant actually starts the program, e.g., if the participant is recruited in one season, but starts 
in the next season 
U of S: Pulse Lifestyle for PCOS                     
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EFFICACY DATA 
 
Note: for the following section, w# represents week number  (e.g., w4 is week 4). 
 
18.1 Imaging Measures 
 
a) Transvaginal Ultrasounds 
Specific measures Ovarian and uterine morphology (i.e., number and distribution 
pattern of ovarian follicles, endometrial thickness and pattern). 
Where measures are taken? PCOS clinic. 
Who takes the measures? Dr. Chizen and Dr. Pierson or trained ultrasound technician. 
Where does the analysis take 
place? 
Dr. Pierson’s laboratory. 
Appointment booking The first ultrasound will occur at the initial visit with Dr. Chizen. 
See section 14.1, 14.2, 14.4 for booking information and 
appointments. 
When measures are taken? 
 
Once at initial visit with Dr. Chizen (pre-diagnosis of PCOS) 
Once at visit for fasting  and 2 hr blood tests (w  ). 
Once at the end of the 16-week program (w18-20). 
Once at 6-month follow-up. 
Once at 12-month follow-up. 
Applicable appendices: None. 
 
 
b) DEXA Reports 
Specific measures Whole body fat mass. 
Abdominal fat mass (trunk fat). 
Whole body lean tissue mass. 
Where measures are taken? DEXA office in the William’s Building. 
Who takes the measures? DEXA technicians. 
Where does the analysis take 
place? 
Dr. Chilibeck’s laboratory. 
Appointment booking Kinesiology RAs will book DEXA scans with the DEXA 
technicians. 
When measures are taken? 
 
Once during phase 0 (between w1 and w4). 
Once at the end of the 16-week program (w20). 
Once at 6-months follow-up. 
Once at 12-months follow-up. 
Applicable appendices: None. 
 
 
18.2 Physical Measures 
 
a) Metabolic Syndrome Physical Measures 
Specific measures Blood pressure (BP), weight, height, and waist 
circumference. 
Where measures are taken? William’s Building Gym. 
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Who takes the measures? Kinesiology RAs. 
Where does the analysis take 
place? 
To be determined. 
Appointment booking Measures will be taken by kinesiology RAs. 
When measures are taken? 
 
Once at initial visit with Dr. Chizen (start of w1). 
Once at the end of the lead-in period (end of w4). 
Once at the end of the 16-week program (18-20 week 
interval). Once at 6-month follow-up. 
Once at 12-month follow-up. 
Applicable appendices Revised Protocol for Measurement of Waist Circumference 
 
 
18.3 Activity measures  
 
a) Accelerometers (activity monitors) 
Specific measures Activity will be measured using the Actical, a uniaxial 
accelerometer that detects vertical acceleration.  
Accelerometers are used at the beginning of the study to 
measure the participants’ usual activity (i.e., before 
exercise program). Accelerometers are not used for activity 
monitoring during the program. 
The Actical (size and dimensions of a small pager) is worn 
by the participants on a belt worn around the waist with the 
accelerometer situated at the hip.  
The participants will be asked to record the time the 
monitor was attached and removed for the purpose of 
calculating activity time and sleeping time. The data are 
electronically downloaded into a data file that contains 
minute-by-minute movement counts for each participant.  
Participants will be wearing the monitor for 7 full days; 
deployed on day 1 and collected on day 9 (or at the TLC 
presentation). Because of the different times of 
deployment, participants will be asked to start wearing the 
accelerometer on day 1 (anytime) but data will only be 
collected from midnight on day 2 and then they wear it past 
midnight on day 7, then the device removed on day 8. 
 
Where measures are taken? 
 
The participants will be asked to wear the monitor at all 
times while awake. Exceptions would include water 
activities like bathing and swimming, or when it is deemed 
inappropriate by the participant.  
Who takes the measures? Participant wears monitor. 
Where does the analysis take 
place? 
Dr. Sherar will analyze the accelerometer data and will 
provide reports on participant activity. 
Appointment booking At enrolment, kinesiology RAs will loan the accelerometers 
to the participants.  
A log will be kept by the kinesiology RAs to record which 
accelerometers are loaned to which participants.  
The kinesiology RAs will teach the participants how to use 
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the accelerometers at enrolment.  
The kinesiology RAs will instruct participants to return the 
accelerometers at the TLC Guidelines presentation.  
When measures are taken? 
 
Once at enrolment (w1). 
*Once at the end of the lead-in period (w4) (*ONLY if 
there is a lag between recruitment and when the participant 
actually starts the program, e.g., if the participant is 
recruited in one season, but starts the study in the next 
season). 
Once at 12-months follow-up.   
Applicable appendices Appendix K: Accelerometer Log. 
 
 
b) Par-Q 
Specific measures Participants will be asked to complete short questionnaires 
called the Par-Q (Canadian Society for Exercise 
Physiology, 2002). 
Where measures are taken? PCOS clinic. 
Who takes the measures? Participant fills out the questionnaire at enrolment. 
Where does the analysis take 
place? 
To be determined. 
Appointment booking Kinesiology RA to administer the questionnaire. 
When measures are taken? Once at the enrolment (w1). 
Applicable appendices Appendix H: Par-Q. 
 
 
c) Leisure-Time Exercise Questionnaire 
Specific measures Participants will be asked to complete the “Leisure-Time 
Exercise Questionnaire” to assess physical activity (Godin 
& Shephard, 1985).  
Where measures are taken? William’s Building Gym. 
Who takes the measures? Kinesiology RAs administer. 
 
Where does the analysis take 
place? 
 
To be determined. 
Appointment booking Kinesiology RAs will administer the questionnaire to 
participant before an exercise session. 
When measures are taken? Once at enrolment (start of w1). 
Twice during the lead-in period (end of w3 and end of w4). 
Four times during the 16-week program (end of w8, end of 
w12, end of w16, and end of w20). 
Once at 6-month follow-up. 
Once at 12-month follow-up. 
Applicable appendices Appendix I: Leisure-Time Exercise Questionnaire. 
 
 
d) Exercise Compliance  
Specific measures Participants will be asked to complete the Aerobic Exercise 
Tracking Logs 
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Where measures are taken? William’s Building Gym (supervised exercise) and at home 
(unsupervised exercise) 
Who takes the measures? Participant fills in form about their perceived compliance to 
the supervised exercise. 
Where does the analysis take 
place? 
To be determined. 
Appointment booking Not applicable. 
When measures are taken? Daily during exercise program. 
Applicable appendices L: Aerobic Exercise Tracking Logs 
 
18.4 Dietary Assessment 
 
a) Food Records 
Specific measures To assess diet, participants will be asked to provide food 
records (records of what they have eaten in a day). These are 
diaries to filled out by the participant throughout the day.    
Note: these are not 24-hr recalls. Because the participant is 
recording what they are eating as the day progresses, they 
will likely change their eating habits to please the 
investigators. This limitation is acknowledged.  
Where measures are taken? Participants complete the records at home. 
Who takes the measures? Participants complete the records. 
Where does the analysis take 
place? 
Dr. Zello’s laboratory (food records will be entered into 
Food Processor by nutrition RAs). 
 
 
 
Appointment booking 
 
 
 
Kinesiology RAs will provide the paper copies of the food 
records at the appropriate times. 
Note: the nutrition RA will give the lead-in food records to 
the participants at the TLC presentation. 
When measures are taken? 1-day food record:  
Once at the start of w1 (at enrolment, PCOS clinic) 
Once at 6-month follow-up 
Once at 12-month follow-up 
4-day food record:  
Twice during lead-in (at the end of w3 and at the end of w4). 
Four times during the 16-week program (at the end of w8, 
end of w12, end of w16, and end of w20) 
Applicable appendices Appendix J: Food Record 
Note: the 4-day food record is the same form as the 1-day 
food record (make four copies of 1-day food record) 
 
 
b) Pulse Consumption 
Specific measures The Pulse Consumption Questionnaire will be administered 
to determine how often participants eat pulse foods. 
Where measures are taken? Participant completes the questionnaire online (or paper 
copy can be made available if no internet access). 
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Who takes the measures? Participant completes the questionnaire online. 
Where does the analysis take 
place? 
Nutrition. 
Appointment booking Kinesiology RA sends email requesting participant to fill out 
questionnaire. 
When measures are taken? Once at enrolment (start of w1). 
Once at the end of the 16-week program (end of w20). 
Once at 6-month follow-up. 
Once at 12-month follow-up. 
Applicable appendices Appendix M: Instructions for Online Questionnaires 
Website. 
 
18.5 Other Questionnaires 
 
a) Quality of Life Questionnaires 
Specific measures Two quality of life questionnaires and a brief motivational 
questionnaire will be administered (Wallston, Rothman, & 
Cherrington, 2007; Cronin et al., 1998; Colwell et a., 2010).  
The questionnaires will be administered via a secured 
website. 
Where measures are taken? Participants complete the questionnaires online (or paper 
copy can be made available if no internet access). 
Who takes the measures? Participant completes the questionnaire online. 
Where does the analysis take 
place? 
Psychology. 
Appointment booking Instructions for accessing the online questionnaires will be 
given by the kinesiology RAs at enrolment. The kinesiology 
RAs will send an email that requests the participant to fill 
out questionnaire. 
When measures are taken? Once enrolment (w1). 
Once at the end of the 16-week program (w20). 
Once at 6-month follow-up. 
Once at 12-month follow-up. 
Applicable appendices Appendix M: Instructions for Online Questionnaires. 
 
 
18.6 Blood Measures 
 
This section has been divided into five categories. Please read each category carefully: 
a) Diagnosis of  PCOS Blood Measures: Analyzed at the Saskatoon Health Region 
Laboratory 
b) Routine PCOS Blood Measures: Analyzed at the Saskatoon Health Region Laboratory 
c) Special Blood Measures That Will Not Be Measured at the Saskatoon Health Region 
Laboratory 
d) Routine Metabolic Syndrome Blood Measures 
e) Two-hour Blood Measures 
f) Saved Blood Measures 
 
a) Diagnosis of  PCOS Blood Measures: Analyzed at Saskatoon Health Region Laboratory 
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Specific 
measures 
These blood for these measures will be requisitioned as clinical care tests and 
participants will attend any of the SDH laboratories for blood draws; tests will 
be analyzed by the Saskatoon Health Region Laboratory as part of routine 
medical care (results are considered imprecise for research purposes). 
 
These measures include: 
CBC                                               (general health indicator) 
TSH                                               (general health indicator). 
Cortisol                                          (to exclude Cushing syndrome) 
Prolactin                                        (to exclude hyperprolactinemia). 
Dehydroepiandrosterone sulphate (to exclude Congenital Adrenal Hyperplasia 
                                                       (CAH)) 
17-hydroxy progesterone.              (to exclude CAH) 
Sex-hormone binding hormone     (to calculate free androgen index) 
Testosterone                                   (to diagnose PCOS-hyperandrogenemia) 
Androstenedione                            (alternate measure of hyperandrogenemia) 
Follicle stimulating hormone (FSH) (exclude other causes of anovulation/                                                                             
                                                        amenorrhea  
Luteinizing hormone (LH)             (as per FSH) 
Estradiol.                                        (as per FSH) 
Beta human chorionic gonadotropin (exclude pregnancy) 
Fasting insulin                                (diagnose hyperinsulinemia) 
Fasting glucose                               (diagnose diabetes  
Hemoglobin A1C                           (glycosylated haemoglobin) 
 
Where measures 
are taken? 
Royal University Hospital (RUH) lab or any other SDH lab 
Who takes the 
measures? 
Lab technician at SDH lab. 
Where does the 
analysis take 
place? 
Will be analyzed by the Saskatoon Health Region Laboratory. 
Appointment 
booking 
Dr. Chizen will give a requisition form for “Diagnosis bloodwork”at the 
history/exam appointment  
When measures 
are taken? 
After initial diagnosis appointment . 
Applicable 
appendices 
None. 
  
  
 
 
 
b) Routine PCOS Blood Measures: Analyzed at Saskatoon Health Region Laboratory 
Specific 
measures 
The blood for these measures will be collected at the RUH laboratory or other 
laboratory in the Saskatoon Health Region and will be analyzed by the 
Saskatoon Health Region Laboratory as part of routine medical care. 
These measures include: 
Beta human chorionic gonadotropin (diagnose pregnancy) 
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Lipid screen                                    (fasting: cholesterol, low density  
                                                        lipoprotein (LDL), high density lipoprotein  
                                                        (HDL), triglycerides 
Sex-hormone binding hormone.     
Testosterone                                    
Androstenedione                           
Follicle stimulating hormone (FSH)  
Luteinizing hormone (LH)              
Estradiol.                                         
Beta human chorionic gonadotropin (exclude pregnancy) 
Fasting insulin                                 
Fasting glucose  
Hemoglobin A1C                               
Where measures 
are taken? 
Royal University Hospital (RUH) lab or other SDH lab 
Who takes the 
measures? 
Lab technician at SDH lab. 
Where does the 
analysis take 
place? 
Will be analyzed by the Saskatoon Health Region Laboratory. 
Appointment 
booking 
The kinesiology RAs  will give the participants the requisitions for blood to be 
drawn during the program. 
Dr. Chizen will give the requisition at follow-up appointments. 
When measures 
are taken? 
Fasting blood tests- early am  
Once at diagnosis appointment enrolment (w1). 
Once at the end of the sixteen-week program (bt w18- w20). 
Once at 6-month follow-up. 
Once at 12-month follow-up. 
Applicable 
appendices 
None. 
 
 
c) Special Blood Measures That Will Not Be Measured at the Saskatoon Health Region 
Laboratory 
Specific 
measures 
These blood for these measures will be collected by Dr Chizen in her office 
and blood samples will be processed in the RUH, SDH laboratory for later 
analysis by the investigators; the Saskatoon Health Region Laboratory will not 
be doing the analysis of these measures (results are not precise for research 
purposes). 
These fasting measures include: 
Estradiol. 
Androgen index (a ratio of testosterone to sex hormone binding globulin). 
FSH  
LH 
MG  
D-Lactate 
Where measures 
are taken? 
Dr Chizen’s office. 
Who takes the Dr Chizen or Research assistant in Dr Chizen’s office; Blood samples will be 
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measures? transferred to the RUH laboratory on ice for processing and freezing. Frozen 
samples will be transferred from the RUH laboratory freezer to the 
investigators’ freezer for storage until all samples can be analysed at 
completion of enrollment 
Where does the 
analysis take 
place? 
Technician at College of Pharmacy and Nutrition. 
Appointment 
booking 
The appointment will be made by Dr Chizen’s research assistant or office 
assistant. The blood tests will be done fasting, at an early am time. If the 
volunteer has menstrual cyclicity, she will be asked to complete the tests 
between day 1-5 of her menstrual cycle. If no menstrual cyclicity exists, the 
appointment will be done at a random time of the menstrual cycle.  
When measures 
are taken? 
Once at enrolment (w1). 
Once at the end of the lead-in period (w4). 
Twice during the sixteen-week program (at w16 and w20). 
Once at 6-month follow-up. 
Once at 12-month follow-up. 
Applicable 
appendices 
None. 
Transport of the 
stored blood 
RAs with biohazard training will be responsible for picking up the stored 
samples twice a week. 
 
 
d) Routine Metabolic Syndrome Blood Measures 
Specific measures The blood for these measures will be collected at the RUH laboratory and 
will be analyzed by the Saskatoon Health Region Laboratory as part of 
routine medical care (results are considered precise for research purposes). 
 
* All these measures should be taken when the participant is in a fasting 
state* 
These measures include: 
C-reactive protein. 
Hemoglobin A1C  (HbA1C). 
LDL-cholesterol.  
HDL-cholesterol.  
Total Cholesterol. 
Triglycerides 
Insulin 
Glucose 
 
Where measures 
are taken? 
RUH lab. 
Who takes the 
measures? 
Lab technician at RUH lab. 
Where does the 
analysis take 
place? 
All these variables from plasma samples will be determined at the RUH 
laboratory. 
Appointment 
booking 
The participant will have the requisition for these lab measures given by Dr. 
Chizen at the appointment to diagnose PCOS; The kinesiology RAs will need 
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to provide the requisitions for the measures that are to occur during the 
program.  
Dr. Chizen will send samples to the laboratory at the time of their GTT. 
When measures 
are taken? 
 
 
 
Fasting tests will be completed at the time of the 2 hour fasting GTT on 4 
occasions: 
Once at enrolment (diagnosis of PCOS) (w1). 
Once during the lead-in period (w1-4). 
Once at the end of the sixteen-week program (w16 -w20). 
Once at 6-month follow-up. 
Once at 12-month follow-up.  
Applicable 
appendices 
None 
 
 
e) Two-hour Blood Measures 
Specific measures 2- hr blood tests taken at 0, 30, 60, 90 and 120 minutes; Oral 
intake of 75 g glucose syrup will occur at time 0 min.  Tests 
include: 
 Insulin  
 Glucose  
 D-lactate  
 Methylglyoaxal (MG). 
Where measures are taken? PCOS clinic (=WHIRL). 
Who takes the measures? Dr. Chizen  (or research assistant) will draw the participant’s 
blood in WHIRL. Blood samples will be transported to RUH 
lab for serum separation and immediate freezing. 
Where does the analysis take 
place? 
Location of final analysis to be determined. 
Appointment booking See sections 14.1, 14.3, 14.4 
After the diagnosis of PCOS is confirmed by receipt of blood 
test results (see 18.6a), an appointment for the first 2hr 
fasting blood tests will be arranged with the participant by 
telephone call. Correspondence with the Kinesiology RA 
regarding confirmation of PCOS diagnosis will allow the 
Kin.RA to complete the enrollment procedure at a pre-
arranged time.  
The kinesiology RAs  and PCOS clinic RA will 
communicate to book appointments for the w18-20, 6month 
and 12 month fasting tests. (See section 14) 
When measures are taken? Once at enrolment (w1). 
Once at the end of the lead-in period (w4). 
Twice during the sixteen-week program (at w16 and w20). 
Once at 6-month follow-up. 
Once at 12-month follow-up. 
Applicable appendices None. 
Transport of samples Research assistant (Shani Serrao) will pick up frozen samples 
from RUH lab and transfer to WHIRL freezer (-70C) for 
temporary storage.  
Samples will be transferred from WHIRL freezer  to 
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Nutrition freezer (-70C, room 331 thorvaldson). 
 
(RAs with biohazard training will be responsible for picking 
up the stored samples twice a month.) 
 
 
f) Saved Blood Measures 
The analysis of these specific measures will occur if funds exist to conduct the 
analysis. 
Specific measures Fasting blood samples will be taken at the time of the 
2hr GTT for the following tests: 
Adiponectin. 
Apolipoprotein B. 
AMH (anti-mullerian hormone). 
Homocysteine. 
Ghrelin. 
GLP-1. 
Leptin. 
Orexin. 
PPY. 
Small LDL. 
Where measures are taken? PCOS clinic(=WHIRL). 
Who takes the measures? Dr. Chizen  (or research assistant) will draw the 
participant’s blood in WHIRL. Blood samples will be 
transported to RUH lab for serum separation and 
immediate freezing. 
Where does the analysis take 
place? 
Location of final analysis to be determined. 
Appointment booking Fasting blood draws will be done at time 0 during 
performance of the 2hr GTT. 
When measures are taken? Once at enrolment (w1-4). 
Twice during the sixteen-week program (at w16 and 
w20). 
Once at 6-month follow-up. 
Once at 12-month follow-up. 
Applicable appendices None. 
Transport of stored samples Research assistant (Shani Serrao) will pick up frozen 
samples from RUH lab and transfer to WHIRL freezer 
(-70C) for temporary storage.  
Samples will be transferred from WHIRL freezer  to 
Nutrition freezer (-70C, room 331 thorvaldson). 
 (RAs with biohazard training will be responsible for 
picking up the stored samples twice a month.) 
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PROCEDURES FOR MONITORING PARTICIPANT COMPLIANCE 
 
There are two study diaries (logs).  
 
19.1 Study Log 1 (Appendix N) is for the lead-in phase (when participant has only received the 
TLC guidelines).  
 
19.2 Study Log 2 (Appendix O) is for the study phase (when participant is participating in the 
diet and exercise program). Participant’s compliance with following the TLC guidelines will be 
recorded in the study log 2. The participant will record whether or not they consumed their 
servings each day. If partial servings were consumed, this will be recorded as estimated 
percentage.  
 
19.3 Compliance to the exercise-training program will be monitored via a daily exercise in Log 
2. The kinesiology RAs will keep a calendar to track the attendance record of participants. 
Participants will also complete compliance to supervised exercise in the Aerobic Tracking Logs 
(Appendix L). 
 
 
FOLLOW-UP  
 
20.1 We will meet with participants at 6 months and 12 months to determine if they continue to 
follow the “standard of care” recommendations (i.e. TLC diet and exercise) and make 
observations of metabolic syndrome and PCOS symptoms. Participants who were randomized to 
the pulse-based diet will be asked if they continue to follow a pulse-based diet. Participants 
randomized to receive the low cholesterol (non-pulse based) diet will be asked if they continue to 
follow the low cholesterol diet. 
20.2With our sample size, we anticipate that we will be able to statistically determine differences 
between individuals who continued to follow the pulse-base diet vs individual who did not 
continue a pulse-based diet.  
 
20.3 Kinesiology RAs will set up the 6-month and 12-month follow-up appointments for the 
participants. The participants will attend the PCOS clinic, where the participant will: 
 Undergo a medical evaluation by Dr. Chizen 
 Receive a requisition for routine bloodwork from Dr. Chizen 
 Receive a transvaginal ultrasound 
 Undergo the fasting 2-hour blood draws 
 Receive a package with the food record, leisure-time questionnaire (include postage-
paid, return addressed envelope) 
 Receive instructions for accessing the online questionnaires 
 
STATISTICAL PROCEDURES 
 
21.1 All raw data will be compiled (on an Excel Spreadsheet) and reviewed for accuracy.  
Descriptive statistics will be performed for all outcome measurements for the presentation of 
group data (e.g. means, SD, etc) and to identify outliers as well as determination of normality of 
the data (for application of either parametric or non-parametric inferential statistics).  
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21.2 Inferential statistics will be carried out to determine if differences exist between the two 
study groups. Baselines measures (dependent variables) will be compared to ensure similarity 
between the two groups (i.e., unpaired t-test).   
 
21.3 Over the course of the study period (baseline, intervention, follow-up), the treatment effect 
on the dependent variables will be assessed by a group by time ANOVA, with repeated measures 
on the time factor (SPSS – Statistical Package). 
 
21.4 Dietary intake data will be analysed for energy and nutrient content using the dietary 
analysis program Food Processor (version 7, ESHA Research, Oregon). This program enables 
the use of both the USDA Handbook 8 (USDA, 1999) and the Canadian Nutrient File (CNF 
1997 version). The database includes more than 20,000 food items, including specialty, ethnic, 
combination and fast foods. Other food items also can be entered from recipes.  Analyses can be 
performed for greater that 130 nutrients and nutrient factors. Intake data obtained will be used 
not only to monitor pulse consumption but also to evaluate the adequacy of the diet in 
comparison to the Dietary Reference Intakes (DRIs). 
 
21.5 Questionnaire data (Quality of Life, Pulse Consumption, Physical Activity) will be 
descriptively presented. Appropriate analyses will be carried out to monitor changes in the 
questionnaire responses.  
 
21.6 Data will be analysed on an intent-to-treat basis; that is, an attempt will be made to re-
measure participants that did not adhere to the exercise or supplementation. An additional valid 
completers analysis will be done including only those Participants completing the entire study 
and who were compliant with their assignment. 
 
 
KNOWN AND POTENTIAL RISKS AND DISCOMFORTS TO 
PARTICIPANTS 
 
22.1 Possible side effects from the ultrasound examination include minor discomfort upon 
insertion of the transvaginal probe and a transient feeling of pressure in vagina or on belly. 
22.2 Possible side effects from blood drawing include fainting, inflammation of the vein, pain, 
bruising or bleeding at the site of puncture. 
22.3 Exercise may result in muscle pulls, strains, or soreness. Participants will be given a proper 
warm-up prior to and qualified exercise trainers will supervise training sessions to minimize 
any risk. Adequate rest will be given between training and testing sessions to ensure that the 
participants’ muscles are recovered by the next training session. Training will initially be 
light and will gradually increase over the first four weeks to allow muscles to get used to the 
training and minimize muscle soreness. See Appendix R: Fitness Testing Data Form. 
22.4 There is a small amount of radiation exposure from the dual energy X-ray scans. This is 
equal to one tenth of the amount of radiation one would receive from taking a trans-Atlantic 
flight from North American to Europe, or less than 0.5% from what one would receive from 
a routine full-mouth dental X-ray. 
22.5 The pulse-based diet is a high fiber diet; therefore, if one is not used to high fiber foods they 
may initially experience some gastrointestinal discomfort and flatulence. 
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22.6 By not taking oral contraceptives, there is a risk of becoming pregnant if no other form of 
birth control is used 
22.7 The questionnaires ask personal questions that one may feel uncomfortable answering. 
Participants have the option of not answering any questions that cause them discomfort or 
distress. 
 
 
STATEMENT ON COMPLIANCE WITH PROTOCOL AND GOOD 
CLINICAL PRACTICE 
 
This trial will be conducted in compliance with the protocol and Good Clinical Practice (GCP). 
 
 
BLINDING 
 
24.1 This is a single blind study. Participants will be aware of the diet and exercise intervention 
they are receiving. Research assistants involved with the training will also not be blind. 
However, the investigators who will be conducting the analyses will remain blind to the 
participants’ group assignments. 
 
24.2 The allocation list will be concealed from the kinesiology RAs, as they will be responsible 
for enrolling participants. The kinesiology RAs will keep the master list of which groups the 
participants are in. 
 
 
RANDOMIZATION 
 
Randomization will be done with a computer-generated allocation schedule with a block size of 
4, making sure that there are equal numbers of subjects on each type of medication across the 
two groups. 
 
ETHICAL APPROVAL 
 
Ethical approval was granted by the University of Saskatchewan Ethics Review Board for 
Biomedical Research in Human Subjects (BIO #10-98) on October 21, 2010. 
 
 
OPERATIONAL APPROVAL 
 
Operational approval was granted by the Saskatoon Health Region on December 14, 2010.  
 
 
CLINICAL TRIALS REGISTRATION 
 
This trial has been registered with clinicaltrials.gov. It is necessary to update the status of the 
trial (i.e., when recruitment begins and ends, when study closes, etc.). Lindsay Tumback has the 
password to access the clinical trials record. 
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QUALITY CONTROL AND QUALITY ASSURANCE PROCEDURES 
 
29.1 A RA will be in charge of data cleaning - checking for mistakes (based on predetermined 
acceptable data ranges) and omissions prior to making entries into the database. The 
primary investigator will be notified if there are invalid or missing values.  
 
29.2 When data corrections and modifications are made, the following will be recorded: the 
change made, the person initiating the change, and the explanation for the change. The 
database will be backed up daily by the RA. Participant data will be chosen at random and 
compared to that entered into the database a second time for quality control purposes. 
 
 
MEDICATIONS / TREATMENTS PERMITTED BEFORE OR DURING 
THE TRIAL 
 
30.1 Participants will be excluded from participation in the study if using the following 
medications during the 3 months prior to at the time of  the study: 
 
30.1.1 Any hormonal contraception or fertility medications  
30.1.2 Use of anticonvulsant medications or psychotropic medications known to increase 
prolactin, increase insulin resistance and induce polycystic ovaries 
30.1.3 Use of estrogen or continuous progestin or androgen hormones 
30.1.4 All prescription medications used by the participant will be reviewed by Dr 
Chizen to determine if there are reasons to restrict use during the study or to 
exclude participation from the study 
 
31.2 All other medications are permitted. The study logs will prompt the participant to 
disclose any prescribed, herbal, or over the counter medication changes on a weekly 
basis. 
 
 
 
31. Visit Protocol in Chronological Order 
 
31.1 Phone conversation about study between potential participant and Kin-RA 
31.2 Phone conversation from Kin-RA with Dr Chizen/WHIRL to arrange PCOS diagnosis 
appt 
31.3 Phone call to potential participant to communicate time of PCOS diagnosis appointment 
and to arrange time to sign consent 
31.4 Participant meets with Kin/NutRA to discuss study and sign consent 
31.5  Participant appointment with Dr Chizen/WHIRL to diagnose PCOS: history, exam, 
ultrasound and receive fasting blood test requisitions (45+ min) 
31.6 Chizen/WHIRL receives all blood tests results and records in database backed up on 
SDH/WHIRL server; ( will send later as excel file) 
31.7 Phone call from Dr Chizen/WHIRL to participant to arrangeappointment for  fasting 2 hr 
blood tests and ultrasound 
31.8 Phone call/email to Kin RA from Chizen/WHIRL to arrange enrolment appointment— 
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31.8.1 If  enrolment appointment is not arranged during 31.5/31.6, Kin RA will contact 
participant 
31.9 Participant appointment for fasting 2 hour blood tests (GTT) and ultrasound exam with 
Chizen/WHIRL (booked for minimum 135-145 min) 
31.10 Kin RA will arrange time for enrolment measures/ tests (anthropometric, DEXA and will 
give instructions for accelerometer,  
31.11 Kin RA will arrange time for TLC education and provide diet questionaire 
31.12 Kin RA will arrange times for exercise  3x/wk 
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APPENDIX A: Participant Information Sheet and Consent Form 
 
 
RESEARCH PARTICIPANT INFORMATION SHEET 
AND CONSENT FORM 
 
A Lifestyle Intervention for Women with Polycystic Ovary Syndrome: 
The Role of a Pulse-Based Diet and Aerobic Exercise on Infertility Measures and Metabolic 
Syndrome Risk 
Funded by: Agriculture and Agri-Food Canada (Growing Canadian Agri-Innovation Program) 
and Pulse Growers of Saskatchewan  
 
RESEARCH TEAM  
 
Principal Investigators: 
Gordon Zello, Ph.D., Professor, College of Pharmacy and Nutrition, phone: 966-5825 
 
Philip Chilibeck, Ph.D., Professor, College of Kinesiology, phone: 966-1072  
 
Sub-Investigators: 
 
Roger Pierson, M.S., Ph.D., FEAS, FCAHS, Professor, Department of Obstetrics, Gynecology 
and Reproductive Sciences, College of Medicine, phone: 966-4458 
 
Donna Chizen, M.D., FRCSC, Associate Professor, Department of Obstetrics, Gynecology and 
Reproductive Sciences, College of Medicine, phone: 966-8623 
 
Karen Lawson, Ph.D., Associate Professor, Department of Psychology, College of Arts and 
Science, phone: 966-2524  
 
Carol Rodgers, PhD, Associate Professor, College of Kinesiology, phone: 966-1061  
 
Lauren Sherar, PhD, Assistant Professor, College of Kinesiology, phone: 966-1119  
 
Shani Serrao, M.Sc. Student, Department of Obstetrics, Gynecology and Reproductive Sciences, 
College of Medicine, phone: 966-8623, 966 7873 
 
Julianne Rooke, B.Sc., and Randi Graham, B.Sc., College of Kinesiology, phone: 966-1082 
 
Kavitha Ramachandran, M.Sc., Nutrition Research Coordinator, Work: 966-6147 & Cell: 881-
7948 
 
The twenty-four hour contact phone number for this study is 230-3849 (Dr. Chilibeck) 
 
INTRODUCTION 
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You are invited to take part in this research study because you have symptoms of Polycystic 
Ovary Syndrome (PCOS). Your participation is completely voluntary and it is up to you whether 
or not you wish to take part in it. Before you give your consent to participate in the study, please 
read the following information sheet and ask as many questions as necessary to be sure that you 
understand what your participation will involve. Please feel free to discuss this with your family, 
friends, or family doctor before you decide. 
 
If you decide to participate, you are still free to withdraw at any time without giving any reasons 
for your decision. If you do not wish to participate, it will not affect your current medical care. 
 
WHO IS CONDUCTING THE STUDY?  
 
The study is being conducted at three sites: the Women’s Health Imaging Research Laboratory (WHIRL) in the 
Department of Obstetrics, Gynecology and Reproductive Sciences at the Royal University Hospital, the College of 
Pharmacy and Nutrition, and the College of Kinesiology at the University of Saskatchewan. The Principal 
Investigators will not receive any payment to conduct this study. Hence there is no monetary gain to the investigator 
if you should decide to become a participant. 
 
WHY IS THIS STUDY BEING DONE? 
 
Some metabolic complications are higher in women with PCOS than the general population. 
They include increased cholesterol levels, type 2 diabetes, and metabolic syndrome. Metabolic 
syndrome occurs when a person has insulin resistance, high blood pressure, abnormal blood fat 
levels, and abdominal obesity. These factors increase the risk for cardiovascular (heart) disease.  
 
The cause of PCOS is not fully understood; however, high blood insulin (a hormone) is believed 
to play a role. Higher amounts of insulin can lead to increased fat storage (and obesity) and 
stimulate male hormone production. Too much male hormone can increase male pattern hair 
growth, interfere with ovulation and cause unpredictable menstrual periods. Suggested treatment 
of PCOS includes nutrition and exercise lifestyle changes to reduce PCOS symptoms and 
metabolic syndrome risk. 
 
Our study is designed to compare two different lifestyle programs for women with PCOS. 
Program 1 includes a heart-healthy diet (the Therapeutic Lifestyle Changes diet) in combination 
with aerobic exercise. Program 2 combines the heart-healthy diet and a pulse-based diet (e.g., 
lentils, chick-peas, peas, and beans) and aerobic exercise. 
 
We would like to observe how each diet and exercise program affects your body shape, hormone 
levels and the appearance of your ovaries. We want to know if your diet and exercise patterns 
change during and after the study. We would also like to understand what you learned from the 
study and will ask for your opinions about participating in the study after the study ends. 
 
WHO CAN PARTICIPATE IN THE STUDY?  
 
If you have been diagnosed with PCOS and are between the ages of 18 and 35 years, you are 
eligible to participate in this study. For a diagnosis of PCOS, two of three criteria must be 
present: 1) irregular or absent menstrual cycles, 2) high blood level of male hormone or male 
pattern hair growth, and 3) polycystic ovaries (enlarged ovaries with multiple small follicles (egg 
sacs) in the ovary) confirmed by transvaginal ultrasound examination. 
 
U of S: Pulse Lifestyle for PCOS                     
 
129 
 
If you are taking birth control medication, or male or female (estrogen-containing) hormones or 
have allergies to a pulse-based diet, you are excluded from the study. If you wish to participate in 
the study, you should use contraception to avoid becoming pregnant during the diet and exercise 
program. You must not use any hormonal contraception or sex-hormone supplements or fertility 
medications for three months prior to the study or during the study. Birth control, sex hormones 
and fertility medications are not permitted because ovarian follicle growth is altered by these 
medications. Women who take some anti-seizure medications or some medications used to treat 
mood disorders may also be excluded because these medications can change the number of 
ovarian follicles.  If the ultrasound examination shows a follicle that may ovulate, you will be 
advised to use a barrier contraceptive method to prevent pregnancy during the diet and exercise 
program (for example, condoms or diaphrams and spermicidal agents). We ask that you tell us 
about any medications (including herbal formulations) you take as some medications can affect 
follicle growth and egg release.  
 
WHAT DOES THE STUDY INVOLVE? 
1. Medical Evaluation 
To determine if you are eligible for this study, you will have a medical evaluation visit with co-investigator Dr. 
Donna Chizen in the Department of Obstetrics, Gynecology, and Reproductive Sciences. This visit will take 
approximately 30 to 45 minutes. You will be asked about your medical and menstrual history. Your body type and 
hair growth pattern will be assessed according to a standard medical scoring system. Your vital signs (pulse, 
respirations, temperature, blood pressure), height, and weight will be measured. A transvaginal ultrasound (a 
procedure where sound waves are sent out by an ultrasound probe that has been inserted in the vagina) will be 
completed to help with the diagnosis of polycystic ovaries. A diary card will be given to you at this visit, to monitor 
menstrual cycles and any health problems. Any health problems will be reviewed, assessed, and documented by the 
investigators throughout the study.  
 
You will be asked to have some blood tests at a Saskatoon Health Region Laboratory after this consultation. Dr 
Chizen will arrange time to review the test results with you and you will have the opportunity to ask questions. If the 
tests confirm that you have PCOS, we will ask you to fast for 12 hours to complete other blood tests done by Dr. 
Chizen. These tests can identify health risk factors typically seen in women with PCOS. One of the tests, the 
Glucose Tolerance Test, is used to diagnose insulin resistance and diabetes. Approximately 2 tablespoons of blood 
will then be collected. Next, you will be asked to drink glucose syrup, followed by collection of 7 ml (one teaspoon) 
of blood every 30 minutes for 2 hours. We will also test to determine if you are pregnant, if you have abnormal 
blood fats, or if you have extra male hormone from your adrenal glands or ovaries. With your permission, if any 
abnormalities are discovered, we will notify your current primary care physician or make a referral to an appropriate 
physician for follow-up medical care. A follow-up medical evaluation may be scheduled.  
 
2. Initial Visit with Study Coordinator 
If Dr. Chizen has diagnosed PCOS, she will direct you to the study coordinator.  You will have your height, weight, 
waist circumference, heart rate and blood pressure recorded. Next you will have your body composition (whole-
body lean tissue and fat mass) assessed. You will be given an accelerometer (a small device that measures your 
physical activity) to wear for one week (these two measures will be described in more detail below). You will 
complete a few questionnaires. 
 
3.  Randomization to Lifestyle Program  
You will be randomly assigned (by chance as determined by a computer) to one of the two programs: 
 
If you are assigned to program 1, you will be asked to follow the Therapeutic Lifestyle Changes (TLC) 
guidelines. You will be given a $40 grocery card every week throughout the intervention period for about 16 
weeks so that you can purchase the foods necessary to follow the TLC diet. You will be asked to attend a 90-
minute diet education session, where a Registered Dietitian will explain the TLC guidelines.  This education session 
will occur at the Williams Building (a map will be provided). The first two weeks of the program are referred to as 
the “lead-in period” (the period of time where all participants follow to the TLC guidelines). Following the “lead-in 
period” you will be asked to continue the TLC guidelines and consume the TLC diet for 16 weeks. The TLC diet 
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will be nutritionally balanced and will contain lean meats as the protein source. Nutritional counseling will be 
provided to you every two weeks throughout the intervention  period of 16 weeks.  
 
If you are assigned to program 2, you will be asked follow the Therapeutic Lifestyle Changes (TLC) 
guidelines and you will receive a pulse-based diet. You will be asked to attend a 90-minute education session, 
where a Registered Dietitian will explain the TLC diet guidelines. This education session will occur at the Williams 
Building (a map will be provided). The first two weeks of the TLC diet are referred to as the “lead-in period” (the 
time where all participants follow to the TLC guidelines). Following the “lead-in period”, you will be asked to 
follow the TLC diet for 16 weeks in addition to consuming a pulse-based diet. The pulse based-diet will include 
meals prepared with dry peas, lentils, chickpeas, and/or beans. Two meals will be supplied daily for 16 weeks to 
those participants on the pulse-based diet program. Meals will be nutritionally balanced and will contain pulses as 
the protein source. The meals will contain approximately 90g dried peas, 225g chickpeas or beans, or 150g lentils. 
 
4.  Exercise Program 
All participants will follow an exercise program for 16 weeks. The program will involve 5 sessions of aerobic 
exercise per week: 3 sessions of supervised exercise training and 2 sessions of unsupervised at-home exercise per 
week. Both the supervised and unsupervised exercise will be at the same intensity: at least 60-75% of your age-
predicted maximal heart rate (220-Age). The supervised exercise training will occur in the College of Kinesiology at 
the Williams Building (treadmill walking and exercising on a rowing machine and exercise bike). The unsupervised 
exercise will involve walking (or other types of aerobic activity if the participant has access to aerobic exercise 
equipment at home). Each exercise session will be 45 minutes long. 
 
5. Measures 
a) Ultrasound Examinations 
The study involves 5 ultrasound examinations that will take approximately 10 minutes each. Transvaginal 
ultrasonography will be used. The procedure involves inserting an ultrasound probe into the vagina to take pictures 
of your ovaries and uterus. The ultrasound exams will be performed by co-investigators Dr. Chizen or Dr. Pierson in 
the Ultrasound Imaging Suite in the Department of Obstetrics and Gynecology at Royal University Hospital (Room 
4511). The examinations will occur at the PCOS diagnosis appointment, at the start of the study, at the end of the 
diet program, and at 6 and 12-months follow-up (after the diet program ends). 
 
 
 
b) Blood Tests 
You will be asked to have some blood tests at a Saskatoon Health Region Laboratory or in Dr Chizen’s office. Tests 
will be done to diagnose PCOS, prior to the start of the diet program, at 9 weeks into the diet program, the end of the 
diet program, and at 6 and 12 months after the diet program ends. These tests can identify health risk factors 
typically seen in women with PCOS. We will determine if you are pregnant, have diabetes or insulin resistance, if 
you have abnormal blood fats, or if you have extra male hormone from your adrenal glands or ovaries. Dr Chizen 
will share the test results with you. With your permission, Dr Chizen will notify your current primary care physician 
if any abnormalities are discovered, or she will refer you to an appropriate physician for follow-up medical care.  
 
c) Body Composition Assessments  
We will measure your body composition (lean tissue and fat mass) with dual energy X-ray 
absorptiometry four times. This examination involves you lying still on a padded table for about 
10 minutes while a low energy X-ray beam scans your body. After this scan, we will assess your 
blood pressure and measure your waist girth. This assessment will take about 30 minutes. The 
body composition assessments will occur at the start of the study, at the end of the diet program, 
and at 6 and 12-months follow-up (after the diet program ends). 
 
d) Physical Activity Assessments  
You will be given a questionnaire called the “Physical Activity Readiness Questionnaire” to see 
if you have any health risks that would make it dangerous to exercise. If you indicate any health 
risks, with your permission, we will contact your family physician to give you clearance to 
participate in the exercise program. Five times during the study you will be asked to complete a 
1-2 minute questionnaire called the “Leisure-Time Exercise Questionnaire.” The questionnaire 
U of S: Pulse Lifestyle for PCOS                     
 
131 
 
will be given the start of the study, one time during the diet program, once at the end of the diet 
program, and at 6 and 12-months follow-up (after the diet program ends). 
 
e) Diet Assessments  
On 9 occasions during the study you will be asked to record the food that you have eaten for one 
to four days. Assessments will occur at the start of the study, twice during the TLC diet, 4 times 
during the study diet, and at 6 and 12-months after the study diet ends. 
 
f) Quality of Life and Motivation Assessments 
Quality of life and motivational questionnaires will be administered at the start of the study, at 
the end of the diet and exercise program, and at 6 and 12 months follow-up. The questionnaires 
will be administered via a secured and confidential website run through the University of 
Saskatchewan. You may complete the questionnaires on your home computer, or you may have 
access to a study computer in a private area. It will take approximately forty minutes to complete 
the questionnaires. 
 
g) Pulse-Consumption Questionnaire 
You will be asked to complete the Pulse Consumption Questionnaire to determine how often you 
eat pulse foods. The dietitian will describe the different types of pulse foods. The questionnaire 
will be given at the start of the study, at the end of the diet and exercise program, and at 6 and 12 
months follow-up. The questionnaire takes approximately 20 minutes to complete. 
 
 
h) Activity Measurement 
Your activity will be measured for one week on three occasions using the Actical accelerometer: 
Once when you enroll in the study, and 12 months after the diet intervention is completed. The 
Actical is a small activity monitor (it is the size and dimensions of a small pager), that is worn on 
a belt around your waist. We will explain how to use the monitor and will also give you written 
instructions. You will be asked to wear the monitor at all times while awake, except when 
bathing, swimming or sleeping. You will be asked to record the time the monitor was attached 
and removed to calculate your activity and sleeping times.  
 
SUMMARY OF TIME COMMITMENT  
 
A summary of the total approximate time commitment throughout the study is as follows:  
 Initial medical appointment with Dr. Chizen (30-45 minutes)  
 Exercise training 45 minutes per session, 5 sessions per week for 16 weeks  
 500  minutes of testing including blood tests and ultrasound examination, DEXA scans, body 
measurements, and exercise testing done on 4 occasions  
 Attendance at TLC diet education session: 90 minutes 
 Total time for diet assessments= 20 minutes per food record on 9 occasions  
 Total time for physical activity assessments= 2 minutes per assessment on 8 occasions  
 Motivation, quality of life, and pulse consumption questionnaires= 60 minutes on 4 
occasions  
 
Total time commitment is approximately 81 hours over 16 months (including follow-up).  
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Week # or 
phase 
Diagnosis Pre-
TLC 
TLC 
week 
1 
TLC 
week 
2 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 6-
months 
after 
end of 
w20 
12-
months 
after 
end of 
w20 
Ultrasounds X X           X       X X X 
DEXA  X                  X X X 
BP and WC  X                  X X X 
Weight and 
height 
 X X X X X X X X X X X X X X X X X X X X X 
Accelerometers  X                    X 
Par-Q  X                     
Leisure Time 
Questionnaire 
 X      X    X    X    X X X 
1-day Food 
Record 
  X X    X    X    X    X   
4-day Food 
Record 
 X                   X X 
Pulse 
Consumption 
Questionnaire 
 X                  X X X 
Other 
Questionnaires 
X                   X X X 
Routine PCOS 
Blood Measures 
X   X         X       X X X 
Routine 
Metabolic 
Syndrome 
Blood Measures 
X   X         X       X X X 
Two-hour 
Blood Measures 
 X                  X X X 
Saved Blood 
Measures 
X X  X         X       X X X 
Diet 
Counselling 
(TLC group 
only) 
     X  X  X  X  X  X  X  X   
DEXA = dual energy x-ray absorptiometry, BP = blood pressure; WC = waist circumference; PAR-q = physical activity readiness questionnaire 
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WHAT ARE THE BENEFITS OF PARTICIPATING IN THIS STUDY?  
 
The benefits to you for participation in this research study include a diet and exercise program. You will be 
given advice regarding your personal risk factors for long-term health problems. You will be informed 
about ways to improve your health and to control undesired hair growth, weight, menstrual cycle regularity 
and fertility. It is hoped the information gained from this study can be used in the future to benefit other 
women with PCOS.  
 
You do not have to participate in this study to reduce your risk of metabolic syndrome. 
You can exercise on your own or arrange for an appropriate program with an exercise 
trainer to reduce your risk of metabolic syndrome. You can also alter your diet by 
reducing saturated fats or take medication to lower your blood cholesterol level and blood 
pressure. 
 
WHAT ARE THE COSTS OF PARTICIPATING IN THIS STUDY? 
 
You will not be charged for any study-related procedures. You will not be paid for participating in this 
study. Parking costs for the medical assessments, and lab tests will be reimbursed with the submission of 
the original receipts. 
 
ARE THERE POSSIBLE RISKS OR DISCOMFORTS? 
 
 Possible side effects from the ultrasound examination include minor discomfort upon insertion of the 
transvaginal probe and a transient feeling of pressure on your vagina or inside your belly. 
 Possible side effects from blood drawing include fainting, infection, bruising or bleeding of a vein at 
the site of skin puncture. You may be given a heating pad to make it easier to see blood vessels. 
 Exercise may result in muscle pulls, strains, or soreness. You will be given a proper warm-up prior to 
and qualified exercise trainers will supervise training sessions to minimize any risk. Adequate rest will 
be given between training and testing sessions to ensure that your muscles are recovered by the next 
training session. Training will initially be light and will gradually increase over the first four weeks to 
allow your muscles to get used to the training and minimize muscle soreness. 
 There is a small amount of radiation exposure from the DEXA scan (dual energy X-ray absorptiometry 
scans). This is much weaker than a typical chest or bone X-ray and is equal to one tenth of the amount 
of radiation you would receive from taking a trans-Atlantic flight from North American to Europe, or 
less than 0.5% from what you would receive from a routine full-mouth dental X-ray. 
 The pulse-based diet is a high fiber diet; therefore, if you are not used to high fiber foods you may 
initially experience some gastrointestinal discomfort and flatulence. 
 By not taking oral contraceptives, there is a risk of becoming pregnant if no other form of birth control 
is used. We ask that you use contraception regularly to avoid the opportunity to become pregnant while 
you are in the study. 
 The questionnaires ask personal questions that you may feel uncomfortable answering. You have the 
option of not answering any questions that cause you discomfort or distress. 
 
 
 
 
RESEARCH RELATED INJURY 
 
In the case of a medical emergency related to the study, you should seek immediate care 
and, as soon as possible, notify the principal investigator. Necessary medical treatment 
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will be made available at no cost to you. By signing this document, you do not waive any 
of your legal rights. 
 
HOW WILL MY PARTICIPATION BE KEPT CONFIDENTIAL? 
 
You will be identified only by your assigned research participant study number. The results of this study 
may also be used for medical and scientific publications; the data will be grouped with that of the other 
participants and your identity will not be disclosed.  
 
With your permission, we will forward a letter to your family doctor’s office to inform him/her of your 
participation in this study and your PCOS condition, unless you specifically request otherwise. We will 
notify your family doctor if we discover any information during the course of the study that may be useful 
for your medical care.  
 
WHAT IF I DECIDE TO WITHDRAW? 
 
You may decide not to participate, or may withdraw at any time. Your refusal to participate in, or your 
withdrawal from, the study will not affect your future medical care. If you wish to withdraw from the study, 
please notify any member of the Research Team as soon as possible. 
  
Your participation in this study may be ended at any time without your consent. Reasons may include, but 
are not limited to, your failure to follow study instructions, adverse events not related to the study, or study 
cancellation due to administrative reasons. 
 
If you are a student, staff, or faculty member at the University of Saskatchewan and you decide not to 
participate or withdraw your consent later, this will not affect your academic standing, employment, 
promotion, or the services you could otherwise expect to receive at the University. 
 
WHO DO I CONTACT IF I HAVE QUESTIONS ABOUT THE STUDY? 
  
If you have any questions regarding your participation in this study, please feel free to contact Dr. Phil 
Chilibeck by phone at 966-1072, cell: 230-3849; or by email at phil.chilibeck@usask.ca. 
 
If you have any questions about your rights as a research subject or concerns about the study, you may 
contact the Chair of the Biomedical Research Ethics Board, care of the Ethics Office, University of 
Saskatchewan at (306) 966-4053 (collect calls accepted). The Research Ethics Board is a group of 
individuals (scientists, physicians, ethicists, lawyers and members of the community) that provide an 
independent review of human research studies. This study has been reviewed and approved on ethical 
grounds by the University of Saskatchewan Biomedical Research Ethics Board. 
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Consent Form 
 
I have read and understood the attached Patient Information Sheet. I freely and voluntarily agree to take 
part in the study entitled “A Lifestyle Intervention for Women with Polycystic Ovary Syndrome: The Role 
of a Pulse-Based Diet and Aerobic Exercise on Infertility Measures and Metabolic Syndrome Risk”. 
 
I have received an explanation of the purpose and duration of the trial, and I am aware of the potential 
benefits and side effect associated with this study. 
 
I was given sufficient time and opportunity to ask questions and to reflect on my understanding of 
participation in the study. My questions have been answered to my satisfaction. 
 
I agree to cooperate fully with the study personnel and will tell him/her of any medicine, drug, or 
alternative therapy (herbal remedy) of whatever nature I have taken in the recent past, or am taking now, 
whether prescribed or not. 
 
I have been given a copy of the Patient Information materials and will be given a copy of this signed and 
dated Consent Form. I am free to withdraw from the study at any time, for any reason, and understand that 
this will not affect my future medical treatment, my academic standing or employment. 
 
Study personnel or other regulatory authorities may wish to review my medical records to verify the 
information collected. I have been assured that my name, address, and telephone number will be kept 
confidential to the extent permitted by applicable laws and/or regulations. By signing and dating this 
document, I give permission for such review and data collection, and grant direct access to my medical 
records. I am aware that none of my legal rights are being waved. 
 
Please check and initial the appropriate box to indicate your decision: 
 
__ ____Yes, I agree that you may inform my family doctor of my participation in this 
study 
 
__ ____No, I do not want you to inform my family doctor of my participation in this study 
 
 
 
Signature of research participant: ___________________________Date:__________________ 
 
Printed name of above:  ________________________________ 
 
I confirm that I have explained the purpose and procedures of this study, as well as any potential risks and 
benefits, to the subject whose name and signature appears above. 
 
Signature of person conducting the consent process:  ______________________ 
 
Date:   ________________ 
 
Printed Name of Above: __________________________ Study Role:   ________________ 
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Appendix B: Researcher’s Summary Form 
* Note: the Appendices mentioned in this Researcher’s Summary are not included. 
 
 
       
  
  
Bio-REB File Number: ____10-98_________ 
 
 
PROJECT TITLE: A Lifestyle Intervention for Women with Polycystic Ovary 
Syndrome: The Role of a Pulse-Based Diet and Aerobic Exercise on Infertility 
Measures and Metabolic Syndrome Risk 
 
PRINCIPAL INVESTIGATOR:  Gordon Zello, Ph.D., Professor, College of Pharmacy 
and Nutrition 
 
DEPARTMENT: College of Pharmacy and Nutrition  
 
SUB-INVESTIGATOR(S):  
Philip D. Chilibeck, Ph.D., Associate Professor, College of Kinesiology  
Roger Pierson, MS PhD FEAS FCAHS, Professor, College of Medicine 
Donna R. Chizen, MD FRCSC, Associate Professor, College of Medicine 
Karen Lawson, Ph.D., Associate Professor, Department of Psychology, College of Arts 
and Science 
 
STUDENT RESEARCHER(S): Lindsay Tumback, MSc, RD, PhD Student, College of 
Pharmacy and Nutrition 
 
DEPARTMENT: College of Pharmacy and Nutrition  
   
RESEARCH WILL BE CONDUCTED AT: College of Pharmacy and Nutrition, College 
of Medicine and College of Kinesiology 
______________________________________________________________________ 
 
1. Hypothesis (State briefly the nature and purpose of the research proposal, and 
the proposition the research is seeking to uphold. What potentially useful 
knowledge or clarification about therapeutic options will be advanced to justify 
the participation of human subjects in this research project?) 
 
The purpose of this study is to evaluate a lifestyle intervention for women with polycystic 
ovary syndrome (PCOS). There are five main objectives of the proposed study:  
 
Biomedical Research Ethics Board  
 
                   RESEARCHER’S SUMMARY FORM 
http://www.usask.ca/research/ethics_review/ 
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1.   To characterize the lifestyles (i.e. diet including pulse consumption and exercise), 
quality of life, other health indicators for risk of disease (e.g. blood parameters, 
anthropometry, body composition) and infertility in a large sample (n>150) of 
women with PCOS (from baseline measures) 
2.   To determine the short-term therapeutic effects of a pulse-based diet on the 
multiple disease measures of PCOS and metabolic syndrome after 16 weeks. 
3.   To determine the long-term therapeutic effects of a pulse-based diet on the 
multiple disease measures of PCOS and metabolic syndrome through follow-up 
measurements of the participants (at 6 months and 12 months post-intervention) 
4.   To measure the effect of a pulse-based diet intervention on participants’ 
consumption of pulse foods after completion of the intervention diet. 
5.   To measure the effect of a pulse-based diet on quality of life scores of women 
with PCOS during the intervention and at 6 months and 12 months follow-up. 
 
Our hypotheses are:  
1.   Introduction of a pulse-based diet for 16 weeks will reduce hyperinsulinemia and 
improve other markers of the metabolic syndrome (i.e. reduce glucose, 
triglycerides, blood pressure, abdominal fat, and increase HDL); and therefore 
reduce the disease measures, symptoms of PCOS (i.e. increase number of ovarian 
follicles, increase levels of estradiol and progesterone and decrease androgens). 
2.   Women with PCOS who are given a 16 week pulse-based diet will continue 
practicing the consumption of pulses for 6 and 12 months after the intervention 
and this will continue to improve their resting insulin levels, markers of metabolic 
syndrome, and symptoms of PCOS. 
3. The pulse-based diet will increase the quality of life of women with PCOS. 
 
2. Academic Validity (Provide evidence that the scientific reasoning and design of 
the project are sufficiently sound to meet the objectives of this project. Provide 
your own comments and if possible those resulting from peer review.  Indicate if 
any other committee or agency has assessed the project’s scientific validity):   
 
Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders in 
women of reproductive age, affecting approximately 105 million women worldwide 
(Azziz, 2005) and an estimated 1.4 million women in Canada (Lujan et al, 2008). Women 
with the syndrome present with several clinical signs, which include menstrual and 
ovulatory dysfunction, hyperandrogenemia (excess male sex hormones), hirsutism (male-
pattern hair growth in women e.g. beard or chest hair), polycystic ovaries, insulin 
resistance, and hyperinsulinism (Azziz et al., 2009). A diagnosis of PCOS is 
accompanied with an increased risk of severe and devastating consequences such as 
infertility, dysfunctional bleeding, endometrial carcinoma, obesity, type 2 diabetes 
mellitus (DM), dyslipidemia (alterations in blood lipids), hypertension, and possibly 
cardiovascular disease (CVD) (Azziz, et al., 2009; Ehrmann, 2005; Liepa, 2008; Lujan et 
al, 2008). 
 
The pathogenesis of PCOS is not fully understood; however, insulin resistance and 
associated hyperinsulinemia are believed to be the key contributing factors (Douglas, 
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2006; Moran & Norman, 2004). Insulin resistance and the subsequent production of 
excessive amounts of insulin are directly associated with the increased ovarian 
production of androgens and the features of PCOS (Blank, McCartney, & Marshall, 
2006). Between 50% and 70% of women with PCOS exhibit insulin resistance.  
 
Metabolic complications of insulin resistance are higher among women with PCOS than 
the general population and include the development of dyslipidemia (i.e. increased 
cholesterol levels), type 2 diabetes mellitus, and metabolic syndrome (Azziz et al., 2009; 
Ehrmann, 2005). Metabolic syndrome is a clinical diagnosis for an individual who 
exhibits the risk factors of insulin resistance, hypertension, abnormal serum lipid levels 
(i.e. high triglycerides and low high-density lipoproteins) and abdominal obesity (Liepa, 
2008). In PCOS women with metabolic syndrome testosterone and serum androgen are 
higher than in non-metabolic syndrome PCOS women, reflecting more severe insulin 
resistance and PCOS disease features in those with metabolic syndrome. In addition, the 
presence of metabolic syndrome places women with PCOS at higher risk of 
cardiovascular disease (Apridonidze, Essah, Iuorno, & Nestler, 2005). 
 
Therefore, lifestyle modifications, including diet and exercise, are essential for effective 
management of PCOS symptoms. Hyperinsulinemia and adiposity exacerbate the 
underlying metabolic and reproductive abnormalities (Lau, 2007) and many of the 
medical therapies for PCOS are less effective in women who are obese (Palomba, 2008). 
Thus, short-term dietary management of PCOS involves control of body weight and 
addressing PCOS symptoms and infertility. Long-term management of PCOS must also 
address the increased risk of the aforementioned metabolic complications and the chronic 
diseases that afflict this vulnerable group of women (Marsh, 2005). 
 
The proposed study will examine a pulse-based diet as a nutrition intervention for the 
PCOS population. The rationale for this intervention is supported by the association of 
pulse-based diets with improved glycemic control (Sievenpiper et al. 2009). The use of a 
pulse-base diet is further supported by data originating from our research group which 
has shown positive effects of including pulses in the diet of individuals at risk for 
metabolic syndrome.  
 
If applicable, please indicate whether Health Canada (TPD) approval has been 
obtained: 
 
 Yes _____  No _____ Pending _____  N/A _X____ 
 
3. Funding (indicate the source of funds supporting the research.  If externally 
funded, state whether the grant or contract is still in application, or has already 
been awarded): 
 
The project has been approved for funding under the Pulse Science Cluster (PSC) 
initiative. The project is financially supported by Agriculture and Agri-Food Canada 
(AAFC). 
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4. Disclosure of Potential Conflicts of Interest (indicate any motivation or 
incentives for conducting this study that arise external to the objectives of the 
study, e.g., will the investigator or institution be paid to conduct this research 
project? Note:  The consent form should also include an introductory disclosure 
of potential conflict of interest statement, where applicable, indicating that this 
is a medical research study for which the study doctor, the institution, or both 
are being paid): 
 
None. 
 
5. Subjects  
a) Target Population (e.g., age, gender, medical condition, target enrollment, 
significant inclusion/exclusion criteria): 
 
We have established a target recruitment of 166 women (n= 83 per group). Inclusion 
criteria include a diagnosis of PCOS and be aged 18-38 years. An age limit of 38 
years was established because the fertility measures of this study are affected by age 
(Canadian Fertility and Andrology Society, 2004). Women who are taking birth 
control or fertility medications with medical conditions that limit exercise or which 
limit consumption of a pulse-based diet (allergies or intolerances) are excluded from 
the study.  
 
b) Proposed Strategies for Recruitment (e.g., use of advertisements, brochures, 
physician patient records):  
 
Two of the researchers on the team, Drs. Pierson and Chizen, frequently conduct 
research with women with PCOS. Women will be recruited through posters 
throughout the University of Saskatchewan, physician offices, health care 
establishments, and advertisements in local newspapers (Appendix A). 
 
6. Procedures (clearly identify treatment allocation design, and describe the 
medical and other procedures to be followed in obtaining research data, 
including questionnaires): 
 
Recruitment 
Women who respond to the advertisement will be scheduled to attend a PCOS 
clinic time and asked to undergo a medical evaluation to determine the presence of 
PCOS.  All women will receive the results of the diagnostic tests and will be called 
in for a follow-up appointment. Only those women who have been diagnosed with 
PCOS will be asked to provide consent to participate in the study and to have their 
assessment data used in the analysis. 
 
Allocation Design 
The study is a single-blind parallel stratified-randomized design. Randomization will 
be stratified based on medication use (i.e. medications for PCOS symptoms, glucose 
control, lipid-lowering, or hypertension and those who are not taking medications). 
U of S: Pulse Lifestyle for PCOS                      
 
140 
 
 
Participants will be randomly assigned to one of two lifestyle programs:  
1) Participants in Program 1 will receive the placebo diet (n= 83) 
2) Participants in Program 2 will receive the pulse-based diet (n= 83) 
 
Standard of Care 
All participants will also receive supervised aerobic exercise training to provide 
recommended standard of care and to reduce variability in this lifestyle factor between 
participants. To control for diet variability, all participants will be instructed to follow the 
dietary recommendations of the Therapeutic Lifestyle Changes (TLC) guidelines 
developed by the National Cholesterol Education Program (NCEP) Expert Panel on 
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult 
Treatment Panel III, 2002).  
 
Randomization to Lifestyle Program  
Participants assigned to program 1 (placebo) will be asked to follow the Therapeutic 
Lifestyle Changes (TLC) diet. Participants will be asked to attend a 90-minute long diet 
education session, where a Registered Dietitian will explain the TLC guidelines. The first 
two weeks of the program are referred to as the “lead-in period” (the period of time 
where all participants follow to the TLC diet). Following the “lead-in period” participants 
in Program 1 will be asked to continue the TLC diet for 16 weeks. Two meals will be 
supplied daily for 16 weeks to those participants in the placebo group. Meals will be 
follow TLC guidelines and will be based on lean-meats for the protein source. The meals 
will exclude pulses.  
 
Participants assigned to Program 2 will be asked follow the TLC diet and will receive a 
pulse-based diet. Participants will be asked to attend a 90-minute long education session, 
where a Registered Dietitian will explain the TLC diet guidelines. Participants will 
follow the TLC diet during the lead-in period and will be asked to follow the TLC diet 
for 16 months in addition to consuming a pulse-based diet. The pulse based-diet will 
include meals prepared with dry peas, lentils, chickpeas, and beans. Two meals will be 
supplied daily for 16 weeks to those participants on the pulse-based diet program. Meals 
will contain approximately 90g dried peas, 225 g chickpeas or beans, or 150g lentils. The 
length of this intervention was based on a review of pulse-based diets for improving 
insulin and glucose levels (Sievenpiper et al., 2009). Also, the length of intervention is 
required to observe changes in fertility measures.  
 
Exercise Program 
All participants will follow an exercise program for 16 weeks. The program involves 5 
sessions of aerobic exercise per week: 3 sessions of supervised exercise training and 2 
sessions of unsupervised at-home exercise. The supervised exercise training will occur in 
the College of Kinesiology at the Williams Building (treadmill walking and exercising on 
a rowing machine and exercise bike). Each exercise session will be 45 minutes long. This 
amount of aerobic exercise is the minimal level of exercise shown to be beneficial for 
increasing high density lipoproteins and lowering triglyceride levels (Durstine, 2002). We 
also have an exercise training laboratory that is fully equipped with all the required 
exercise machines and reserved exclusively for research participants. Participants will be 
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encouraged to exercise at an intensity of at least 60% of their age-predicted maximal 
heart rate (i.e. 220-age).  
 
Measured Outcomes 
PCOS disease measures assessed include: ovarian and uterine morphology (i.e., number 
and distribution pattern of ovarian follicles, endometrial thickness and pattern as assessed 
by trans-vaginal ultrasonography) and levels of estradiol, progesterone and an androgen 
index (a ratio of testosterone to sex hormone binding globulin). These measures are 
components of routine clinical practice for Drs. Pierson and Chizen.  
 
Metabolic syndrome risk assessment will include fasting plasma glucose, HgA1C, 
insulin, triglycerides, lipoproteins, and C-reactive protein (for inflammation), as well as 
measures of abdominal obesity, and blood pressure. All these variables from plasma 
samples will be determined at our University Hospital or in our research laboratories by 
trained technicians. Blood pressure, waist girth, and abdominal obesity (by dual energy 
X-ray absorptiometry) will be measured in our laboratory by trained technicians. All 
these measurements are routinely performed by Drs. Chilibeck and Zello and have been 
used by us in previous research studies (Cornish et al., 2009; Little et al., 2009; 
Vatanparast et al. 2009). 
 
Activity will be measured on three occasions using the Actical, a uniaxial accelerometer 
that detects vertical acceleration. The Actical (size and dimensions of a small pager) is 
worn by the participants on a belt worn around the waist with the accelerometer situated 
at the hip. The women will be instructed both verbally and in written form on how to 
attach the accelerometer. The participants will be asked to wear the monitor at all times 
while awake. Exceptions would include water activities like bathing and swimming, or 
when it is deemed inappropriate by the participant. The participants will be asked to 
record the time the monitor was attached and removed for the purpose of calculating 
activity time and sleeping time. The data are electronically downloaded into a data file 
that contains minute-by-minute movement counts for each participant.  
 
Participants will be asked to complete short questionnaires called the Par-Q Canadian 
Society for Exercise Physiology, 2002) (Appendix B) and the “Leisure-Time Exercise 
Questionnaire” to assess physical activity (Godin & Shephard, 1985) (Appendix C). To 
assess diet, participants will be asked to provide food records (records of what they have 
eaten for one to four days) (Appendix D).  A Pulse Consumption Questionnaire will be 
administered to determine how often participants eat pulse foods (Appendix E). 
 
Quality of life questionnaires and a brief motivational questionnaire will be administered 
(Appendix F). (Wallston, Rothman, & Cherrington, 2007; Cronin et al., 1998; Colwell et 
a., 2010). The questionnaires will be administered via a secured website. Participants will 
have the option of completing the questionnaires on their home computer or on a study 
computer in a private area. 
 
We will follow-up with participants at 6 months and 12 months to determine if they are 
continuing to follow the “standard of care” recommendations (i.e. TLC diet and exercise) 
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and for those randomized to the pulse-based diet if they continue to follow a pulse-based 
diet and continue to show improvements in measures of metabolic syndrome and PCOS 
symptoms. With our sample size, we anticipate that we will be able to statistically 
determine differences in those individuals who continued to follow the pulse-base diet 
and those who did not. 
  
7. Time Period (indicate the dates when the research project is expected to begin 
and to be completed.  A final status report must be filed with the Ethics Office 
once data collection from the last subject is complete. The Ethics Office should 
be notified once the study site is closed.): 
 
8.    Data Storage (In accordance with recommended guidelines provide a statement    
        outlining the procedures you will use to store securely the research data.  State  
        how long and where the data will be stored and identify the person who will be  
        assuming responsibility for data storage): 
 
Electronic data will be password-protected and stored in a locked office with 
restricted access (Thorvaldson G30) in the College of Pharmacy and Nutrition for a 
period of 10 years. Dr. Zello and Ms. Tumback will be responsible for the security of 
this data. 
 
9. Consent Form (include a copy of the consent form and/or any study information 
that will be used.  If not using a consent form give reasons why).   
 
 Attached. 
 
10. Signatures 
 
 
 _______________________________              ________________________ 
Timeline 
April 2010 –
December 2010 
January 2011- 
January  2012 
November 2011 
to 
July  2012 
January 2012- 
January 2013 
Ethics submission, 
hiring research 
personnel, 
recruitment and 
enrollment of 
participants 
TLC-diet lead-in 
phase. 
Intervention: 16 
weeks per 
participant 
(participants 
phased in to 
account for 
seasonal 
variability) 
6 month follow-up 
12 month follow-
up 
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   Printed Name of Principal Investigator              Date 
 
 ______________________________ ______________________________ 
 Signature of Principal Investigator Phone 
 
 ______________________________           ______________________________ 
 e-mail      Fax 
 
    _______________________________ ______________________________ 
      Signature of Student Researcher(s) Phone 
 
 ______________________________  
 e-mail 
 
 _______________________________________ 
 Department Head, Dean, Director, or Administrative Head   
 
11.  Contact Person and Mailing Address for Correspondence: 
 
Gordon A. Zello, Ph.D. 
Division Head and Professor of Nutrition and Dietetics 
College of Pharmacy and Nutrition 
University of Saskatchewan 
110 Science Place 
Saskatoon, SK, Canada S7N 5C9 
Phone: (306) 966-5825 
Fax: (306) 966-6377 
Email: gordon.zello@usask.ca 
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Appendix C: Adverse Events Forms 
 
PCOS PULSE STUDY 
 
SUBJECT ID #: _______    SUBJECT INITIALS: _______  
_____________________________________________________________________ 
ADVERSE EVENT FORM 
 
Describe the adverse event: _________________________________________________ 
______________________________________________________________________________
__________________________________________________________________ 
(Record diagnosis where available or describe event in as few words as possible.) 
 
Is this event a new event? _____ – assign a new number  
Is this event a change/resolution of an ongoing event? _____ – use the existing number 
 
Onset of Adverse Event (date): _______________________________ 
Resolution of Adverse Event (date): ____________________________ 
________________________________________________ 
 
Is this event Serious?       Yes   No  
(Results in death, is life threatening, requires hospitalization, results in persistent or 
significant disability.*) 
Is this event intermittent?       Yes   No  
 
1. Rate Intensity (severity):        
 
Mild  Moderate  Severe  Life threatening 
2. Is the adverse event is still present:     Yes   No   
 
3. Frequency: ___________________________________________________ 
4. Relationship to experimental procedure (food, exercise or other procedure): Please circle one 
 
Not related Unlikely Possible Probable Definite 
_______________________________________________________________ 
 
Was treatment administered?       Yes   No  
 
Details: _________________________________________________________________ 
________________________________________________ 
* This is a SERIOUS ADVERSE EVENT - will be reported to the Research Ethics Board 
through their Status Report Form. For definitions of mild, moderate, severe, life threatening, not 
related, unlikely, possible, probable and definite, refer to MOP (pages 10-16). 
 
Signature:_________________________   Date: __________________ 
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PI Signature:_______________________   Date: __________________ 
 
 
 
U of S: Pulse Lifestyle for PCOS                      
 
149 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix D: Recruitment Poster 
 
 
Do you have: 
Irregular periods? 
Difficulty becoming pregnant 
Unwanted facial/body hair? 
Difficulty losing weight? 
A family history of diabetes? 
 
If you have one or more of these symptoms, you may have 
Polycystic Ovary Syndrome (PCOS). 
 
The Colleges of Pharmacy and Nutrition, Medicine and Kinesiology are 
conducting a diet and exercise program study for women with PCOS. 
 
Volunteers must be: 
• Between 18 and 38 years old. 
• Not taking hormonal contraceptives in the last three months.  
• Not taking fertility medications in the last three months. 
 
The study runs 20 weeks long, with follow-up at 6 and 12 months. 
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For more information about participating in this 
study, please call Dr. Phil Chilibeck at 966-1072 or 
phil.chilibeck@usask.ca
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Appendix E: Inclusion and Exclusion Checklist 
 
INCLUSION AND EXCLUSION CHECKLIST 
 
SUBJECT INITIALS: _______   RECRUITMENT ID #: _______  
  
Inclusion Criteria 
 
 Are you a female between the ages of 18 and 38 years   Yes   No  
 Have you been diagnosed with PCOS    Yes   No  
Do you have: 
 Irregular periods?       Yes   No   
 Difficulty becoming pregnant?     Yes   No  
 Unwanted facial/body hair?     Yes   No  
 Difficulty losing weight?      Yes   No   
 A family history of diabetes?     Yes   No  
 
Exclusion Criteria 
 
 Have taken hormonal contraceptives in the last three months  Yes   No  
 Have taken fertility medications in the last three months   Yes   No  
 Do you have any allergies to a pulse-based diet    Yes   No  
 
Additional Information 
List any medications (including herbal formulations) you take.   
 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________ 
 
Signature: __________________________________  Date: __________________ 
Signature of PI: _____________________________   Date: __________________ 
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Appendix F: Medical Assessment Form  
 
Leave space for form 
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Appendix G: Subject Information Form  
 
Subject Information Sheet  
 
(Use black ink only) 
 
 
Name:______________________________________________________ 
 (First)          (Middle Initial)      (Last) 
 
 
 
Date of Birth: __________________  SK Health Card#______________________ 
      (day/month/year) 
 
Address: _______________________ E-mail:______________________________ 
______________________________ 
______________________________ 
______________________________ 
 
 
Phone: (h) _______________          (w) _______________       (other) _______________ 
 
 
Preferred number and time to call: ____________________________________________ 
 
 
 
 
Physician Name: _______________________ Phone: _______________________ 
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Address:________________________________
__________________________ 
_________________________________ 
_________________________________ 
_________________________________ 
 
Would you like your family physician to be 
notified of your participation in the study?      
 Yes 
 No 
 
Comments:______________________________
_______________________________________
_______________________________________
_______________________________________
_______________________________________
_______________________________________
_______________________________________
______________  
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Appendix H: Par-Q 
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Appendix I: Leisure Time Questionnaire 
 
LEISURE-TIME EXERCISE QUESTIONNAIRE 
(Godin and Shephard, Canadian Journal of Applied Sport Sciences 10: 141-146, 1985). 
 
* Please do not include activities performed from our study-specific exercise program. 
  
1. Considering a 7-day period (a week), how many times on the average do you do the following 
kinds of exercise for more than 15 minutes during your free-time? 
(Write the appropriate number in each box) 
 
 TIMES PER WEEK 
 
a) STRENUOUS EXERCISE (Heart beats rapidly) 
 (i.e. running, jogging, hockey, football, soccer, squash, basketball, cross-country skiing, judo, roller skating, 
vigorous swimming, vigorous long-distance bicycling). 
  
b) MODERATE EXERCISE (Not exhausting) 
 (i.e. fast walking, baseball, tennis, easy bicycling, volley ball, badminton, easy swimming, alpine skiing, popular 
and folk dancing). 
  
c) MILD EXERCISE (Minimal effort) 
 (i.e. yoga, archery, bowling, horseshoes, golf, snow-mobiling, easy walking) 
 
2. Considering a 7-day period (a week), during your leisure-time, how often do you engage in any 
regular activity long enough to work up a sweat (heart beats rapidly)? 
 
OFTEN SOMETIMES NEVER/RARELY 
1.  2.  3.  
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Appendix J: Food Record 
 
Subject code_______________________ 
 
 
How to Use the Food Diary 
 
1. It is important to keep up-to date notes in your food diary.  List foods immediately after they 
are eaten.  Please print or write legibly all entries. 
 
2. Please record only one food item per line in this record booklet. 
 
3. Be as specific as possible when describing the food item that you eat.  We need to know the 
way you cook your food (if food was cooked) and the amount that was eaten. 
 
4. Include the method that was used to prepare the food item - for example:  fresh, frozen, 
stewed, fried, baked, canned, broiled, raw or braised. 
 
5. Include brand names and restaurant names whenever possible. 
 
6. Report only the food portion that was actually eaten - for example:  chicken leg, 3 oz. baked 
with skin.  (Do not include the weight of the bones and indicate part of food eaten.) 
 
7. Record amounts as weights or volumes.  You may use household measures - for example: 
tablespoons, cups, slices or units, as in one cup skim milk. 
 
8. For canned foods, include the type of liquid in which it was canned:  sliced peaches in heavy 
syrup, fruit cocktail in light syrup or tuna in water. 
 
9. Do not alter your normal diet habits during the time that you keep this diary.  
 
10. Remember to record the amounts of fats used in mixed dishes (such as sandwiches). These fats 
include oils, butter, salad dressings, margarine, miracle whip, mayonaise. 
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PLEASE LIST Every FOOD and DRINK as you consume it DATE: ___________________________ 
 
 
Time 
 
Food Items 
 
Type & 
Preparation 
 
Amount 
 
Brand Name or 
Where Bought 
 
Code 
 
Morning 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mid-morning 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Noon Meal 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Midday 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Evening Meal 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Before Bed 
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Was this intake usual?  Circle one: Yes No (if No, explain why not _____________________________________) 
 
 
Did you take any vitamins/minerals during this time? Circle one: Yes No (if Yes, list names on next page) 
 
 
 
Recipe Information:  
_________________________________________________________________________ 
_________________________________________________________________________ 
_________________________________________________________________________ 
_________________________________________________________________________ 
_________________________________________________________________________ 
_________________________________________________________________________ 
_________________________________________________________________________
BRAND NAME OF SUPPLEMENT NUTRIENTS AMOUNT 
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Appendix K: Accelerometer Log 
 
Activity Monitor Log Sheet  
 - ___  ___  ___  SERIAL NUMBER: C 8 4______________  
  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8  
Date          
On at wake up                  
Please 
return this 
log and 
your 
accelerom
eter to the 
TLC 
guidelines 
presentatio
n 
(time you put 
monitor on for the 
day)                 
Off at bedtime               
  
(time you took off 
monitor before bed) 
              
          
  
          
NOTES          
1.  The activity monitor is to be worn securely on the RIGHT hip using the 
belt provided.     
2.  The monitor can be worn over or under your clothing (your 
choice).      
3.  Although the monitors are fairly durable, care should be taken when wearing them as they are quite 
expensive.   
4. Please wear your monitor everyday, even if you've stayed home from work (e.g., due to illness).    
          
NOTE:   If you have to take off the monitor for any reason please record the reason why 
below.    
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Appendix L: Aerobic Exercise Tracking Logs 
 
Tracking Log for Supervised Aerobic Exercise 
 
Name:     Age:    
Aerobic Training 
Heart Rate Ranges: 60 – 75% of Max Heart Rate 
_______Beats per 10sec. count 
 
Date: Type of Training Duration Intensity 
HR 1 HR 2 
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Tracking Log for Unsupervised Aerobic Exercise 
 
 
 
Funded by: 
 
Agriculture and Agri-Food  
Canada 
         Pulse Growers of Saskatchewan 
 
 
   University of Saskatchewan 
  966-1082 
 
   College of Kinesiology 
  Phil Chilibeck Ph.D. 
         87 Campus Drive     Aerobic Exercising at home Tracking Log Book  
       Saskatoon, SK  S7N 5B2      
 
e-mail:phil.chilibeck@usask.ca 
                      
 
 
 
 
 
 
 
Date: Type Duration Intensity 
HR 1 HR 2 
Dec. Bike 35min √ √ 
A Lifestyle Intervention for Women 
with Polycystic Ovary Syndrome: 
The Role of a Pulse-Based Diet and 
Aerobic Exercise on Infertility 
Measures and Metabolic Syndrome 
Risk 
Write the type of Aerobic exercise and duration of exercise in 
appropriate box. Check off HR 1 and HR 2 after reading your 
Heart Rate. Write date as shown below. Please contact  
966-1305 or 966-1082 if you have any questions or concerns. 
 
Aerobic Training 
Heart Rate Ranges: 60 – 75% of Max Heart Rate 
_______Beats per 10sec. count 
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Name:_______________________ 
17/08 
Date: Type Duration Intensity  Date: Type Duration Intensity 
HR 1 HR 2 HR 1 HR 2 
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Appendix M: Online Questionnaire Instructions 
 
Leave room for instructions 
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Appendix N: Study Log 1 
 
 
Study Log 1 
 
 
Phase 1: Lead-In (weeks 1-2) 
 
 
 
Participant Code:________ 
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Please write on the back of this page if there is not enough room for your responses 
WEEK 1 DAY 1 Date: 
TLC DIET GUIDELINES  
Did you follow the TLC Guidelines 
today? 
Yes       No   
If no, please state what you ate that was 
different from the guidelines. 
 
 
WEEK 1 DAY 2 Date: 
TLC DIET GUIDELINES  
Did you follow the TLC Guidelines 
today? 
Yes       No   
If no, please state what you ate that was 
different from the guidelines. 
 
 
WEEK 1 DAY 3 Date: 
TLC DIET GUIDELINES  
Did you follow the TLC Guidelines 
today? 
Yes       No   
If no, please state what you ate that was 
different from the guidelines. 
 
 
WEEK 1 DAY 4 Date: 
TLC DIET GUIDELINES  
Did you follow the TLC Guidelines 
today? 
Yes       No   
If no, please state what you ate that was 
different from the guidelines. 
 
 
Please write on the back of this page if there is not enough room for your responses 
WEEK 1 DAY 5 Date: 
TLC DIET GUIDELINES  
Did you follow the TLC Guidelines 
today? 
Yes       No   
If no, please state what you ate that was 
different from the guidelines. 
 
 
WEEK 1 DAY 6  
TLC DIET GUIDELINES  
Did you follow the TLC Guidelines 
today? 
Yes       No   
If no, please state what you ate that was 
different from the guidelines. 
 
 
WEEK 1 DAY 7  
TLC DIET GUIDELINES  
Did you follow the TLC Guidelines 
today? 
Yes       No   
 
If no, please state what you ate that was 
different from the guidelines. 
 
 
Have there been changes in the medications or supplements you are taking? If yes, please list: 
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Please write on the back of this page if there is not enough room for your responses 
WEEK 2 DAY 1 Date: 
TLC DIET GUIDELINES  
Did you follow the TLC Guidelines 
today? 
Yes       No   
If no, please state what you eat 
differently from the guidelines. 
 
WEEK 2 DAY 2 Date: 
TLC DIET GUIDELINES  
Did you follow the TLC Guidelines 
today? 
Yes       No   
If no, please state what you ate that was 
different from the guidelines. 
 
WEEK 2 DAY 3 Date: 
TLC DIET GUIDELINES  
Did you follow the TLC Guidelines 
today? 
Yes       No   
If no, please state what you ate that was 
different from the guidelines. 
 
 
WEEK 2 DAY 4 Date: 
TLC DIET GUIDELINES  
Did you follow the TLC Guidelines 
today? 
Yes       No   
If no, please state what you ate that was 
different from the guidelines. 
 
 
Please write on the back of this page if there is not enough room for your responses 
WEEK 2 DAY 5 Date:  
TLC DIET GUIDELINES  
Did you follow the TLC Guidelines 
today? 
Yes       No   
If no, please state what you ate that was 
different from the guidelines. 
 
 
WEEK 2 DAY 6  
TLC DIET GUIDELINES  
Did you follow the TLC Guidelines 
today? 
Yes       No   
If no, please state what you ate that was 
different from the guidelines. 
 
 
WEEK 2 DAY 7  
TLC DIET GUIDELINES  
Did you follow the TLC Guidelines 
today? 
Yes       No   
If no, please state what you ate that was 
different from the guidelines. 
 
 
Have there been changes in the medications or Supplements you are taking? If yes, please list: 
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Appendix O: Study Log 2 
 
 
 
 
Study Log 2 
 
 
Phase 2: Program (weeks 3-18) 
 
Participant Code:________ 
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Please write on the back of this page if there is not enough room for your responses. 
WEEK __________ Day 1 Day 2 Day 3 Day 4 
MEAL 1     
Recipe name of meal 
1  
 
    
Percent eaten (out of 
100%)  
 
    
If not 100% eaten, 
please tell us why not 
  
 
    
MEAL 2     
Recipe name of meal 
2 
 
    
Percent eaten (out of 
100%) 
 
    
If not 100% eaten, 
please tell us why not 
 
    
TLC DIET 
GUIDELINES 
    
Did you follow the 
TLC Guidelines for 
breakfast and snacks 
today?  
Yes       No  Yes       No  Yes       No  Yes       No  
If no, please state 
what you ate that was 
different from the 
guidelines. 
 
 
 
 
    
EXERCISE     
Did you exercise 
today? (circle one) 
Yes       No Yes       No Yes       No Yes       No 
What kind of 
exercise?  How long?  
    
OTHER 
COMMENTS 
    
Is today different than 
usual days (for 
example are you sick, 
away from home...)? 
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Please write on the back of this page if there is not enough room for your responses. 
WEEK ____________ Day 5 Day 6 Day 7 
MEAL 1    
Recipe name of meal 1  
 
   
Percent eaten (out of 100%)  
 
   
If not 100% eaten, please 
tell us why not 
  
 
   
MEAL 2    
Recipe name of meal 2 
 
   
Percent eaten (out of 100%) 
 
   
If not 100% eaten, please 
tell us why not 
 
   
TLC DIET GUIDELINES    
Did you follow the TLC 
Guidelines for breakfast and 
snacks today?  
Yes       No  Yes       No  Yes       No  
If no, please state what you 
ate that was different from 
the guidelines. 
 
 
 
 
   
EXERCISE    
Did you exercise today? 
(circle one) 
Yes       No Yes       No Yes       No 
What kind of exercise?  
How long?  
   
OTHER COMMENTS    
Is today different than usual 
days (for example are you 
sick, away from home...)? 
   
 
Have there been changes in the medications or supplements you are taking? If yes, please list changes: 
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Appendix P: Physical Measures Data Collection Form 
 
PHYSICAL MEASURES DATA COLLECTION FORM 
PCOS STUDY 
 
 
Participant Code 
 
 
Date 
 
 
Measure 
 
Check one 
 
 Week 1 (Enrolment) 
 
 Week 4 (End of lead-in period) 
 
 Week 20 (End of 16-week program) 
 
 6-Month Follow-Up 
 
 12-Month Follow-Up 
 
Blood Pressure 
 
 
Weight 
 
 
Height 
 
 
Waist 
Circumference 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
U of S: Pulse Lifestyle for PCOS                      
 
172 
   
 
 
 
 
 
 
 
Appendix Q: 
Revised Protocol 
for Measurement 
of Waist 
Circumference 
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Appendix R: Fitness Testing Data Form 
 
SUBJECT INITIALS: _______   RECRUITMENT ID #:_________ 
 
TREATMENT: Fitness Testing – Baseline  
 
 
 
 
Date of measurement: ______________________ 
    (Day/month/year) 
 
Was DXA scan completed?   
 
 
Vital Signs 
 
 BP:  ________________ (mmHg) 
   ________________ (mmHg)      
   ________________ (mmHg)   
 HR:  ________________ (bpm) 
 
Anthropometry 
 
 Waist Girth:     ________________ (mm) 
 Weight: ________________ (kg) 
 Height:  ________________ (m) 
 BMI:   ________________ 
 
 
 
 
Form Complete by: ____________________ Date: _________________________ 
 
Signature of PI: ________________________ Date: _________________________ 
 
 
 
 
 
 
 
 
